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10 | Chapter 1
General introduction
The history of Ankylosing Spondylitis
Ankylosing spondylitis (AS; σκληρός= stiff σπονδύλων= vertebrae) is a chronic inflammatory 
rheumatic disease with a long history, primarily affecting the axial skeleton. For example, 
evidence of ossification of joints and entheses corresponding with lesions seen in AS was 
already seen in a 5000-year old Egyptian mummy 1. Realdo Colombo, an Italian surgeon and 
professor in anatomy, probably described AS-like characteristics for the first time in 1559, and 
in 1691 Bernard Connor described pathologic changes of the skeleton possibly associated 
with AS 2, 3. The symptoms and complaints of Leonard Trask (1805-1861) - he developed 
progressive severe thoracic kyphosis after he fell from a horse, resulting in invalidating 
disabilities - were extensively described as he was considered a medical curiosity. Until his 
death, his condition remained a medical mystery, however, post-mortem he was diagnosed 
with AS 4.
In 1893, descriptions of what might have been AS were given by the neurologist and 
psychologist Vladimir Bekhterev, as well as by the neurologists Adolph Strümpell in 1897 
and Pierre Marie in 1898 4-6. The disease was long known as morbus Bechterew and Pierre 
Marie Strümpell disease although it is not certain the cases these authors described were 
what is now known as AS. Initially, AS was not identified as a separate entity, but considered 
as a subtype of rheumatoid arthritis (“rheumatoid spondylitis”) until the 1960s 5. Only during 
the mid-1960s, AS was recognized as a separate entity with well-defined manifestations and 
radiographic criteria 6, 7.
Clinical manifestations and epidemiology
AS is characterized by inflammation in the sacroiliac joints (SI-joints) and the vertebrae, 
causing severe pain and stiffness in the back and/or buttock area. In some patients the 
inflammation ultimately leads to bone formation in the SI-joints and/or spine, thereby 
deteriorating spinal mobility resulting in impaired daily functioning. Complaints associated 
with AS usually start in the 2nd and 3rd decade of life, and by the age of 45 years, more than 
95% of the patients are symptomatic 8, 9.
The cause of AS is multifactorial, consisting of genetic and environmental factors, but is not 
completely elucidated yet. Regarding genetic factors, a strong association with the major 
histocompatibility complex (MHC) class I human leukocyte antigen (HLA)-B27, present in 
80-95% of the AS patients, is known 10. In addition to the prototypical genetic risk factor 
HLA-B27, HLA-B60 is a modest risk factor for AS 11. Moreover, several new genetic risk factors 
outside of the MHC locus, including genetic variants in the ERAP1 and IL-23 receptor gene, 
have been discovered recently 12.
Worldwide, the prevalence of AS varies depending on the prevalence of HLA-B27. In central 
Europe, the prevalence of HLA-B27 varies from 6 to 9% and the estimated prevalence of 
AS ranges between 0.1-0.7% 13-16. In northern Europe the prevalence of HLA-B27 is higher, 
around 14%, and the estimated prevalence of AS is accordingly higher as well: 1.1-1.4% 17. In 
the USA the prevalence of HLA-B27 is also around 6% and the estimated prevalence of AS is 
around 0.5% 18, 19, and among Haida Indians the prevalence of HLA-B27 is very high, around 
50%, and the prevalence of AS is estimated around 6% 20.
In addition to complaints in the axial skeleton, AS patients may suffer from complaints 
in peripheral joints (peripheral arthritis, dactylitis and enthesitis) and extra-articular 
manifestations (uveitis, psoriasis and inflammatory bowel disease (IBD)), often with 
substantial overlap. The estimated prevalence of peripheral complaints and extra-articular 
manifestations differ in various studies, due to differences in inclusion criteria and 
methodological characteristics resulting in different study populations regarding clinical 
characteristics, as well as due to differences in geographical area. Pooled prevalence 
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revealed that approximately 25.8% (95% CI: 24.1%-27.6%) of the patients suffer from at 
least one episode of acute anterior uveitis during their disease course. Approximately 9.3% 
(95% CI: 8.1%-10.6%) of the patients have psoriasis, and the pooled prevalence of IBD is 
6.8% (95% CI: 6.1%-7.7%) 21. Reported prevalence of peripheral arthritis ranges from 14.4% 
to 46.6% 22-24, of dactylitis it ranges from 1.9 to 3.1% 23, 24 and the reported prevalence of 
enthesitis ranges from 9.8% to 49% 22-26. 
Classification and diagnostic criteria
Appropriate diagnostic criteria for AS are lacking, but classification criteria are available. 
According to the modified New York criteria (table 1), the presence of radiographic sacroiliitis 
(grade at least 2 bilaterally or grade 3-4 unilaterally) in combination with one of the clinical 
criteria, is mandatory in order to classify a patient as AS 27. 
Table 1: the modified New York criteria for Ankylosing Spondylitis.
Definite ankylosing 
spondylitis
If the radiological criterion is associated with at least 1 clinical 
criterion
Clinical criteria Low back pain and stiffness for >3 months which improves with exercise, but is not relieved by rest.
Limitation of motion of the lumbar spine in both the sagittal and 
frontal planes.
Limitation of chest expansion relative to normal values correlated for 
age and sex.
Radiological criterion Sacroiliitis grade ≥2 bilaterally or grade 3-4 unilaterally
Grading of radiographic sacroiliitis
        Grade 0 Normal
        Grade 1 Suspicious changes
        Grade 2 Minimal abnormality – small localized areas with erosion or sclerosis, without alteration in the joint width
        Grade 3
Unequivocal abnormality – moderate or advanced sacroiliitis with 
one or more of: erosions, evidence of sclerosis, widening, narrowing 
or partikal ankylosis
        Grade 4 Severe abnormality – total ankylosis
Adapted from van der Linden et al. A&R 1984;27:361-8 27.
However, it often takes 6-8 years from the onset of symptoms before radiographic 
sacroiliitis can be detected on plain radiographs 28-30. It is thought that radiographic changes 
(erosions, sclerosis, joint space narrowing/widening, ankylosis) reflect the consequences of 
inflammation rather than inflammation itself 28-30 (figure 1). 
However, the underlying mechanisms of the inflammatory process leading to new bone 
formation are not fully understood 31, 32. Moreover, not every patient with symptoms will 
develop radiographic sacroilitis 28-30. AS is therefore considered as the prototype disorder 
of the whole concept of spondyloarthritis (SpA), which is a group of interrelated rheumatic 
diseases with common features (figure 2). 
Furthermore, in some SpA patients the disabling problems are not the back pain and/or 
stiffness of the back, but predominantly peripheral and/or extra-articular complaints, at 
least during some periods of the disease course. To be able to classify the whole group of 
SpA, the Amor and ESSG criteria have been developed in the 1990s. In these classification 
General introduction |
12 | Chapter 1
	  






















Modified	  New	  York	  Criteria	  1984	  
Sacroiliitis	  on	  MRI	  
Axial	  spondyloarthritis	  
Figure 1: Axial spondyloarthritis. Reprinted from Rudwaleit et al. A&R 2005;52:1000-8 29.
Figure 2: The concept of spondyloarthritis (SpA). Reprinted from the ASAS website 48.
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criteria, radiographic sacroiliitis is included as one of the SpA-features, but in contrast to 
the modified New York criteria, it is not a mandatory criterion 33, 34. The entry criteria of the 
ESSG criteria are inflammatory back pain (IBP) and/or peripheral arthritis. According to the 
ESSG criteria, patients with at least one of the entry criteria in combination with one minor 
criterion are classified as having SpA. The Amor criteria consist of a list of signs, none of 
which is required to classify a patient as having SpA 9, 35, 36.
	  
Sacroiliitis	  on	  
imaging*	  plus	  ≥1	  
SpA-­‐feature
In	  patients	  with	  ≥3	  months	  back	  pain	  (with/without	  
peripheral	  manifestations)	  and	  age	  at	  onset	  <45	  years	  
HLA-­‐B27	  plus	  ≥2	  
other	  SpA-­‐featuresOR
SpA-­‐features
·∙ 	   Inflammatory	  back	  pain	  (IBP)
·∙ 	   Arthritis**
·∙ 	   Enthesitis	  (heel)
·∙ 	   Uveitis
·∙ 	   Dactylitis
·∙ 	   Psoriasis
·∙ 	   Crohn’s/	  ulcerative	  colitis
·∙ 	   Good	  response	  to	  NSAIDs
·∙ 	   Family	  history	  for	  SpA
·∙ 	   HLA-­‐B27
·∙ 	   Elevated	  CRP
*Sacroiliitis	  on	  imaging
·∙ 	   Active	  (acute)	  
inflammation	  on	  MRI	  
highly	  suggestive	  of	  
sacroiliitis	  associated	  
with	  SpA
·∙ 	   Definite	  radiographic	  
sacroiliitis	  according	  to	  
the	  modified	  New	  York	  
criteria
In	  patients	  with	  peripheral	  manifestations	  ONLY:
Arthritis**	  or	  enthesitis	  or	  dactylitis
plus
≥1	  SpA-­‐feature
·∙ 	   Uveitis
·∙ 	   Psoriasis
·∙ 	   Crohn’s/	  ulcerative	  colitis
·∙ 	   Preceding	  infection
·∙ 	   HLA-­‐B27
·∙ 	   Sacroiliitis	  on	  imaging*
≥2	  other	  SpA-­‐features
·∙ 	   Arthritis**
·∙ 	   Enthesitis
·∙ 	   Dactylitis
·∙ 	   IBP	  ever
·∙ 	   Family	  history	  for	  SpA**Peripheral	  arthritis:	  usually	  predominantly	  lower	  limb	  and/or	  assymmetric	  arthritis
Figure 3: Combined use of the ASAS criteria for axial SpA and ASAS criteria for peripheral SpA in the 
entire SpA population. Reprinted from Rudwaleit et al. ARD 2011;70:25-31 23.
Both the ESSG and Amor classification criteria were developed before Magnetic Resonance 
Imaging (MRI) became widely available. Yet, the introduction of MRI in the field of SpA made 
it possible to detect inflammation in the SI-joints and spine, which is considered the first 
step in the development of structural damage as seen in AS 31, 32. In 2009, the Assessment 
of SpondyloArthritis international Society (ASAS) proposed two classification criteria 
sets for SpA (figure 3). One set can be applied in patients with predominantly peripheral 
manifestations (peripheral SpA) 23 and the other set in patients with predominantly axial 
manifestations (axial SpA) 30. For the first time in history, MRI was included in classification 
criteria for SpA and plays an important role in especially the axial SpA criteria. The axial 
SpA criteria can only be applied in patients with back pain for more than 3 months and the 
onset of back pain before the age of 45 years and consists of two arms. In the imaging arm, 
patients can be classified as axial SpA if one SpA-feature is present in addition to sacroiliitis 
on MRI or radiographs sacroiliitis 30. Patients can be classified as axial SpA in the clinical arm 
if in addition to HLA-B27 positivity two other SpA-features are present 30. The classification 
criteria for peripheral SpA can be applied in patients with currently peripheral manifestations 
only. In order to classify a patient as having peripheral SpA, other SpA-features should be 
present in addition to peripheral arthritis compatible with SpA (usually asymmetric and/
or predominantly involvement of the lower limb), enthesitis or dactylitis. A patient with 
current peripheral arthritis/enthesitis/dactylitis can fulfill the ASAS peripheral SpA criteria 
if at least one of the following SpA-feature is present: uveitis, psoriasis, IBD, preceding 
infection (urethritis/cervicitis or diarrhea within one month before the onset of arthritis/
enthesitis/dactylitis), HLA-B27 positivity or sacroiliitis on imaging. A patient with current 
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peripheral arthritis/enthesitis/dactylitis can also fulfill the ASAS peripheral SpA criteria if 
at least two of the following SpA-features are present: peripheral arthritis compatible with 
SpA (present or past), enthesitis (present or past), dactylitis (present or past), IBP ever, or a 
positive family history for SpA (figure 3) 23. Definitions of all SpA-features are given in table 2.
Table 2: Definitions of SpA-features applied in the ASAS classification criteria for axial and peripheral 
spondyloarthritis.
SpA-feature Definition
Inflammatory back pain 
(IBP)
IBP according to experts: 4 out of 5 of the following paramters 
present:
1. Age at onset <40 years
2. Insidious onset
3. No improvement with exercise
4. No improvement with rest
5. Pain at night (with improvement upon getting up)
Arthritis Past or present active synovitis diagnosed by a physician
Enthesitis (heel) Heel enthesitis: past or present spontaneous pain or tenderness at 
examination of the site of the insertion of the Achilles tendon or 
plantar fascia at the calcaneus
Uveitis Past or present uveitis anterior, confirmed by an ophthalmologist
Dactylitis Past or present dactylitis, diagnosed by a physician
Psoriasis Past or present psoriasis, diagnosed by a physician
Inflammatory bowel 
disease (IBD)
Past or present Crohn’s disease or ulcerative colitis, diagnosed by a 
physician
Good response to 
NSAIDs
24-48 hours after a full dose of a non-steroidal anti-inflammatory 
drug (NSAID) the back pain is not present anymore or is much better
Family history Presence in first-degree (mother, father, sisters, brothers, children) 
or second-degree (maternal and paternal grandparents, aunts, 





5. Inflammatory Bowel Disease
Elevated CRP C-reactive protein (CRP) concentration above upper normal limit 
in the presence of back pain, after exclusion of other causes for 
elevated CRP concentration
HLA-B27 Positive testing according to standard laboratory techniques
Sacroiliitis by 
radiographs
Bilateral grade 2-4 or unilateral grade 3-4 sacroiliitis on plain 
radiographs, according to the modified New York criteria
Sacroiliitis by MRI Active inflammatory lesions of sacroiliac joints with definite bone 
marrow edema/osteitis, suggestive of sacroiliitis associated with 
spondyloarthritis
Reprinted from Rudwaleit et al. ARD 2009;68:777-83 30.
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Since the clinical presentation of SpA is heterogeneous and because of the lack of 
diagnostic criteria, diagnosing SpA can be challenging for physicians, especially in the 
absence of (radiographic) sacroiliitis. Because no single shared distinguishing feature exists, 
the diagnosis is usually based on the combination of symptoms, the findings of physical 
examination, imaging and laboratory results 37, 38. To assist in the diagnostic process, a tool 
based on Bayes’ theorem has been developed by a group of rheumatologists, incorporating 
all relevant SpA-features 35. The formula of this tool, which is known as the Berlin algorithm, 
allows calculation of the disease probability for any individual patient with IBP according to 
the clinical presentation, and the final post-test probability may help in making the diagnosis 
of axial SpA. In general, three other SpA-features in addition to the presence of IBP result 
in a probability of about 90% for axSpA. However, the drawback of this algorithm is that it 
is developed for patients with IBP, while it is becoming more and more evident that many 
patients with axial SpA do not have IBP, and vice versa, that many patients with IBP do not 
have axial SpA 8, 39.
Magnetic Resonance Imaging
To provide a solid basis for the application of MRI of the sacroiliac joints (MRI-SI) in the 
ASAS axial SpA criteria, ASAS developed recommendations how to perform an optimal MRI-
SI and how to define a positive MRI-SI 40, 41. Inflammatory changes are best visualized by 
a water-sensitive sequence; a T2-weighted turbo spin-echo sequence with fat-saturation 
(T2 TSE fatsat) or a short tau inversion recovery (STIR) sequence with a high resolution. 
Figure 4: Scout view of the SI-joints in a semi-coronal section orientation along the long axis of the 
sacral bone.
However, the STIR sequences and the T1 post-Gd sequences give largely overlapping 
information 42, 43. Therefore, the administration of Gd is not recommended by ASAS 40.
The clear presence of one BME lesion highly suggestive of SpA visible on a T2 or STIR 
sequence (or alternatively osteitis (on T1 post-Gd)) located in the typical anatomical areas 
The latter has a robust performance 
and a high sensitivity and is therefore 
preferred. Structural changes such 
as erosions and fatty depositions are 
best visualized using a T1-weighted 
turbo spin-echo sequence (T1 TSE). 
Therefore, ASAS recommends to 
perform T1 TSE sequence and STIR 
sequence of the SI-joints in a semi-
coronal section orientation along 
the long axis of the sacral bone with 
slices of 4mm thickness using an MR 
machine with a field strength of 1.5 
Tesla (figure 4) 40. 
Alternatively, the administration of 
a paramagnetic contrast medium 
(gadolinium-chelate; Gd) in a T1 TSE 
sequence with fat saturation (T1 
TSE fatsat) could be considered as it 
occasionally gives additional value, 
especially in depicting enthesitis and 
capsulitis. 
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(subchondral or periarticular bone marrow) on at least two consecutive slices or the clear 
presence of several lesions on a single slice allows to define the MRI-SI as positive. The 
presence of isolated synovitis, enthesitis or capsulitis without the presence of BME (or 
osteitis) is only occasionally seen 42 and is not sufficient for a positive MRI-SI 41. Furthermore, 
the presence of isolated structural lesions without concomitant BME (or osteitis) does not 
suffice for the definition of a positive MRI-SI either 41.
In addition to the dichotomous evaluation of an MRI-SI according to the ASAS definition, 
MRI-SIs can be evaluated in a semi-quantitative manner, for example according to the 
Spondyloarthritis Research Consortium of Canada (SPARCC) method 44. The SPARCC-score 
ranges from 0 to 72 points and has a high sensitivity to change. Therefore, the SPARCC-score 
is of particular value in clinical trials, testing the efficacy of (biological) treatment in terms of 
changes in inflammation over time.
Treatment
In 2006, ASAS in collaboration with EULAR developed evidence -based recommendations 
for the management of AS in order to contribute to the improvement of outcomes in 
patients 45. Treatment should not only aim on improving signs and symptoms, but also on 
improving function and socioeconomic factors as well as preventing structural damage, 
thereby improving the quality of life of patients 46. The standard treatment of AS patients 
consists of a combination of non-pharmacological and pharmacological treatment. The non-
pharmacological treatment comprises education, exercise, physical therapy, rehabilitation, 
patient associations and self-help groups. Pharmacological treatment comprises treatment 
with non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclo-oxygenase 2 
(COX-2) inhibitors, as first line drug. NSAIDs may rapidly improve spinal pain, peripheral joint 
pain and function. In patients with peripheral complaints, disease modifying antirheumatic 
drugs (DMARDs), including sulfasalazine and methotrexate, might be considered, but effect 
on axial complaints is lacking. Moreover, in patients with persistently high disease activity 
despite conventional treatments according to the ASAS recommendations, treatment with 
tumor necrosis factor-alpha (TNF-α) inhibitors should be considered 45.
Outline of this thesis
The recognition and treatment of SpA has been improved a lot over the last 10-15 years. 
These improvements resulted, inter alia, in the development of the ASAS classification 
criteria. At the same time, the ASAS classification criteria are contributing to further 
enhancements. Moreover, the treatment armamentarium has been broadened with TNF-α 
inhibitors.
However, there are still major challenges in recognizing, diagnosing, classifying and treating 
(early) SpA patients. Those aspects will be addressed in this thesis in three dedicated parts. 
Part I focuses on the early recognition of SpA and on the evaluation of classification criteria 
of SpA. The focus of part II is on the role of imaging in the early diagnosis of SpA. The current 
recommendations for management of AS and axSpA and the evidence as the base for these 
recommendations is the focus of part III.
The studies described in part I and II are largely performed in the SPondyloArthritis Caught 
Early (SPACE)-cohort and the DEvenir des Spondylarthropathies Indifférenciées Récentes 
(the evaluation of outcome of recent onset undifferentiated spondyloarthritis; DESIR)-
cohort 25. Both cohorts include patients with back pain to study - among other research 
questions - how patients with SpA can best be differentiated from patients without SpA, 
which factors are predictive for SpA and which factors are predictive for the progression of 
the disease. Therefore, information about the presence/absence of all SpA-features in all 
patients is collected in both the SPACE-cohort and the DESIR-cohort. Besides the similarities 
17
between the two cohorts, small differences exist. The DESIR-cohort is a purely French 
cohort, with 25 participating centers across France, while the SPACE-cohort started as a 
Dutch single-center cohort in the LUMC. In the meantime, the SPACE-cohort has become 
an international multi-center cohort with participating centers in Norway, Italy and Sweden 
in addition to other participating hospitals in the Netherlands as well. Another difference 
between the DESIR-cohort and the SPACE-cohort is that the DESIR-cohort includes patients 
with inflammatory back pain (≥3 months, but <3 years) aged 18-50 with a suspicion of SpA 
while the SPACE-cohort includes patients with chronic back (pain ≥3 months, but ≤2 years) 
with the onset <45 years. As a consequence, the populations in both cohorts are slightly 
different.
One of the research questions we have is to assess the performance of existing classification 
criteria, including the recently developed ASAS axial SpA and peripheral SpA criteria. It is 
of particular interest to know the performance of the ASAS axial SpA and peripheral SpA 
criteria as this has not yet been evaluated in another cohort than the validation cohort. 
Some experts in the field impeach the ASAS axial SpA criteria as they question whether 
patients fulfilling the clinical arm reflect the same disease as patients fulfilling the imaging 
arm. Since the inclusion criteria of the SPACE-cohort yield also the inclusion of a control 
group with similar age, gender and symptom duration as the patients with axial SpA, the 
SPACE-cohort offers the opportunity to investigate this research question. The results of 
this investigation, as well as an extensive description of the SPACE-cohort, are presented 
in chapter 2.  Some experts in the field who fear that the ASAS peripheral SpA criteria are 
not specific enough impeach the ASAS peripheral SpA criteria too. Therefore, a very similar 
analysis on the performance of the various classification criteria as described in chapter 2, 
is performed in the Early Arthritis Clinic (EAC)-cohort in chapter 3.
The Leiden EAC-cohort is a population-based prospective cohort, started in 1993 in 
order to detect and treat inflammatory disorders early in the disease state, especially 
early rheumatoid arthritis (RA). Patients with suspected arthritis are referred by general 
practitioners to the LUMC as soon as possible, and are seen within 2 weeks from referral. 
Patients are included in the EAC-cohort if arthritis of recent onset (<2 years) is confirmed by 
the rheumatologist 47. Since it is known that up to 67% of the SpA patients with a symptom 
duration <2 years report arthritis as the first symptom, SpA and PsA are important parts of 
the differential diagnosis. Therefore, the EAC-cohort is a suitable cohort to try to answer this 
research question.
In chapter 4, the performance of the Berlin algorithm is evaluated. The inclusion criterion 
of the Berlin algorithm is IBP, however, the increasing evidence that not all patients with 
axial SpA have IBP stimulated us to propose two modifications of the algorithm. We test 
these proposed modifications in the SPACE-cohort since the inclusion criteria of the SPACE-
cohort are chronic back pain (and not IBP) thereby offering the possibility of yielding axial 
SpA patients without IBP. In addition, we tested the proposed modifications in the original 
validation cohort of the ASAS classification criteria (chapter 4).
The focus of part II is on the role of imaging in classifying and diagnosing patients. It is known 
that it is challenging to reliably judge imaging of the SI-joints, especially plain radiographs. 
However, the consequences of a different judgment of the same set of imaging by different 
readers on the classification of patients, and in turn the consequences of a possibly other 
classification on the access to treatment is not known.  As the DESIR-cohort contains 
judgments of MRIs and X-rays of the SI-joints by local radiologists and/or rheumatologists 
as well as judgments of the same images by central trained readers, this cohort offered the 
unique opportunity to study this. In chapter 5 the evaluation of X-rays of the SI-joints by 
local readers is compared to the evaluation by central readers in terms of agreement on 
abnormal versus normal SI-joints permitting to diagnose radiographic sacroiliitis. Chapter 
6 is about the role of differences in judgments by local readers and central readers of all 
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imaging (combined radiographs and MRI of the SI-joints) and the effect on the ASAS axial 
SpA criteria.
Nowadays, more and more trials are being performed in patients with non-radiographic axial 
SpA. Eligibility of patients for these trials is often based on the judgment of local readers on 
a positive/negative MRI (ASAS definition). Within clinical trials, semi-quantitative scoring 
methods like the SPARCC-score method are used to measure changes in inflammation over 
time, evaluated by central trained readers. However, interreader reliability of the SPARCC-
score in terms of smallest detectable change (SDC) is not known. Moreover, it is known that 
inflammation may spontaneously change over time, but it is not sufficiently investigated 
how many SPARCC-score points these spontaneous changes comprise. Furthermore, in 
case one needs to link the read for eligibility to the efficacy reading, it is not known what 
SPARCC-score cut-off value the equivalent is of a positive MRI (ASAS definition). These three 
questions are addressed in chapter 7.
As the field of SpA is rapidly moving, the ASAS in collaboration with EULAR intends to update 
the current recommendations for both the treatment of AS with TNF-α inhibitors and the 
recommendations for the management of AS which is the focus of part III. Preambles to these 
updates, up-to-date overviews regarding the implementation of these recommendations 
worldwide and regarding clinical trials and publications on AS therapy were needed. First, 
a comparison of national recommendations on TNF-α inhibitor use is made, with a focus 
on the similarities and differences compared to the ASAS/EULAR recommendations of 
2006 (chapter 8). Second, a systematic literature review about the management of AS with 
non-pharmacological treatment and non-biologic drugs is performed (chapter 9). Third, 
a systematic literature review on biologic treatment of AS is performed (chapter 10). The 
results of these studies are presented to the working group of international experts who 
met during ASAS workshops to develop the new management recommendations, presented 
in chapter 11.
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Abstract
Objectives
The objectives of the study are to describe the Spondyloarthritis Caught Early (SPACE) 
cohort, present the performance of various SpA classification criteria and compare patients 
fulfilling the imaging arm with patients fulfilling the clinical arm of the Assessment of 
Spondyloarthritis international Society (ASAS) axSpA criteria on demographics, presence of 
SpA-features and level of disease activity.
Methods
Patients with back pain (≥3 months but ≤2 years, onset <45 years) visiting the rheumatology 
outpatient clinic of the Leiden University Medical Center were included in the SPACE-
cohort. Patients were classified according to the modified New York (mNY), ESSG, Amor 
and ASAS axSpA criteria. The sensitivity and specificity of criteria were tested against a 
rheumatologist’s diagnosis.
Results
In total, 157 patients were included; 92 patients fulfilled any criteria, 11 fulfilled the mNY 
(sensitivity 16.9%, specificity 100%), 68 the ESSG (sensitivity 64.6%, specificity 71.7%), 48 
the Amor (sensitivity 47.7%, specificity 81.5%) and 60 the ASAS axSpA criteria (sensitivity 
84.6%, specificity 94.6%). Of those 60 patients, 30 fulfilled the imaging arm and 30 the 
clinical arm. Patients in the imaging arm are statistically significantly more often male, have 
a longer symptom duration and less often a positive family history for SpA than patients 
fulfilling the clinical arm. Patients in both arms are very similar regarding all other SpA-
features and level of disease activity.
Conclusion
The inclusion criteria of the SPACE-cohort yield the same high numbers of SpA patients 
compared with referral strategies like inflammatory back pain, HLA-B27+ or sacroiliitis, yet 
are easier to apply. The ASAS axSpA criteria outperformed the other criteria; 38.2% fulfilled 
the ASAS axSpA criteria. Patients fulfilling the clinical arm of the ASAS axSpA reflect a group 
of patients similar to those fulfilling the imaging arm.
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Introduction
SpA comprises a group of interrelated rheumatic diseases, including AS, PsA and arthritis 
associated with IBD 1. The diagnosis is challenging because of the lack of diagnostic criteria 
for (early) SpA. 
Over the years, several criteria sets have been developed to classify patients with SpA. The 
modified New York (mNY) criteria are available to classify patients with AS 2, however, they 
are of limited use in early disease or other subtypes of SpA 3. The ESSG and the Amor criteria 
are widely used to define the whole concept of SpA 4, 5. More recently, the Assessment 
of  Spondyloarthritis international Society (ASAS) developed criteria to classify patients 
with predominantly axial SpA (axSpA) and criteria to classify patients with predominantly 
peripheral SpA 6, 7. It is possible to classify patients as having axSpA according to the imaging 
arm if they have sacroiliitis on radiographs and/or MRI plus at least one additional SpA 
feature, or according to the clinical arm based on HLA-B27 positivity in combination with 
at least two other SpA-features 6. Yet the question arose of whether patients fulfilling the 
clinical arm reflect a group of patients similar to those fulfilling the imaging arm. 
The ASAS axSpA criteria should be applied in patients with back pain (almost daily for 
≤3 months, onset <45 years) of unknown origin, which is considered to be the leading 
symptom of axSpA 8. However, it is difficult to recognize axSpA in an early stage among the 
enormous number of patients with back pain, since the clinical presentation of axSpA is 
very heterogeneous and there is no single shared distinguishing feature 9. Hence some have 
stated that not just chronic back pain, but specific inflammatory back pain (IBP) is typical of 
axSpA 10. Therefore IBP is often proposed as one of the referral parameters 11, 12. However, 
there is increasing evidence that not all patients with axSpA have IBP, and vice versa, which 
is also evident from the relatively low sensitivity and specificity of IBP criteria (e.g. 79.6% 
and 72.4%, respectively, for the ASAS IBP criteria) 3, 13-16. 
The SpondyloArthritis Caught Early (SPACE) cohort in the Leiden University Medical Center 
(LUMC) in Leiden, the Netherlands, uses chronic back pain (≥3 months but ≤2 years, onset 
<45 years) as the only inclusion criteria. These inclusion criteria are, to our knowledge, 
unique for a SpA cohort. Other early back pain cohorts like ESPAC (the Early SPondyloArthritis 
Clinic) and DESIR (DEvenir des Spondylarthropathies Indifférenciées Récentes) included only 
patients with IBP 17, 18. 
The goal of this study is to give a description of the characteristics of the patients included 
in the SPACE-cohort. The percentage of patients fulfilling at least one of the classification 
criteria sets for SpA is given. Second, the performance of the various classification criteria 
for SpA is tested. Furthermore, demographics, number of SpA-features and level of disease 
activity in patients fulfilling the imaging arm and patients fulfilling the clinical arm of the 
ASAS axSpA criteria are compared.
Patients and methods
Patients
The SpondyloArthitis Caught Early (SPACE) cohort started in January 2009 and is an ongoing 
project. General practitioners as well as other specialists such as ophthalmologists and 
gastroenterologists were informed about the start of the SPACE-cohort and about the 
inclusion criteria. Patients aged 16 years and older with chronic (almost daily) back pain 
for ≥3 months but ≤2 years with the onset before the age of 45 years referred to the 
rheumatology outpatient clinic of the LUMC were included after signing informed consent. 
The SPACE study protocol was approved by the local medical ethics committee of the 
LUMC. Patients could not be included if other painful conditions not related to SpA could 
interfere with the evaluation of disease activity or if any reason was present that was likely 
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to invalidate informed consent or limit the ability of the subject to comply with the protocol 
requirements.
Assessments and visits
All patients underwent a diagnostic workup at baseline; descriptions of the performed 
diagnostic workup follow below. Thereafter only patients with definite or possible SpA were 
included for follow-up visits after 3, 12 and 24 months. Definite axSpA is defined as a patient 
fulfilling the ASAS axSpA criteria. Possible SpA is defined as the presence of at least one 
of the following specific SpA-features [high likelihood ratio (LR+) 6, 14: HLA-B27 positivity, 
positive family history for SpA, sacroiliitis (MRI or radiographs), acute anterior uveitis] or 
at least two of the following less-specific SpA-features [lower LR+: IBP (ASAS definition 16), 
(heel) enthesitis, peripheral arthritis, psoriasis, IBD, good response to NSAIDs or elevated 
levels of ESR or CRP], but not fulfilling any of the classification criteria. Annual visits after 
the first 2 years were scheduled for patients with definite axSpA (ASAS criteria). Unless 
otherwise specified, all measurements were performed by one of the researchers (RvdB or 
MdH) during every visit.
Physical examination
In total, 68 joints were examined for tenderness and 66 for swelling. Entheses were examined 
according to the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) index 19. Spinal 
mobility was assessed by measuring chest expansion, occiput to wall distance, modified 
Schober test, cervical rotation, lateral spinal flexion and intermalleolar distance as described 
in the ASAS handbook 20. The tragus-to-wall distance was derived from the OWD by adding 
8 cm to the OWD score. By doing so, the value of zero in the OWD corresponds to a score 
of zero in the calculation of the BASMI 21. Based on these measurements, the BASMI was 
calculated 21.
Patient-reported questionnaires
Patients completed the BASDAI 22 and BASFI 23.
Other parameters
Overall assessment of disease activity was done by the physician on an 11-point numerical 
rating scale (NRS), 0 representing inactive disease and 10 extremely active disease. The 
presence (past or current) of extra-spinal and extra-articular manifestations (acute anterior 
uveitis, urethritis, balanitis, cervicitis, IBD and psoriasis, enthesitis) and a positive family 
history of SpA (AS, reactive arthritis, psoriasis, IBD, uveitis) all according to the definition of 
the ASAS criteria 6 was recorded. Treatment with NSAIDs, DMARDs and biologic therapies 
was recorded. NSAID intake is recorded according to the ASAS recommendations 24. A 
good response of back pain to a full dose of NSAID was defined as not present anymore or 
much better 6. Furthermore, the Ankylosing Spondylitis Disease Activity Score (ASDAS) was 
calculated 25. More information about performed measurements during the visits can be 
found in the supplementary data, available at Rheumatology Online.
Laboratory assessment
The laboratory assessment during each visit consisted of measurements of ESR (Westergren 




MR imaging was performed on a 1.5T (Philips Medical Systems, Best, Netherlands) T1 
weighted turbo spin echo (T1TSE) (TR 550/TE 10) and short tau inversion recovery (STIR) (TR 
2500/TE 60) sequences were acquired, coronal oblique of the SI joints (MRI-SI). The slice 
thickness was 4 mm. Radiographs of the pelvis (anterior-posterior view) were performed at 
baseline, after 1 and 2 years, and thereafter every second year. 
SI joints, both on MRI and on radiograph, were independently scored by two trained readers 
(MdH and RvdB). MRI-SIs were scored on the presence of bone marrow edema (BME) 
according to the ASAS/OMERACT definition 26, according to the Spondyloarthritis Research 
Consortium of Canada (SPARCC) score 27 and on the presence of capsulitis/enthesitis. All 
radiographs of the SI joints (X-SIs) were scored according to the modified mNY criteria 2. 
In case the first two readers disagreed on an image [MRI (ASAS/OMERACT definition) or 
radiograph], a third trained reader (VN) served as adjudicator. If two of three readers scored 
positive, the image was marked positive. Moreover, all positive X-SIs were checked by a 
senior rheumatologist (DvdH) who gave a final judgement about the X-SI. All readers were 
blinded for clinical and laboratory data as well as the results of the other imaging modality.
Diagnosing the patients
A rheumatologist experienced in the field of SpA diagnosed all patients as predominantly 
axSpA, both axSpA and peripheral SpA, or no SpA based on all collected information, including 
imaging and HLA-B27 status. For this analysis, patients with only axSpA were used. In the 
case of no SpA, the rheumatologists filled out another suitable diagnosis. Furthermore, the 
rheumatologist marked the level of confidence about the diagnosis, either SpA or no SpA, 
on an 11-point NRS from 0 (not confident at all) to 10 (very confident).
Classification of patients
All patients were classified according to the Amor, ESSG, mNY and ASAS axSpA criteria 2, 4-6. 
In addition, both the ESSG and AMOR criteria were modified by judging active sacroiliitis on 
MRI similarly to radiographic sacroilitis. 
Data analysis
For the present analysis, only data of the baseline visit were used. First, it was investigated 
how many patients fulfilled at least one of the classification criteria sets for SpA, shown in 
Venn diagrams. 
Next, the number of patients diagnosed as axSpA according to the rheumatologist was 
described. The diagnosis of the rheumatologist served as external standard to test the 
performance of the various classification criteria. The performance was determined by 
calculating sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood 
ratio (LR-). For further analyses, the ASAS axSpA criteria set was selected to differentiate 
between SpA and no SpA patients. Characteristics of the patients were described using 
t-tests and χ2-tests. In a following step, the ASAS axSpA criteria were studied in more detail. 
Patients fulfilling the clinical arm and patients fulfilling the imaging arm were compared 
on demographics, the presence of SpA-features and level of disease activity. Furthermore, 
within the imaging arm, patients with sacroiliitis on radiograph were compared with patients 
with sacroiliitis on MRI only, also by t-tests and χ2-tests. 
Missing values for the presence of SpA-features were interpreted as being absent. All 
analyses were performed using SPSS version 17. P-values <0.05 were considered significant.
Performance classification criteria in the SPACE-cohort |
28 | Chapter 2
Results
Performance of classification criteria
In total, 157 patients were included in the SPACE-cohort. The mean age at inclusion was 
31.2 (SD 12.6) years, the mean symptom duration was 13.5 (SD 7.2) months and 33.1% were 
male. Of the 157 patients, 92 (58.6%) fulfilled any classification criteria set at baseline. Sixty 
(38.2%) patients fulfilled the ASAS axSpA criteria; this percentage has been similar over the 
years the SPACE-cohort has been running (40.4% in 2009, 36.2% in 2010, 38.9% in 2011 and 
34.1% in 2012). Thirty-nine of these 60 patients fulfilled at least one other criteria set as 
well. Sixty-eight (43.3%) patients fulfilled the ESSG criteria; 53/68 fulfilled at least one other 
criteria set as well. Forty-eight (30.6%) patients fulfilled the Amor criteria; the majority of 
the patients (45/48) also fulfilled another criteria set. Eleven (7.0%) patients fulfilled the 
mNY criteria; all fulfilled at least one other classification criteria as well. Nine patients 
fulfilled all four criteria sets, 15 patients fulfilled three criteria sets (14 the combination of 
ASAS axSpA, ESSG and Amor and 1 the combination of ASAS axSpA, Amor and mNY) and 38 
patients fulfilled two criteria sets (16 both ASAS axSpA and ESSG, 7 both ASAS axSpA and 

















Not fulfilling these criteria 
65 
Figure 1: Venn-diagram representing the overlap between the various classification criteria for axial 
SpA.
To calculate the performance of the various classification criteria, the diagnosis of the 
rheumatologist was used as external standard. The rheumatologist diagnosed 65 patients 
(41.4%) as axSpA and 92 patients as no SpA. The mean level of confidence about the diag-
nosis is similar for patients fulfilling the ESSG, Amor and ASAS axSpA criteria (6.2-6.7 out of 
10), but higher for patients fulfilling the mNY criteria (7.8 out of 10) (table 1). The mNY cri-
teria showed the lowest sensitivity (16.9%) but highest specificity (100%). The Amor criteria 
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showed a sensitivity of 47.7%, which increased to 67.7% in the modified version, without 
a decrease in specificity (71.7%). The ESSG criteria showed a sensitivity of 64.6%, which in-
creased to 75.4% in the modified version without a decrease in specificity (81.5%). The ASAS 
axSpA criteria outperformed all other classification criteria, including the modified Amor 
and modified ESSG criteria, in terms of sensitivity (84.6%), specificity (94.6%), LR+ (15.6) and 
LR- (0.16) (table 1). For all further analyses we used the ASAS axSpA criteria for the defini-
tion if a patient fits into the category axSpA or no SpA. This criterion is exactly defined and 
reproducible for readers, while the diagnosis by the rheumatologist is not. 
Table 1: Performance of the various classification criteria for axial spondyloarthritis with the 
diagnosis and the level of confidence about the diagnosis of axSpA of rheumatologist as external 
standard for axSpA versus no SpA.
axSpA patients versus no 
axSpA patients
axSpA patients (n=65), 
N positive (sensitivity)
no axSpA patients (n=92), 
N negative (specificity) LR+ LR
ASAS axSpA 55 (84.6) 87 (94.6) 15.6 0.16
mNY 11 (16.9) 92 (100) 15.6 0.99
ESSG 42 (64.6) 66 (71.7) 2.3 0.49
Amor 31 (47.7) 75 (81.5) 2.6 0.64
Modified ESSG (with MRI) 49 (75.4) 66 (71.7) 2.7 0.34
Modified Amor (with MRI) 44 (67.7) 75 (81.5) 3.7 0.40
ESSG, European Spondylarthropathy Study Group; ASAS, Assessment of SpondyloArthritis international 
Society (ASAS); mNY, modified New York; LR+, positive likelihood ratio; LR-, negative likelihood ratio. 
Level of confidence about the diagnosis SpA on an 11-point NRS from 0 (not confident at all) to 10 
(very confident).
Patient characteristics
The majority of the patients referred to the SPACE-cohort were from the Leiden area; over 
the years, 17.0%, 7.3%, 10.2% and 17.7% of the referrals in 2009, 2010, 2011 and 2012, 
respectively, were from outside the Leiden area. 
Thirty-three patients were not included for follow-up because of the lack of specific SpA-
features; 13 patients did not have any SpA-features and the remaining 20 patients had only 
one less specific SpA feature (1 patient with peripheral arthritis only, 1 patient with heel 
enthesitis only, 6 patients with a good response to NSAIDs only, 12 patients with IBP only). 
Of the patients included for follow-up, 64 had possible SpA and the remaining 60 patients 
fulfilled the ASAS axSpA criteria. 
Patients classified as axSpA according to the ASAS axSpA criteria were compared with the 
group of noaxSpA patients including possible SpA patients and patients excluded for follow-
up, revealing some statistically significant differences. AxSpA patients are more frequently 
male (p=0.001), more often have a positive family history for SpA (p=0.001), IBP (p=0.001), 
a good response to NSAIDs (p=0.004) and sacroiliitis on radiograph (p<0.001) and MRI 
(p<0.001), and are more often HLA-B27 positive (p<0.001) compared with no axSpA patients. 
Furthermore, there was a trend that axSpA patients more often have uveitis (p=0.07) and 
higher levels of ESR (p=0.08) (table 2).
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versus no axSpA 
patients
Age (years) at inclusion, mean ± SD 29.5 ± 8.7 32.3 ± 14.4 0.17
Male, n (%) 29 (48.3) 23 (23.7) 0.001
Duration of back pain (months), mean ± SD 13.4 ± 7.7 13.6 ± 6.9 0.88
HLA-B27 positive, n (%) 47 (79.7) 6 (6.2) <0.001
Pos. Fam. History SpA, n (%) 31 (51.7) 25 (25.8) 0.001
IBP, n (%) 50 (83.3) 55 (56.7) 0.001
Psoriasis, n (%) 8 (13.3) 8 (8.2) 0.31
Dactylitis, n (%) 3 (5.0) 3 (3.1) 0.55
Enthesitis, n (%) 8 (13.3) 17 (17.5) 0.49
Uveitis, n (%) 9 (15.0) 6 (6.2) 0.07
IBD, n(%) 3 (5.0) 6 (6.2) 0.76
Preceding infection, n (%) 1 (1.7) 1 (1.0) 0.73
CRP (mg/l), mean ± SD 8.4 ± 11.9 5.8 ± 6.9 0.12
ESR (mm/h), mean ± SD 14.4 ± 16.7 10.1 ± 10.6 0.08
Alternating buttock pain, n (%) 16 (26.7) 17 (17.5) 0.17
Good response to NSAIDs, n (%) 29 (48.3) 25 (25.8) 0.004
Elevated CRP/ESR, n (%) 16 (26.7) 15 (15.5) 0.09
Asymmetric lower limb arthritis, n (%) 8 (13.3) 15 (15.5) 0.71
Sacroiliitis radiograph, n (%) 11 (18.3) 1 (1.1) <0.001
Sacroiliitis MRI, n (%) 25 (41.7) 2 (2.1) <0.001
IBP, Inflammatory Back Pain; IBD, Inflammatory Bowel Disease; age, age at baseline; CRP, 
C-reactive protein; ESR, erythrocyte sedimentation rate; HLA-B27, Human Leukocyte Anti-
gen; preceding infection can be balinitis, urethritis, cervicitis and/or acute diarrhea. 
ASAS imaging arm versus clinical arm
The comparison of patients fulfilling the imaging arm with patients fulfilling the clinical 
arm revealed that patients in the imaging arm are more often male (p=0.02), have a longer 
symptom duration (p=0.04) and less often have a positive family history for SpA (p=0.001) 
than patients fulfilling the clinical arm. However, patients fulfilling the clinical arm reflect a 
group of patients similar to those fulfilling the imaging arm with respect to the presence of 
other SpA-features and level of disease activity (table 3). Nevertheless, the mean level of 
confidence about the diagnosis axSpA in patients fulfilling the clinical arm of the ASAS axSpA 
criteria (4.9 ± 1.5) is lower in comparison to the level of confidence about the diagnosis in 
patients fulfilling the imaging arm (7.7 ± 0.8). Within the imaging arm, patients with and 
without sacroiliitis on radiographs were compared. Remarkably, there was no difference in 
symptom duration (table 3).
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Table 3: Characteristics of patients in the clinical arm compared to patients in the imaging arm of the 
ASAS axSpA criteria.
Imaging arm, n=30 Clinical- 
arm, n=30
P-value 
imaging arm vs 
clinical armmNY+, n=11 mNY-, n=19 Total, n=30
Age (years) at inclusion, 
mean ± SD 28.6 ± 9.6 32.9 ± 8.7 31.2 ± 9.0 28.2 ± 8.4 0.14
Male, n (%) 8 (72.7) 11 (57.9) 19 (63.3) 10 (33.3) 0.02
Duration of back pain  
(months), mean ± SD 15.6 ± 8.5 16.0 ± 6.9 15.5 ± 7.6 11.4 ± 7.3 0.04
HLA-B27 positive, n (%) 6 (54.5) 11 (61.1) 17 (58.6) 30 (100) <0.001
Pos. Fam. History SpA, 
n (%) 4 (36.4) 5 (26.3) 9 (30.0) 22 (73.3) 0.001
IBP, n (%) 9 (81.8) 14 (73.7) 23 (76.7) 27 (90.0) 0.17
Psoriasis, n (%) 2 (18.2) 2 (10.5) 4 (13.3) 4 (13.3) 1
Dactylitis, n (%) 0 (0.0) 2 (10.5) 2 (6.7) 1 (3.3) 0.55
Enthesitis, n (%) 2 (18.2) 2 (10.5) 4 (13.3) 4 (13.3) 1
Uveitis, n (%) 1 (9.1) 1 (5.3) 2 (6.7) 7 (23.3) 0.07
IBD, n(%) 2 (18.2) 1 (5.3) 3 (10.0) 0 (0.0) 0.08
Preceding infection, 
n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.3) 0.31
CRP (mg/l), mean ± SD 6.9 ± 7.2 7.6 ± 8.6 7.3 ± 8.0 15.6 ± 18.9 0.58
ESR (mm/h), mean ± SD 11.4 ± 13.9 14.2 ± 14.8 13.2 ± 14.3 9.4 ± 14.9 0.50
Alternating buttock 
pain, n (%) 6 (54.5) 5 (26.3) 11 (36.7) 5 (16.7) 0.08
Good response to 
NSAIDs, n (%) 6 (54.5) 10 (52.6) 16 (53.3) 13 (43.3) 0.44
Elevated CRP/ESR, n (%) 4 (36.4) 5 (26.3) 9 (30.0) 7 (23.3) 0.56
Asymmetric lower limb 
arthritis, n (%) 0 (0.0) 4 (21.1) 4 (13.3) 4 (13.3) 1
Sacroiliitis radiograph, 
n (%) 11 (100) - 11 (36.7) - -
Sacroiliitis MRI, n (%) 6 (54.5)† 19 (100)† 25 (86.2) - -
BASDAI 3.7 ± 1.8 4.0 ±2.5 3.9 ± 2.3 3.9 ± 1.9 0.97
ASDAS 2.4 ± 0.7 2.5 ± 0.9 2.4 ± 0.8 2.4 ± 0.9 0.94
BASFI 3.3 ± 1.9 2.4 ± 2.2 2.7 ± 2.1 2.3 ± 2.2 0.50
BASMI 1.9 ± 0.7 1.6 ± 0.5 1.7 ± 0.6 1.6 ± 0.8 0.51
NSAID use, n (%) 9 (81.8) 15 (78.9) 24 (80.0) 22 (73.3) 0.54
DMARD use, n (%) 1 (9.1) 1 (5.3) 2 (6.7) 1 (3.3) 0.55
Biological use, n (%) 0 (0.0) 1 (5.3) 1 (3.3) 0 (0.0) 0.31
Confidence diagnosis 
axSpA, mean ± SD 7.8 ± 1.1 7.5 ± 0.6 7.7 ± 0.8 4.9 ± 1.5 <0.001
Performance classification criteria in the SPACE-cohort |
32 | Chapter 2
† Statistically significant difference between patients fulfilling the modified New York criteria and 
patients not fulfilling the modified New York criteria within the total imaging arm. IBP, Inflammatory 
Back Pain; IBD, Inflammatory Bowel Disease; age, age at baseline; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate; HLA-B27, Human Leukocyte Antigen; preceding infection can be 
balinitis, urethritis, cervicitis and/or acute diarrhea; mNY, modified New York criteria; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; 
BASMI, Bath Ankylosing Spondylitis Metrology Index; ASDAS, Ankylosing Spondylitis Disease Activity 
Score; NSAID, Non-Steroidal Anti-Inflammatory Drug; DMARD, Disease Modifying AntiRheumatic 
Drug. Level of confidence about the diagnosis SpA on an 11-point NRS from 0 (not confident at all) to 
10 (very confident).
Discussion
The SPACE-cohort consists of patients with chronic back pain (≥3 months, but ≤2 years, 
onset <45 years). The only available numbers about the prevalence of chronic back pain 
(≥3 months duration) in the Netherlands stem from the mid-90s and show a prevalence of 
20.8% 28. The majority of these patients (90%) have non-specific back pain 29. Hence Dutch 
rheumatologists in general, and likewise rheumatologists in our department, feared that 
outpatient clinics would be overloaded by patients with non-specific back pain by using 
the above-described criteria as the sole referral symptom, although we showed that this 
fear is unfounded in at least the setting of a tertiary hospital, since -60% of the patients in 
the SPACE-cohort fulfill one or more axSpA classification criteria at baseline and 41.4% of 
patients are directly diagnosed as SpA by the rheumatologist. Moreover, in the light of these 
results, the value of the numbers about prevalence of chronic back pain from the mid-90s is 
questionable, thereby indicating that more up-to-date numbers are needed. Furthermore, 
this percentage of SpA is similar to the percentage of 41.8% found by a muticenter study 
using a referral strategy consisting of the presence of either IBP or HLA-B27 or sacroiliitis 
on imaging (MRI and/or radiograph) 11 and the 35.1% found in a study using IBP or a good 
response to NSAIDs as referral symptom 12. Although the test result for the presence of HLA- 
B27 is not difficult to interpret, it is challenging for referring physicians to interpret back pain 
as inflammatory or not and to detect sacroiliitis, as demonstrated by the low agreement 
between general practitioners and rheumatologists 11. 
It could be argued that our observed prevalence of axSpA is influenced by referral bias; e.g. 
that due to increased awareness among referring physicians about the SPACE-cohort over 
time, patients from areas other than the Leiden area are referred to the LUMC or that only 
patients with a high suspicion of axSpA are referred. However, the percentage of axSpA 
among all referred patients over the years was similar, and the percentage of referrals from 
outside the Leiden area was also similar over time. Moreover, 33 of the 157 patients (21.0%) 
included at baseline had none or only one less specific SpA feature. This indicates, but does 
not prove, that there is no referral bias, thereby suggesting that the observed prevalence of 
axSpA could be generalized to primary care. In addition, other studies should investigate the 
prevalence of SpA among patients with chronic back pain >2 years previously not recognized 
as SpA. 
Around 80% of the axSpA patients in the SPACE-cohort have IBP, thereby confirming that IBP 
is not present in all SpA patients 13. Moreover, IBP is frequently (56.7%) present in no SpA 
patients in the SPACE-cohort, which is consistent with the 45.1% found in another study 11. 
These results show that IBP is not a strong discriminating feature and that if IBP was used 
as an inclusion criterion instead of chronic back pain, 20% of the SpA patients would have 
been missed. 
Depending on the presence and type of SpA-features, patients fulfill various classification 
criteria. The performance of the Amor, ESSG and ASAS axSpA criteria was better than the 
mNY criteria at the time of presentation of patients to rheumatologists. This can be explained 
by the fact that it takes several years before patients develop radiographic sacroiliitis 30. 
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Moreover, the ASAS axSpA criteria outperformed the Amor and ESSG criteria, even after 
adding active sacroiliitis (MRI) to the list of SpA-features. These results are in contrast with 
the results found in a more established cohort [the Cochin Spondyloarthritis (COSPA) cohort] 
where the ASAS axSpA criteria (fulfilled by 90% of the patients) did not have additional value 
in comparison to the Amor (fulfilled by 96% of the patients) and ESSG criteria (fulfilled by 
83% of the patients) 31. A possible explanation for these contrasting results is that the longer 
the symptom duration, the more chance that (extra-articular) features develop. To fulfill the 
Amor criteria, a patient needs to have at least 6 points representing three to four items. This 
is quite difficult to reach, especially for patients early in the disease, as in the SPACE-cohort, 
reflected by the fact that only 31% of these patients fulfilled the Amor criteria. Patients in 
the COSPA cohort, however, had a mean symptom duration of 16 years (range 8-27 years) 
and therefore fulfill the Amor criteria more easily. 
To fulfill the ESSG criteria, a patient needs to have either IBP or synovitis (asymmetric or 
predominantly in the lower limbs) and at least one additional feature. The focus of the 
SPACE-cohort is towards axSpA and not peripheral SpA, and therefore the number of 
patients with peripheral complaints (synovitis) is low. Furthermore, IBP is only present in 
about 80% of the axSpA patients in the SPACE-cohort. Therefore it is not possible for some 
patients to fulfill the ESSG criteria. 
It could be argued that the good performance of the ASAS axSpA criteria might be biased 
by the fact that patients are diagnosed by only one rheumatologist accustomed to work 
with the ASAS axSpA. However, this bias is unlikely when looking at the level of confidence 
about the diagnosis, which is similar for patients fulfilling the ESSG, Amor and ASAS axSpA 
criteria, and when looking at the small numbers of misclassifications by the ASAS axSpA 
criteria compared with the diagnoses yielded by the modified Berlin algorithm, which is a 
diagnostic tool 32. The ASAS axSpA criteria yield 3.8-6.1% of wrongly diagnosed patients as 
SpA and 7.6-10.2% of missed diagnoses compared with the modified Berlin algorithm. It 
might even support the rationale to use the ASAS axSpA criteria as diagnostic criteria in this 
type of setting with referrals to rheumatologists based on chronic back pain starting before 
the age of 45. 
Within the ASAS axSpA criteria, it was questioned whether patients fulfilling the clinical arm 
of the ASAS axSpA criteria reflect the same disease as patients fulfilling the imaging arm. We 
found that patients in the SPACE-cohort fulfilling the clinical arm were remarkably similar to 
patients fulfilling the imaging arm with respect to the presence of most SpA-features and 
level of disease activity. Another study (ABILITY I trial) found the same results 33. However, 
the difference in level of confidence about the diagnosis indicates that the judgement by the 
rheumatologist is heavily weighted by positive imaging. Furthermore, within the imaging 
arm of the ASAS axSpA criteria, patients with sacroiliitis on radiographs have the same level 
of disease activity and symptom duration as patients with sacroiliitis on MRI only. 
In conclusion, the inclusion criteria used for the SPACE-cohort, almost daily chronic back 
pain of short duration (≤2 years) starting before the age of 45 years (in accordance with the 
entry criteria for the ASAS axSpA criteria), yield the same high number of patients with SpA 
compared with other referral strategies such as IBP, HLA-B27+ or sacroiliitis, yet are easier to 
apply. Furthermore, the ASAS axSpA criteria outperformed the other classification criteria; 
almost 40% fulfilled the ASAS axSpA criteria. Patients fulfilling the clinical arm of the ASAS 
axSpA reflect a group of patients similar to those fulfilling the imaging arm.
Supplementary data
Supplementary data are available at Rheumatology Online.
Performance classification criteria in the SPACE-cohort |
34 | Chapter 2
1. Khan M. Update on spondyloarthropathies. 
Ann Intern Med 2002;136:896-907.
2. van der Linden S, Valkenburg H, Cats A. 
Evaluation of diagnostic criteria for ankylos-
ing spondylitis. A proposal for modification 
of the New York criteria. Arthritis Rheum 
1984;27:361-8.
3. Rudwaleit M, Landewé R, van der Heijde D, 
et al. The development of Assessment of 
SpondyloArthritis international Society clas-
sification criteria for axialspondyloarthritis 
(part I): classification of paper patients by 
expert opinion including uncertainty ap-
praisal. Ann Rheum Dis 2009;68:770-6.
4. Dougados M, van der linden S, Juhlin R, et 
al. The European Spondylarthropathy Study 
Group preliminary criteria for the classifica-
tion of spondylarthropathy. Arthritis Rheum 
1991;34:1218-27.
5. Amor B, Dougados M, Mijiyawa M. Classi-
fication criteria of spondyloarthropathies. 
Rev Rhum Mal Osteoartic 1990; 57:85-9.
6. Rudwaleit M, van der Heijde D, Landewé R, 
et al. The development of Assessment of 
SpondyloArthritis international Society clas-
sification criteria for axial spondyloarthritis 
(part II): validation and final selection. Ann 
Rheum Dis 2009;68:777-83.
7. Rudwaleit M, van der Heijde D, Landewé R, 
et al. The Assessment of SpondyloArthritis 
international Society classification criteria 
for peripheral spondyloarthritis and  for 
spondyloarthritis in general. Ann Rheum Dis 
2011;70:25-31.
8. Rudwaleit M, Khan M, Sieper J. The chal-
lenge of diagnosis and classification in early 
ankylosing spondylitis: do we need new cri-
teria? Arthritis Rheum 2005;52:1000-8.
9. van Tubergen A, Weber U. Diagnosis and 
classification in spondyloarthritis: iden-
tifying a chameleon. Nat Rev Rheumatol 
2012;8:253-61.
10. Braun J, Sieper J. Ankylosing spondylitis. 
Lancet 2007;369:1379-90.
11. Poddubnyy D, Vahldiek J, Spiller I, et al. Eval-
uation of 2 screening strategies for early 
identification of patients with axial spon-
dyloarthritis in primary care. J Rheumatol 
2011;38:2452-60.
12. Braun A, Saracbasi E, Grifka J, et al. Identi-
fying patients with axial spondyloarthritis in 
primary care: how useful are items indica-
tive of inflammatory back pain? Ann Rheum 
Dis 2011;70:1782-7.
13. Rojas-Vargas M, Munoz-Gomariz E, Escu-
dero A, et al. First signs and symptoms of 
spondyloarthritis—data from an inception 
cohort with a disease course of two years 
or less (REGISPONSER-Early). Rheumatology 
2009;48:404-9.
14. Rudwaleit M, van der Heijde D, Khan M, et 
al. How to diagnose axial spondyloarthritis 
early. Ann Rheum Dis 2004;63:535-43.
15. Rudwaleit M. New approaches to diagno-
sis and classification of axial and peripher-
al spondyloarthritis. Curr Opin Rheumatol 
2010;22:375-80.
16. Sieper J, van der Heijde D, Landewé R, et al. 
New criteria for inflammatory back pain in 
patients with chronic back pain: a real pa-
tient exercise by experts from the Assess-
ment of SpondyloArthritis international So-
ciety (ASAS). Ann Rheum Dis 2009;68:784-8.
17. Heuft-Dorenbosch L, Landewé R, Weijers 
R, et al. Performance of various criteria 
sets in patients with inflammatory back 
pain of short duration; the Maastricht ear-
ly spondyloarthritis clinic. Ann Rheum Dis 
2007;66:92-8.
18. Dougados M, D’Agostino M, Benessiano J, 
et al. The DESIR-cohort: a 10-year follow-up 
of early inflammatory back pain in France: 
study design and baseline characteristics of 
the 708 recruited patients. Joint Bone Spine 
2011;78:598-603.
19. Heuft-Dorenbosch L, Spoorenberg A, van 
Tubergen A, et al. Assessment of enthesitis 
in ankylosing spondylitis. Ann Rheum Dis 
2003;62:127-32.
20. Sieper J, Rudwaleit M, Baraliakos X, et al. 
The Assessment of SpondyloArthritis inter-
national Society (ASAS) handbook: a guide 
to assess spondyloarthritis. Ann Rheum Dis 
2009;68(Suppl2):ii1-44.
21. van der Heijde D, Landewé R, Feldtkeller E. 
Proposal of a linear definition of the Bath 
Ankylosing Spondylitis Metrology Index 
(BASMI) and comparison with the 2-step 




22. Garrett S, Jenkinson T, Kennedy L, et al. A 
new approach to defining disease status in 
ankylosing spondylitis: the Bath Ankylosing 
Spondylitis Disease Activity Index. J Rheu-
matol 1994;21:2286-91.
23. Calin A, Garrett S, Whitelock H, et al. A new 
approach to defining functional ability in 
ankylosing spondylitis: the development of 
the Bath Ankylosing Spondylitis Functional 
Index. J Rheumatol 1994;21:2281-5.
24. Dougados M, Simon P, Braun J, et al. ASAS 
recommendations for collecting, analysing 
and reporting NSAID intake in clinical trials/
epidemiological studies in axial spondyloar-
thritis. Ann Rheum Dis 2011;70:249-51.
25. Lukas C, Landewé R, Sieper J, et al. Develop-
ment of an ASAS-endorsed disease activity 
score (ASDAS) in patients with ankylosing 
spondylitis. Ann Rheum Dis 2009;68:18-24.
26. Rudwaleit M, Jurik A, Hermann K, et al. 
Defining active sacroiliitis on magnetic res-
onance imaging (MRI) for classification bof 
axial spondyloarthritis: a consensual ap-
proach by the ASAS/OMERACT MRI group. 
Ann Rheum Dis 2009;68:1520-7.
27. Maksymowych W, Inman R, Salonen D, et al. 
Spondyloarthritis Research Consortium of 
Canada magnetic resonance imaging index 
for assessment of sacroiliac joint inflam-
mation in ankylosing spondylitis. Arthritis 
Rheum 2005;53:703-9.
28. Picavet H, Schouten J. Musculoskeletal pain 
in the Netherlands: prevalences, conse-
quences and risk groups, the DMC(3)-study. 
Pain 2003;102:167-78.
29. Deyo R, Rainville J, Kent D. What can the his-
tory and physical examination tell us about 
low back pain? JAMA 1992;268:760-5.
30. Feldtkeller E, Khan M, van der Heijde D, et 
al. Age at disease onset and diagnosis delay 
in HLA-B27 negative vs. positive patients 
with ankylosing spondylitis. Rheumatol Int 
2003;23:61-6.
31. Cheung P, Paternotte S, Burki V, et al. Per-
formance of the assessment in SpondyloAr-
thritis international Society classification 
for axial and peripheral spondyloarthritis in 
an established clinical cohort: comparison 
with criteria sets of amor and the European 
Spondylarthropathy Study Group. J Rheu-
matol 2012;39:816-21.
32. van den Berg R, de Hooge M, Rudwaleit M, 
et al. ASAS modification of the Berlin algo-
rithm for diagnosing axial spondyloarthritis: 
results from the SPondyloArthritis Caught 
Early (SPACE)-cohort and from the Assess-
ment of SpondyloArthritis international 
Society (ASAS)-cohort. Ann Rheum Dis 
2013;72:1646-53.
33. Sieper J, van der Heijde D, Dougados M, 
et al. Comparable levels of disease activity 
between axial spondyloarthritis patients 
classified through the MRI or HLA-B27 path-
way of the ASAS criteria. Ann Rheum Dis 
2011;70(Suppl3):332.
Performance classification criteria in the SPACE-cohort |

3ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohortAnn Rheum Dis 2013;72:1645-53R. van den BergM. de HoogeM. RudwaleitJ. SieperF. van GaalenM. ReijnierseR. LandewéT. HuizingaD. van der Heijde
38 | Chapter 3
Abstract
Objective
To compare the original Berlin algorithm for diagnosing axial Spondyloarthritis (axSpA) with 
two modifications in the SPondyloArthritis Caught Early (SPACE)- cohort and the Assessment 
of SpondyloArthritis international Society (ASAS) axSpA criteria validation (ASAS)-cohort.
Methods 
Patients in the SPACE-cohort (back pain ≥3 months, ≤2 years, onset <45 years) and the ASAS-
cohort (undiagnosed chronic back pain) were diagnosed according to three algorithms: 
original (inflammatory back pain (IBP) mandatory), modification 1 (IBP defined by ≥3/5 
IBP-features instead of ≥4/5) and modification 2 (IBP deleted as obligatory entry criterion, 
added as SpA-feature). Diagnosis by rheumatologist, ASAS axSpA criteria and likelihood ratio 
product were used as external standards to test the performance of the algorithms. 
Results 
SPACE-cohort: Compared to the diagnosis by rheumatologist (either axSpA or no axSpA), the 
original algorithm agreed in 120 patients (76.4%). Agreement decreased using modification 
1 (119 patients; 75.8%), increased using modification 2 (125 patients; 79.6%). Sensitivity 
increased from 66.2% (original) to 72.3% (modification 1) and 78.5% (modification 2). 
Specificity decreased more using modification 1 (83.7% to 78.3%) than when using 
modification 2 (83.7% to 79.6%). 
ASAS-cohort: Compared to the diagnosis by rheumatologist (either axSpA or no axSpA), the 
original algorithm agreed in 484 patients (70.7%). Agreement increased using modification 
1 (520 patients; 75.9%) and modification 2 (548 patients; 80.0%). Sensitivity increased from 
65.3% (original) to 77.9% (modification 1) and 79.6% (modification 2). Specificity decreased 
more using modification 1 (79.2% to 72.2%) than when using modification 2 (79.2% to 
75.6%).
Conclusions 
ASAS accepted a modified algorithm for diagnosing axSpA in which IBP is excluded as 
obligatory entry criterion and added as SpA-feature.
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Introduction
Spondyloarthritis (SpA) consists of a heterogeneous group of inter-related rheumatic 
diseases, divided into categories according to the predominant site of involvement: axial 
SpA (axSpA) or peripheral SpA. AxSpA is the overall umbrella term for both patients with 
damage visible on radiographs of the sacroiliac joints (X-SI) and nonradiographic axSpA. 
The heterogeneity of SpA makes early detection challenging 1. A helpful tool in the early 
diagnosis of axSpA is the Berlin diagnostic algorithm; a decision tree applicable to patients 
with inflammatory back pain (IBP). 
The algorithm is fully based on data from the literature on the sensitivity and specificity of 
characteristic SpA-features. The likelihood ratio (LR)-product of (past or current) SpA-features 
is calculated for each patient as they follow the algorithm taking into account the a priori 
probability of SpA, thereby avoiding unnecessary diagnostic tests. The algorithm consists 
of several diagnostic steps, of which assessment of IBP is the first critical step. Patients may 
follow the algorithm in various ways depending on whether they have sacroiliitis on x-ray, 
the number of (past or current) SpA-features, human leukocyte antigen (HLA)-B27 positivity 
and sacroiliitis on MRI. 
Since only 70–80% of patients with axial SpA have typical IBP symptoms, IBP as an obligatory 
entry criterion in the algorithm has some limitations because patients with axSpA but 
without IBP will not be captured 2–5. To circumvent this limitation, it was proposed in 2004 
that in back pain patients without IBP other causes of back pain should be considered 
in general, unless SpA is suspected because of the presence of other SpA-features. This 
recommendation, however, was not further specified in the original algorithm. 
This has stimulated us to test two modifications of the algorithm in two independent 
cohorts; an observational inception cohort including patients with chronic back pain (the 
SPondyloArthritis Caught Early (SPACE)-cohort) and a larger, international cohort created 
for the validation of the new Assessment of SpondyloArthritis international Society (ASAS) 
axSpA criteria (the ASAS-cohort).
Methods
SPACE-cohort 
Patients with chronic (almost daily) back pain for ≥3 months but ≤2 years, with the onset 
<45 years University Medical Center, were included in the SPACE-cohort since January 2009. 
At baseline, patients underwent a diagnostic work-up consisting of physical examination, 
MRI and X-rays of the SI-joints (MRI-SI and X-SI) and laboratory assessments including 
HLA-B27 testing (online supplementary text 1). Furthermore, the presence of SpA-features 
is recorded (online supplementary table S1) 2. After that, a rheumatologist experienced in 
SpA diagnosed all patients as having SpA or no SpA. 
All MRI-SIs and X-SIs were independently scored by two trained readers (MdH and RvdB) 
according to the ASAS/ OMERACT definition (MRI-SI) 6, and the modified New York (mNY) 
criteria (X-SI) 7. A third trained reader (VNC) served as adjudicator and scored only the 
images in which the first two readers disagreed. If two/three readers scored positive, the 
image was scored accordingly. All readers were blinded for clinical and laboratory data, and 
for the results of the other imaging method. 
ASAS-cohort 
The ASAS-cohort was compiled for the validation of the new classification criteria for axSpA. 
Patients with chronic back pain of ≥3 months with onset <45 years and with a suspicion 
of SpA but without a definite diagnosis were included and assessed according to a fixed 
protocol by rheumatologists who are experts in the field of SpA. 
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Complete and detailed data collection of the ASAS-cohort has been described before 8. This 
included assessment of (past or current) SpA-features 2, C-reactive protein, and HLA-B27 
typing. Plain radiographs of the pelvis were taken in all patients. The local rheumatologist 
and/or radiologist assessed sacroiliitis on X-SI (mNY criteria) 9, and the presence or absence 
of typical signs of active inflammation on MRI-SI 8. 
Diagnosis of patients according to the Berlin algorithm 
According to the original algorithm (figures 1A and 2A), patients were diagnosed as having 
axSpA if they had IBP and ≥3 SpA-features, or if patients had IBP with 1-2 SpA-features 
and were HLA-B27 positive. Patients with no other SpA-features besides IBP could only be 
diagnosed as having axSpA if both HLA-B27 and active sacroiliitis (MRI-SI) were present.
In the original algorithm, IBP was defined according to the Calin criteria 10. In the SPACE-
cohort and ASAS-cohort, however, IBP was defined according to the ‘ASAS expert criteria’, 
which are slightly more specific 5. 
Subsequently, two modifications of the algorithm were constructed. In modification 1, 
fulfilllment of the ASAS IBP criteria 11, was adapted (figures 1B and 2B). The IBP criteria are: 
onset of back pain before the age of 40, insidious onset, improvement of back pain with 
exercise, no improvement of back pain with rest and pain at night with improvement upon 
getting up 5. Patients who fulfilled ≥3 IBP criteria instead of ≥4 out of 5 criteria could now 
be diagnosed as having IBP. During validation of these ASAS IBP criteria sensitivity (79.6%) 
and specificity (72.4%) were found to be best when patients fulfilled ≥4/5 criteria, a higher 
sensitivity (95.1%) was reached at the cost of specificity (47.5%) if ≥3/5 criteria for IBP were 
considered sufficient 5, 12. 
Modification 2 slightly changed the structure and the set of SpA-features by deleting IBP as 
obligatory entry criterion, and adding it as SpA-feature. This resulted in three entry groups 
based on the requirement of ≥4, 2-3 and 0-1 SpA-features (figures 1C and 2C). All patients 
were diagnosed according to the three algorithms. 
Statistical methods 
The disease probability in each patient was calculated by multiplying the individual likelihood 
ratios (LRs) of all identified SpA-features. An LR-product of 79 results in a positive predictive 
value of 80% in patients with chronic back pain with an assumed disease prevalence of 
axSpA of 5% 2. Missing values for the presence of SpA-features were interpreted as being 
absent and were included in the following analyses with the missing values set as ‘negative’. 
Because of the lack of a true gold standard, the fulfilllment of the ASAS axSpA criteria 7, the 
disease probability based on the likelihood ratio (LR)-product 13, and the diagnosis by the 
rheumatologist were used as external standards to test the performance of the algorithms. 
The performance was assessed by calculating the sensitivity, specificity, percentage of 
agreement on the diagnosis as well as the percentage of patients erroneously diagnosed as 




In total, 157 patients were included in the analyses of the SPACE-cohort. The rheumatologist 
diagnosed axSpA in 65/157 (41.4%) of the patients. Characteristics are presented in table 1. 
41
Table 1: Baseline characteristics of patients in the SPACE-cohort and the ASAS-cohort; SpA versus no 










Age (years) at inclusi-
on, mean ± SD 31.5 ± 16.6 31.1 ± 8.8 0.86 31.0 ± 10.8
35.8 ± 
10.5 0.839
Male, n (%) 29 (44.6) 23 (25.0) 0.01 225 (53.4) 87 (33.0) <0.001
Duration of back 
pain, mean ± SD
13.4 ± 7.4 
(months)
13.7 ± 7.1 
(months) 0.79
6.3 ± 7.8 
(years)
9.3 ± 10.7 
(years) 0.792
HLA-B27 positive, 
n (%) 44 (67.7) 9 (9.8) <0.001 270 (64.1) 73 (27.7) <0.001
Pos. fam. history SpA, 
n (%) 31 (47.7) 25 (27.2) 0.01 106 (25.2) 52 (19.7) 0.097
IBP, n (%) 52 (80.0) 53 (57.6) 0.003  324 (77.0) 125 (47.3) <0.001
Psoriasis, n (%) 10 (15.4) 6 (6.5) 0.07 36 (8.6) 13 (4.9) 0.073
Dactylitis, n (%) 4 (6.2) 2 (2.2) 0.20 28 (6.7) 5 (1.9) 0.005
Enthesitis, n (%) 10 (15.4) 15 (16.3) 0.88 86 (20.4) 38 (14.4) 0.046
Uveitis, n (%) 10 (15.4) 5 (5.4) 0.04 43 (10.2) 21 (8.0) 0.323
IBD, n(%) 4 (6.2) 5 (5.4) 0.85 14 (3.3) 4 (1.5) 0.149
Preceding infection, 
n (%) 2 (3.1) 0 (0.0) 0.09 12 (0.17) 5 (0.14) 0.434
CRP (mg/l), mean 
± SD 8.3 ± 11.6 5.7 ± 6.9 0.11 7.1 ± 14.9 2.4 ± 4.4 <0.001
ESR (mm/h), mean 
± SD 13.6 ± 16.3 10.4 ± 10.7 0.17 # #
Alternating buttock 
pain, n (%) 15 (23.1) 18 (19.6) 0.60 174 (41.3) 65 (24.6) <0.001
Good response to 
NSAIDs, n (%) 27 (41.5) 27 (29.3) 0.11 259 (61.5) 73 (27.7) <0.001
Elevated CRP/ESR, 
n (%)  15 (23.1) 16 (17.4) 0.38 170 (40.4) 43 (16.3) <0.001
Arthritis, n (%) 13 (20.0) 10 (10.9) 0.11 171(40.6) 59 (22.3) <0.001
Sacroiliitis X-ray, n (%) 11 (16.9) 1 (1.1) <0.001 123 (29.2) 9 (3.4) <0.001
Sacroiliitis MRI, n (%) 27 (41.5) 0 (0.0) <0.001 202 (48) 8 (3) <0.001
* Diagnosis according to rheumatologist. # Not estimated in ASAS-cohort. P-values <0.05 are defined 
statistically significant. HLA-B27, Human Leukocyte Antigen; IBP, Inflammatory Back Pain; preceding 
infection can be balinitis, urethritis, cervicitis and/or acute diarrhea; CRP, C-reactive protein; IBD, 
Inflammatory Bowel Disease; ESR, erythrocyte sedimentation rate; MRI, magnetic resonance imaging. 
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Figure 1a: Original Berlin algorithm (SPACE-cohort).
ASAS-cohort 
From the 685 patients of the ASAS-cohort used in this study, 421 (61.5%) were diagnosed as 
axSpA by the rheumatologist. Characteristics are presented in table 1. 
Diagnosis by the algorithms 
SPACE-cohort 
According to the original algorithm, 58 patients were diagnosed as having axSpA. Nine of 
them were diagnosed as ankylosing spondylitis (AS), based on the presence of radiographic 
sacroiliitis, 27 patients had axSpA based on clinical grounds (≥3 SpA-features present), the 
remaining 22 patients were HLA-B27 positive with 1-2 SpA-features present (figure 1A). 
According to modification 1, 22 patients immediately leave the algorithm. A total of 56 
patients are diagnosed as having axSpA: 11 patients are directly diagnosed as AS, 29 patients 
had ≥3 SpA-features and 27 HLA-B27 positive patients had 1-2 SpA-features (figure 1B). 
In modification 2, 69 patients were diagnosed as having axSpA: 12 patients were diagnosed 
as AS, 27 patients had ≥4 SpA-features and 29 patients were HLA-B27 positive and had 2-3 
SpA-features. In addition, there was one patient with 0-1 SpA-features, HLA-B27 positivity 
and a positive MRI-SI who was diagnosed as having SpA (figure 1C). 
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Table 2: Sensitivity, specificity, percentage of axSpA diagnosis missed and erroneously diagnoses 
of axSpA by the algorithm in the SPACE-cohort and ASAS-cohort according to the three external 













Original 72.6 86.3 80.9 10.8 8.3
Modification 1 81.7 81.4 81.5 7.0 11.5
Modification 2 89.8 83.7 86.0 3.8 10.2
LR-product probability ≥80%
Original 85.5 94.7 91.1 5.7 3.2
Modification 1 92.4 93.4 93.0 3.2 3.8
Modification 2 100 92.6 95.5 0.0 4.5
Diagnosis rheumatologist
Original 66.2 83.7 76.4 14.0 9.6
Modification 1 72.3 78.3 75.8 11.5 12.7
Modification 2 78.5 80.4 79.6 8.9 11.5
ASAS
ASAS axial SpA
Original 72.6 84.1 77.5 15.6 6.9
Modification 1 86.7 78.3 83.1 7.6 9.3
Modification 2 89.4 83.0 88.8 6.1 7.6
LR-product probability ≥80%
Original 83.5 99.3 90.2 9.5 0.3
Modification 1 96.0 85.6 91.2 2.2 6.6
Modification 2 97.2 90.7 96.6 1.6 4.2
Diagnosis rheumatologist
Original 65.3 79.2 70.7 21.3 8.0
Modification 1 77.9 72.2 75.9 13.6 10.8
Modification 2 79.6 75.6 80.0 12.7 9.8
Modification 1: IBP 3/5 instead of 4/5. Modification 2: IBP as additional SpA-feature instead of entry 
criterion. LR-product: Likelihood Ratio-product.
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Figure 1b: Modification 1 of the Berlin algorithm; IBP defined when 3 out of 5 criteria are fulfilled 
instead of 4 out of 5 criteria (SPACE-cohort).
In 120 patients (76.4%) the diagnosis of the rheumatologist and the original algorithm agreed. 
Modification 1 (IBP 3/5) diagnosed nine more patients as having axSpA, and modification 
2 (IBP excluded as obligatory entry criterion) diagnosed 11 more patients as having axSpA, 
resulting in agreement with the diagnosis of the rheumatologist in 119 (75.8%) and 125 
patients (79.6%) respectively (table 2). Compared to the diagnosis of the rheumatologist as 
external standard, sensitivity was 66.2% using the original algorithm. Sensitivity was higher, 
77.9% (+11.7% compared to the original algorithm) using modification 1 and increased more 
using modification 2, 79.6% (+13.4%). Yet specificity slightly decreased from 83.7% using 
the original algorithm to 78.3% (−5.4%) using modification 1 and to 80.4% (−3.3%) using 
modification 2. The same trend was observed compared to the other external standards. 
The best balance between sensitivity and specificity is present in modification 2 (table 2). 
ASAS-cohort 
In the original algorithm (figure 2A), 236 patients immediately leave the algorithm. Out of 
the 449 patients that continue in the algorithm, 330 were diagnosed as having axSpA: 102 
fulfilled the mNY criteria for AS, 138 patients with ≥3 SpA-features and another 86 HLA-B27 
positive patients with 1-2 SpA-features are diagnosed as having axSpA. In addition, four 
HLA-B27 positive patients with active sacroiliitis (MRI-SI), but without other SpA-features 
are diagnosed as having axSpA. In all HLA-B27 negative patients with 1-2 SpA-features 
(n=93), patients without SpA-features (n=19) and patients without sacroiliitis (MRI-SI) (n=7), 
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Figure 1c: Modification 2 of the Berlin algorithm; IBP is deleted as entry criterion and implemented as 
an additional SpA-feature (SPACE-cohort).
In modification 1 (figure 2B), 113 patients immediately leave the algorithm and 402 patients 
are diagnosed as having axSpA: 122 patients are directly diagnosed as AS, 164 patients with 
≥3 SpA-features, 111 HLA-B27 positive patients with 1-2 SpA-features and five HLA-B27 
positive patients with a positive MRI-SI but without SpA-features. In 150 HLA-B27 negative 
patients and in 10 HLA-B27 positive patients with a negative MRI-SI, the algorithm suggested 
another diagnosis than axSpA. 
In modification 2 (figure 2C), the number of patients immediately leaving the algorithm is 
reduced to 17 patients. In total, 407 patients are diagnosed as having axSpA. Of those, 132 
patients are directly diagnosed as AS, 148 patients with ≥4 SpA-features are diagnosed as 
having axSpA, as were 115 HLA-B27 positive patients with 2-3 SpA-features and 12 HLA-B27 
positive patients with a positive MRI-SI and 0-1 SpA-features. For the remaining 278 patients 
another diagnosis than axSpA should be considered. 
The rheumatologist diagnosis and the original algorithm agreed in 70.7% of the patients. 
Modification 1 showed agreement with the diagnosis of the rheumatologist in 75.9% of the 
patients (+5.2% compared to the original algorithm). Modification 2 showed a similar trend; 
80% (+9.3% compared to the original algorithm) agreement. Sensitivity increased from 
65.3% in the original algorithm to 77.9% (+12.6%) in modification 1 and 79.6% (+14.3%) 
in modification 2, when using the diagnosis of the rheumatologist as external standard. 
Specificity decreased from 79.2% in the original algorithm to 72.2% (−7.0%) in modification 
1 and to 75.6% (−3.6%) in modification 2 (table 2). The performance of the three algorithms 
with the ASAS axSpA criteria and the LR-product as external standard are also presented in 
table 2 and show similar results. 
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Asymmetrical arthritis 
In additional calculations on the performance, we replaced the SpA-feature ‘peripheral 
arthritis’ with ‘asymmetrical arthritis preferentially of the lower limbs’ (only performed in 
the ASAS-cohort). When doing so, sensitivity decreased while specificity increased in all 
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Figure 2a: Original Berlin algorithm (ASAS-cohort).
Reasons for misdiagnoses 
SPACE-cohort 
Compared to the diagnosis of the rheumatologist as external standard, 15 patients (9.6%) 
were erroneously diagnosed as having axSpA by the original algorithm and in 22 patients 
(14.0%) the diagnosis axSpA was missed by the algorithm, especially in the group of patients 
without IBP. In both modifications, a few more patients, n=20 by modification 1 and n=18 by 
modification 2, were erroneously diagnosed as having axSpA (12.7% (+3.2% compared to the 
original algorithm) by modification 1 and 11.5% (+1.9%) by modification 2) but the number 
of patients in which the diagnosis axSpA was missed dropped to 18 (11.5% by modification 1 
(−3.8% compared to the original algorithm)) and 14 patients (8.9% by modification 2 (−7%)) 
(table 2). 
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Table 3: Misdiagnoses by the three versions of the Berlin algorithm in the SPACE-cohort (diagnosis of 

















































Modification 2 (IBP excluded as 
entry criterion)
No. SpA-features, 



















*Patients following the original cohort and modification 1 have IBP in addition to the other SpA-
features, otherwise they did not enter the algorithm, except the patients that are excluded because 
they had no IBP. Imaging +: sacroiliitis present on MRI and/or X-rays. Imaging -: no sacroiliitis present 
on MRI and/or X-rays. HLA-B27: Human Leukocyte Antigen. A list of SpA-features is given in table S1 
(online supplementary material).
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Table 4: Misdiagnoses by the three versions of the Berlin algorithm in the ASAS-cohort (expert 
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*Patients following the original cohort and modification 1 have IBP in addition to the other SpA-
features, otherwise they did not enter the algorithm, except the patients that are excluded because 
they had no IBP. Imaging +: sacroiliitis present on MRI and/or X-rays. Imaging -: no sacroiliitis present 



































Figure 2b. Modification 1 of the Berlin algorithm; IBP defined when 3 out of 5 criteria are fulfilled instead 
of 4 out of 5 criteria (ASAS-cohort). 
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Figure 2b: Modification 1 of the Berlin algorithm; IBP defined when 3 out of 5 criteria are fulfilled 
instead of 4 out of 5 criteria (ASAS-cohort).
An extensive description of all misdiagnoses is given in table 3. Most patients who were 
erroneously diagnosed with axSpA by the algorithm have ≥4 SpA-features (including IBP) 
and were therefore diagnosed as SpA according to the algorithm, but are HLA-B27 negative 
and do not have sacroiliitis (X-SI or MRI-SI) and are not considered as having axSpA according 
to the rheumatologist. This pattern was seen in all three algorithms. Most patients in 
whom the diagnosis axSpA was missed by the algorithm are HLA-B27 negative, and have 
≤3 SpA-features (including IBP) and were therefore diagnosed as no axSpA according to 
the algorithm. However, those patients do have sacroiliitis (MRI-SI), which is missed by the 
algorithm since the patients were excluded before the MRI-step. Again, this pattern was 
seen in all three algorithms. 
ASAS-cohort 
Table 2 also shows the misdiagnoses of the algorithms in the ASAS-cohort. 
Using the rheumatologist diagnosis as external standard, 8.0% of the patients were 
erroneously diagnosed as axSpA and in 21.3% of the patients the diagnosis axSpA was 
missed by the original algorithm. Modification 1 showed in 10.8% (+2.8% compared to the 
original algorithm) of the patients an erroneous diagnosis of axSpA and in 13.6% (−7.7%) of 
the patients the diagnosis of axSpA was missed. Modification 2 showed a similar trend; 9.8% 
(+1.8%) of the patients were erroneously diagnosed as axSpA and in 12.7% (−8.6%) of the 
patients the diagnosis axSpAwas missed by the algorithm. 
As shown in table 4, the majority of the patients (n=53) erroneously diagnosed as axSpA, 
have a negative MRI-SI. Two third of these patients (n=35) are HLA-B27 positive with one or 
more SpA-features present. This trend is seen in all three algorithms. 
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Figure 2c: Modification 2 of the Berlin algorithm; IBP is deleted as entry criterion and implemented 
as an additional SpA-feature (ASAS-cohort).
Most of the patients in whom the diagnosis of axSpA was missed by the algorithm are 
HLA-B27 negative (n=89). Almost half of these misdiagnosed patients (n=40) have a positive 
MRI-SI. Again, this trend is also seen using the two modifications.
Discussion
In this study we investigated the performance of the original Berlin algorithm and two 
modifications in the SPACE-cohort and the ASAS-cohort. 
In modification 1, the ASAS criteria for IBP were defined less stringent (≥3/5 instead of ≥4/5 
IBP criteria). In both cohorts this resulted in a major increase in sensitivity, while specificity 
only slightly decreased. Modification 2 (IBP excluded as obligatory entry criterion) resulted 
in an even further decrease of missed axSpA diagnoses by the algorithm. Modification 2 
showed the best combination of sensitivity and specificity in both cohorts. 
Our findings show that IBP as obligatory entry criterion induces too many misdiagnoses, 
thereby confirming the results found before of a percentage of axSpA-patients without IBP up 
to 30% 4, 5. Moreover, this is also the reason that the ASAS axSpA criteria are formed without 
IBP as entry criterion 4, 12. However, IBP is suitable for screening for axSpA in primary care as 
several studies have shown 14–16, hence also a good (albeit non-mandatory) SpA-feature, as 
modification 2 suggests. Also for general practitioners it is important to realise that absence 
of IBP does not exclude axSpA. Furthermore, a relatively young age at onset of chronic back 
pain is a strong signal that the back pain might be a symptom of SpA. This is one of the 
factors explaining the difference of the 5% of SpA in the general population at the general 
practitioner level, and the 61% in this age-selected population seen by rheumatologists with 
a special interest in SpA. It should be noted that the algorithm is intended for use by the 
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rheumatologist, in this specific age-defined patient population, and not in an unselected 
population of patients with chronic back pain. 
According to all versions of the algorithm, MRI-SI is not performed in HLA-B27 negative 
patients with 2-3 other SpA-features; those patients leave the algorithm as no axSpA patients. 
In order to further decrease these missed axSpA diagnoses, it could be considered to perform 
MRI-SI in HLA-B27 negative (especially male) patients with 2-3 other SpA-features 17. There 
are suggestions that an MRI-SI should be classified as positive on the basis of inflammatory 
lesions and structural changes to increase sensitivity of the MRI-SI. Moreover, there are data 
showing that spinal changes on MRI-spine might be present in absence of inflammation on 
MRI of the SI-joints, yet this accounts for no more than 5% of patients 12. The importance of 
these findings in the process of diagnosis is unclear at the moment. 
It was not possible to decrease the number of patients who were erroneously diagnosed 
as axSpA by the proposed modifications. This might be caused by the fact that this mostly 
concerns patients with an (atypical) presentation of ≥3 SpA-features, but who are HLA-B27 
negative and do not have sacroiliitis (X-SI and/or MRI-SI). Those patients are considered 
by rheumatologists as no axSpA, suggesting that rheumatologists base their diagnosis, 
besides the total presentation, to a large extent on MRI-SI and HLA-B27 findings. For the 
same reasons, those patients could never be classified according to the imaging arm, nor 
the clinical arm of the ASAS axSpA criteria. However, missed axSpA diagnoses in 3.8% to 
6.1% and erroneously diagnosed axSpA patients in 7.6% to 10.2% of the cases (table 2), is 
surprisingly good. This also favours using the ASAS axSpA classification criteria in a diagnostic 
approach. 
The use of both cohorts has strengths and limitations. A limitation of the use of the ASAS-
cohort is that the ASAS axSpA criteria have been validated in this cohort while the ASAS 
axSpA criteria are used as one of the three external standards to test the performance 
of the algorithms. However, this is obviated since similar results are found in the SPACE-
cohort, which is independent of the validation of the ASAS axSpA criteria. A downside of 
the SPACE-cohort is that the diagnosis of patients was based on the judgment of a single 
rheumatologist, what in turn is a strong point of the ASAS-cohort where the diagnosis was 
made by several ASAS-rheumatologists. For both cohorts the lack of follow-up data, which 
reduces the certainty on the diagnosis, is a limitation. 
The results of both cohorts on the performance of the three diagnostic algorithms were 
presented to the ASAS-members during the January 2012 meeting in Amsterdam. The 
membership voted for modification 2 as the diagnostic algorithm of their choice. 
In conclusion, ASAS accepted a modified algorithm in which IBP is excluded as obligatory 
entry criterion and is added as additional SpA-feature. We have added an online figure 
without the data on the cohorts that can be used in daily practice (online supplementary 
figure S1). This modification yields a higher agreement on the diagnoses in accordance with 
the diagnosis by the rheumatologist, the ASAS axSpA criteria and the LR-product probability 
≥80%, mainly as a result of the reduction of missed axSpA diagnoses by the algorithm. This 
modified algorithm might be a useful tool for rheumatologists in daily practice.
Supplementary data
Additional data are published online only. To view these files please visit the journal online 
(http://dx.doi.org/ 10.1136/annrheumdis-2012- 201884)
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Abstract
Objectives
The performance of spondyloarthritis (SpA) classification criteria is not well-established 
in general early arthritis cohorts. Therefore, the authors tested their performance in the 
Leiden Early Arthritis Clinic (EAC)-cohort and assessed whether these criteria can assist 
rheumatologists in diagnosing patients.
Methods
The authors identified all SpA and psoriatic arthritis (PsA) patients in the EAC-cohort 
according to the diagnosis of the treating rheumatologist. A control group consisting of 
arthritis patients with other diagnoses was matched to the SpA and PsA patients on gender, 
age and symptom duration. The authors assessed the fulfilllment of SpA criteria in all three 
groups.
Results
Of the patients in the EAC-cohort (n=2011), 7.5% was diagnosed with PsA and 3.8% with 
SpA. In the PsA group, the ClASsification criteria for Psoratic Arthritis (CASPAR) criteria 
had the highest sensitivity (88.7%). In the SpA group, the Assessment of SpondyloArthritis 
international Society (ASAS) peripheral SpA and European Spondylarthropathy Study Group 
(ESSG) criteria had the highest sensitivity (both 48.7%). Specificity of all criteria sets was 
good: ranging from 88.5% (ESSG) to 100% (Amor).
Conclusions
In early arthritis, sensitivity of SpA classification criteria is modest except for the CASPAR 
criteria in PsA. However, specificity of classification criteria, including the new ASAS 
peripheral SpA criteria, is high.
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Introduction
Early recognition of spondyloarthritis (SpA) is challenging since the concept of SpA comprises 
a heterogeneous group of diseases 1. Over the years, several classification criteria have been 
developed. The European Spondylarthropathy Study Group (ESSG) criteria and the Amor 
criteria were developed to classify patients with all subtypes of SpA 2, 3. Recently, two new 
sets were developed by the Assessment of SpondyloArthritis International Society (ASAS) to 
distinguish between patients with predominantly axial SpA (axSpA) and with predominantly 
peripheral SpA (pSpA) 4, 5. Furthermore, the ClASsification criteria for Psoriatic ARthritis 
(CASPAR), is a classification set especially for psoriatic arthritis (PsA) 6. 
The performance of all classification criteria was good when tested in the original validation 
population, frequently with longstanding symptoms 2, 3, 6–8. The performance was less known 
in general early arthritis cohorts like the Leiden Early Arthritis Clinic (EAC)-cohort. It is 
known that 67% of the SpA-patients with a disease duration <2 years report arthritis as the 
first symptom 9. So, in an EAC, SpA and PsA are important parts of the differential diagnosis. 
Therefore, it is important to test the performance of classification criteria in early disease 
cohorts. 
First, we described the prevalence of SpA and PsA among patients presenting with peripheral 
arthritis in the Leiden EAC-cohort. Thereafter, we tested the performance of the described 
classification criteria and investigated whether these criteria sets can assist rheumatologists 
in diagnosing patients with peripheral arthritis.
Methods
Patients
Data from the Leiden EAC-cohort were used; a population-based prospective cohort 
including patients with recent-onset arthritis. Since 1993, general practitioners in the Leiden 
area referred patients with suspected arthritis as quickly as possible to the rheumatology 
department of the Leiden University Medical Center to detect and treat inflammatory 
disorders early. Patients with an objective evidence of arthritis, with a symptom duration <2 
years and a signed informed consent, were included 10. 
A database was built consisting of, among others: medical history, physical examination 
and laboratory tests according to the EAC protocol. Besides these parameters, individual 
patients’ charts were reviewed for additional extra-articular SpA-features (past and/or 
present), necessary to apply the criteria sets (online supplementary table S1). Furthermore, 
in all patients, human leucocyte antigen (HLA)-B27 typing was performed if possible. All 
collected data (baseline to 1 year) was used for analysis. The diagnosis of the treating 
rheumatologist recorded from a list of proposed diagnoses including PsA and SpA after 1 
year served as the gold standard. 
Between 1 February 1993 and 1 February 2009, 2011 patients with early arthritis were 
included in the EAC-cohort. All PsA and SpA patients, according to the treating rheumatologist 
(n=226) at 1-year follow-up visit, were included in the present analysis. In the SpA group, 13 
patients dropped out after 3 months; in the PsA group, 8 patients; and in the control group 
36 patients. Of these patients, we used all available data which is until the third visit after 
3 months. 
Furthermore, a control group (n=226) was selected from the EAC-cohort, matched to the 
combined SpA-PsA group on gender, age and symptom duration (p=0.978, p=0.637 and 
p=0.03, respectively). Thereafter, the combined SpA-PsA group was split into the SpA group 
and PsA group. The control group included patients with the following diagnoses at 1 year: 
82 with rheumatoid arthritis (1987 ACR criteria); 60 with undifferentiated arthritis; 13 with 
post-streptococcal reactive arthritis; 12 with osteoarthritis; 8 with gout; 15 with sarcoidosis; 
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and 26 patients with other diagnoses like palindromic arthritis and post-traumatic arthritis.
Data analysis
Baseline characteristics of the three groups (SpA, PsA and control group) were analysed 
using t-tests and χ2-tests. 
For each patient with SpA or PsA, we assessed the fulfilllment of the criteria sets and 
compared this with the fulfilllment of the criteria in patients in the control group using 
cross-table analysis. Missing values for the presence of SpA-features were interpreted as 
being absent. The checked diagnosis after 1 year was used as the gold standard. 
Furthermore, the performance of the various criteria sets was determined by calculating 
sensitivity, specificity, positive likelihood ratio (LR+), and negative likelihood ratio (LR−). All 
analyses were performed using SPSS V. 17.0; p values <0.05 were considered significant.
Results
Patient characteristics during the first year of inclusion
Of the 2011 patients included in the EAC-cohort, 150 (7.5%) were diagnosed with PsA and 
76 (3.8%) with SpA. 
The control group was matched to the combined group of patients with SpA and PsA on 
gender, age and symptom duration. After splitting the patients into the SpA group and 
PsA group, differences with the control group were observed. The mean age of the SpA 
group was significantly lower (p<0.001), and of the PsA group significantly higher (p=0.03) 
compared with the control group. In the SpA group, 55 (72.3%) patients, in the PsA group, 
64 (42.6%) patients, and in the control group, 121 (53.5%) patients were diagnosed before 
the age of 45 years. 
Moreover, patients within the SpA group with a preceding infection had a significantly 
shorter self-reported symptom duration (6.4 (SD 9.4) versus 22.1 (SD 27.9) weeks; p<0.001), 
while patients without a preceding infection in the SpA group and PsA patients had a longer 
duration than patients in the control group (30.3 (SD 42.6) and 35.5 (SD 58.0) weeks; p=0.10 
and p=0.01, respectively). 
In the SpA group, all patients had at least one other SpA feature in addition to arthritis. In 
the control group, 66.4% of the patients had 1 or 2, and 22.1% had 3 or more SpA-features 
in addition to the arthritis, while in the PsA group and SpA group, respectively, 16.0% and 
21.0% had 1 or 2 SpA-features, and 82.7% and 79.0% of the patients had 3 or more SpA-
features (see online supplementary figure S1). 
The most frequently reported SpA-features in the PsA group were psoriasis (94.0%), positive 
family history (89.2%) and dactylitis (36.7%). The PsA group differed significantly from the 
control group on these SpA-features, and on a higher prevalence of enthesitis, HLA-B27 
positivity and rheumatoid factor (RF) negativity. By contrast, inflammatory back pain was 
significantly less frequent, and C-reactive protein levels significantly lower in the PsA group 
than in the control group. In the SpA group, HLA-B27 positivity (47.5%), positive family 
history (47.4%) and preceding infection (36.8%) were the most frequent SpA-features. SpA 
patients differed significantly from the control group on these features and on the presence 
of inflammatory back pain, enthesitis, uveitis, inflammatory bowel disease, negative RF and 
elevated erythrocyte sedimentation rate levels (table 1).
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*Patient reported. **Patients with preceding infection. ***Patients without preceding infection
IBP, Inflammatory Back Pain; IBD, Inflammatory Bowel Disease; RF, Rheumatoid Factor; age, age at 
baseline; delay, duration between first complaints and first visit outpatient clinic Rheumatology; 
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA-B27, Human Leukocyte Antigen; 















































































































































































Figure 1: Venn-diagram representing the number of patients from the Leiden Early Arthritis Clinic 
meeting different criteria for spondyloarthritis. ESSG, European Spondylarthropathy Study Group; 
ASAS, Assessment of SpondyloArthritis International Society; CASPAR, ClASsification criteria for Psora-
tic ARthritis in the SpA-group (a), PsA-group (b), control-group (c).
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Performance of classification criteria
In the PsA group, 133 patients fulfilled the CASPAR, and 78 the ASAS-pSpA criteria, (sensitivity 
of 88.7% and 52.0%, respectively). In the SpA group, 37 patients fulfilled the ASAS-pSpA and 
ESSG criteria each, (sensitivity both 48.7%). Specificity of all criteria sets was good, ranging 
from 88.5% (ESSG criteria) to 100% (Amor criteria). In the PsA group, LR+ and LR− of the 
CASPAR criteria were the best (20.04 and 0.12). In the SpA group, the best LR+ was identified 
for the ASAS-aSpA criteria, and the best LR− was identified for the ASAS-pSpA criteria (7.3 
and 0.57, respectively) (table 2). 
In the control group, 186 patients (82.3%) did not fulfill any of the four classification criteria, 
and 13 (8.7%) in the PsA group and 30 patients (39.5%) in the SpA group. The overlap of the 
criteria is presented in figure 1. In the PsA group, 16 patients fulfilled all four criteria sets 
and 39 fulfilled the combination of Amor, ASAS-pSpA and CASPAR criteria. Also in the SpA 
group many patients fulfilled at least two criteria sets (1 patient fulfilled all four criteria, 13 
the combination of ASAS-pSpA, ESSG and Amor, and 15 the combination of ASAS-pSpA and 
ESSG criteria). In contrast in the control group, very few patients fulfilled more than one 
criteria set, and none of them all four criteria.
Furthermore, the concordance between the CASPAR and ASAS-pSpA criteria was calculated. 
In the PsA group, 75 patients fulfilled both the CASPAR and the ASAS-pSpA criteria, 58 
patients fulfilled the CASPAR criteria and 3 fulfilled the ASAS-pSpA criteria only (59.3% 
agreement). Only 3 patients in the SpA group fulfilled both the CASPAR and the ASAS-pSpA 
criteria, 34 fulfilled the ASAS-pSpA criteria only, and one patient fulfilled the CASPAR criteria 
only (53.9% agreement). 
Table 2: Number of patients fulfilling the various criteria sets and performance of the various criteria 
sets.
PsA vs control ASAS peripheral ESSG Amor CASPAR
PsA N pos. (sensitivity) 78 (52.0)* 39 (26.0)* 55 (36.7)* 133 (88.7)*
LR+ 5.11 2.26 - 20.04
LR- 0.53 0.84 0.63 0.12
SpA vs control ASAS peripheral ESSG Amor CASPAR
SpA N pos. (sensitivity) 37 (48.7)* 37 (48.7)* 20 (26.3)* 4 (5.3)
LR+ 4.78 4.2 - 1.19
LR- 0.57 0.58 0.74 0.99
Control N neg. (specificity) 203 (89.8) 200 (88.5) 226 (100) 216 (95.6)
* Marks a p-value <0.05, PsA-group or SpA-group is significantly different than the control-group 
on fulfilling the criteria ESSG, European Spondylarthropathy Study Group; ASAS, Assessment of 
SpondyloArthritis international Society (ASAS); CASPAR, Classification of Psoriatic Arthritis; LR+, 
positive likelihood ratio; LR-, negative likelihood ratio; PPV, positive predictive value; NPV, negative 
predictive value.
Discussion
More than 10% of the patients in the EAC-cohort were diagnosed with PsA or SpA. 
Unquestionably, this discovered prevalence is not representative for the whole concept of 
SpA among patients referred to rheumatologists since this cohort does not include patients 
with dactylitis or enthesitis, or patients with predominantly axSpA (back pain).
The sensitivities found in this report are lower for all criteria sets than the reported 
sensitivities as tested in the original cohorts with established disease patients 2–4, 6, 8.
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A different patient selection in the EAC-cohort compared with the original cohorts can 
explain this difference. The EAC-cohort consists of patients with early arthritis, while the 
original cohorts included patients with various presenting features, not only arthritis, and a 
longer symptom duration. The longer the symptom duration, the more chance that (extra-
articular) features develop.
Except for these issues related to symptom duration there are also factors related to more 
specific characteristics of the criteria sets. The sensitivity of the ESSG criteria may be limited 
by the lack of HLA-B27 in the list of SpA-features. The poor sensitivity of the Amor criteria in 
the EAC-cohort may also partially be explained by the strict definition of peripheral arthritis as 
oligoarthritis (2–4 joints). Besides, to fulfill the Amor criteria, at least six points are necessary 
corresponding to 3–4 items. Since some of these items are more seen in axSpA patients, this 
seems quite difficult to reach for patients with peripheral manifestations only 5. Although it 
was expected that the sensitivity was lower than reported in the original cohorts it may also 
indicate that it is difficult to cover all pSpA-patients according to rheumatologists by existing 
criteria in recent onset disease, which confirms that these criteria are classifications and not 
diagnostic criteria sets 5.
On the other hand, it is very reassuring that the specificity of all sets were in accordance 
with the reported specificities, even in this cohort of early arthritis 2–4, 6, 8 . This is especially of 
note for the ASAS-pSpA criteria as these are quite new, and there was a fear that they might 
not be specific enough.
In conclusion, the various criteria sets are very good in classifying patients, but are limited in 
assisting rheumatologists in diagnosing patients.
Supplementary data
An additional supplementary material is published online only. To view this file please visit 
the journal online (http://ard.bmj.com/content/early/recent).
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Abstract
Objective
Investigating agreement on presence/absence of radiographic sacroiliitis between local 
rheumatologists/radiologists and central trained readers (external standard).
Method
Inflammatory back pain patients (IBP; ≥3 months, <3 years) suggestive of axial 
spondyloarthritis (axSpA) were included in the DESIR-cohort. Baseline sacroiliac-joint-
radiographs were read by two central readers (modified New York), adjudicated by a third 
reader in case of disagreement, yielding a positive or a negative result (central reading). 
The same radiographs were also read by local radiologists/rheumatologists rated ‘normal’, 
‘doubtful sacroiliitis’, ‘obvious sacroiliitis’ or ‘SI-joint fusion’ (local reading); positivity defined 
as: 1) at least unilateral ‘obvious sacroiliitis’ 2) ‘bilateral ‘obvious sacroiliitis’ or at least 
unilateral ‘fusion’’. Agreement and misclassifications between central readers and central 
reading versus local reading were calculated (kappas). 
Results
Interreader agreement between the central readers was moderate (κ=0.54); 108/688 
radiographs (15.7%) were adjudicated. According to local reading (at least unilateral ‘obvious 
sacroiliitis’), 183/688 patients (26.6%) had sacroiliitis; according to central reading, 145/688 
patients (21.1%). Agreement between local reading and central reading was also moderate 
(κ=0.55); 76/183 patients (41.5%) with at least unilateral ‘obvious sacroiliitis’ (positive by 
local reading) and 32/109 patients (29.4%) with ‘bilateral ‘obvious sacroiliitis’ or at least 
unilateral ‘fusion’’ (positive by local reading) were rated ‘negative’ by central reading; 
38/505 patients (7.5%) and 68/579 (11.7%) respectively without sacroiliitis (negative by 
local reading) were read ‘positive’ by central reading. 
Conclusion
In recent onset IBP-patients, both trained readers and local rheumatologists/radiologists 
agree only moderately in recognizing radiographic sacroiliitis. A significant proportion of 
locally recognized ankylosing spondylitis patients is not confirmed by central reading (false-
positive), while a small minority is false-negative, indicating the necessity of re-evaluating 
the role of radiographic sacroiliitis as diagnostic criterion for axSpA.
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Introduction 
Sacroiliitis, detected on plain radiographs, is considered as the hallmark of ankylosing 
spondylitis (AS) and is mandatory for the classification of AS according to the modified 
New York criteria 1. However, it is known that a major delay between symptom onset 
and the development of radiographic sacroiliitis exists 2. Recently, the Assessment of 
SpondyloArthritis international Society (ASAS) published classification criteria to be able 
to classify patients with non-radiographic axial SpA (nr-axSpA) in addition to AS patients 3. 
The classification of nr-axSpA, which was described for the first time already 29 years ago 4, 
is based on the absence of radiographic sacroiliitis but presence of SpA-features such as 
uveitis and dactylitis complementary to the presence of HLA-B27 and/or sacroiliitis visible 
on MRI. Although diagnostic criteria do not exist, radiographic sacroiliitis is also playing an 
important role in the diagnostic process of patients suspected of having axial SpA 5. Axial 
SpA comprises the entire spectrum of patients with radiographic and non-radiographic 
disease, sacroiliitis on the radiograph being in fact the only discriminating feature. Though, 
the recognition of radiographic sacroiliitis is considered difficult because of the complex 
anatomy of the SI-joints, and the undulating articular surface makes the SI-joints hard to 
image on conventional radiographs, resulting in misinterpretations 6, 7. A study including 100 
rheumatologists and radiologists showed major discrepancies in grading of the SI-joints, 
especially in grades 1 and 2. Unfortunately, extensive training by workshops and self-
education, did not enhance the performance of diagnosing sacroiliitis 7.
The distinction between AS and nr-axSpA based on the presence/absence of radiographic 
sacroiliitis becomes even more evident by the fact that in many countries TNF-inhibitors 
(TNFi) are currently approved for patients with established AS but not for nr-axSpA patients 8. 
Moreover, the European Medical Agency has approved TNFi for nr-axSpA patients only if 
additional signs of objective inflammation such as a positive MRI and/or an elevated CRP are 
present, while this is not required for patients with radiographic axSpA. So there are major 
consequences depending on the judgement of a pelvis radiograph.
In daily practice, the diagnosis of AS is based on the judgement of the SI-joints on plain 
radiographs by the local radiologist and/or rheumatologist, frequently with knowledge 
of the clinical signs and symptoms. In cohorts and clinical trials on the other hand, the 
quantitative scoring of structural damage on radiographs of the SI-joints is usually done 
by one or more trained readers blinded for clinical information. In the DESIR (DEvenir 
des Spondylarthropathies Indifférenciées Récentes)-cohort, radiographs of the SI-joints 
at inclusion are scored by the local rheumatologist or radiologist and also by two trained 
central readers, including a third reader in case of discrepancy. Therefore, this cohort offers 
the unique opportunity to compare the evaluation of the local reading to the centralized 
reading, as external standard, in terms of agreement on abnormal versus normal SI-joints 
permitting to diagnose radiographic sacroiliitis.
Methods
Patients
For this analysis, baseline data from the DESIR-cohort were used. The DESIR-cohort is 
described extensively before 9. In short, consecutive patients aged 18-50 from 25 centers in 
France with inflammatory back pain (IBP) in the thoracic spine, lumbar spine and/or buttock 
area (≥3 months, but <3 years) based on either the Calin (4/5 items) or the Berlin (2/4 
items) criteria 10, 11, suggestive of axSpA according to the rheumatologist with a score of ≥5 
on a scale of 0 to 10 (where 0 was not suggestive of axSpA and 10 was very suggestive of 
axSpA), were included in this prospective longitudinal cohort to study the natural course 
and prognosis of axSpA starting at symptom onset. Between December 2007 and 29th of 
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April 2010, 708 patients were included.
The study fulfilled Good Clinical Practice Guidelines and was approved by the appropriate 
medical ethical committees. Participants gave written informed consent before they were 
included in the study. A detailed description of the study protocol is available at the website 
(http://www.lacohortedesir.fr/desir-in-english/). The research proposal for this particular 
analysis was approved by the scientific committee of the DESIR-cohort.
Data collection
A database was built by the use of standardized Case Record Form (CRF) on which the 
following, among others, needed to be filled out: physical examination, on-going treatment, 
co-morbidities, laboratory tests and questionnaires, according to the DESIR protocol 9. The 
database used for this analysis was locked on October 30th 2012.
Images and scoring methods
Two central readers (RvdB and GL), both familiar with scoring SI-joints on plain radiographs 
(X-SI) in the anteroposterior view according to the modified New York (mNY) method, 
participated in a calibration session. A grade 0 is given for a normal SI-joint; 1 for suspicious 
changes; 2 for minimal abnormality - small localised areas with erosions or sclerosis without 
alteration in joint width; 3 for unequivocal abnormality - with one or more erosions, 
evidence of sclerosis, joint space narrowing or widening or partial ankylosis, and grade 4 
for severe abnormality - a complete ankylosis of the SI-joint. Sacroiliitis is defined as grade 
≥2 bilaterally or grade 3-4 unilaterally 1. The calibration session was a systematic conducted 
exercise, executed by two senior radiologists (MR and AF) and two senior rheumatologists 
(PC and MD), who already did such calibration sessions before. The whole process was 
supervised by an expert in AS and imaging scoring (DvdH). During the first step of the 
calibration process, definitions of lesions, examples and pitfalls were discussed. The second 
step of the calibration session consisted of independently reading of training cases by the two 
readers, under the supervision of those radiologists and rheumatologists. The results of the 
readings were discussed plenary by the senior radiologists and rheumatologists, focussing 
on disagreement regarding specific lesions between the two readers in order to achieve 
agreement. In the third step of the calibration process, 30 X-SIs were read independently 
by the two central readers. The fourth step consisted of a consensus meeting in which the 
same four senior radiologists/rheumatologists participated as well. Again, during a plenary 
presentation the disagreements between the two readers were discussed by one of the 
senior radiologists/rheumatologist in order to achieve agreement. Next, in a fifth step a 
second set consisting of 20 X-SIs were read independently, again followed by the last step 
consisting of a consensus meeting with the same senior radiologists/rheumatologists 
executed in the same manner. At that time, interreader agreement largely improved 
even though we recognized that the kappas were still moderate (kappa=0.55). However, 
considering the results of the study by van Tubergen et al. showing that training did not 
improve performance 7, we didn’t expect significant further improvements in agreement. 
Moreover the kappas were in the same range as what have been found in other studies as 
well (kappas ranging between 0.12 and 0.69) 6, 12, thereby justifying the decision that the two 
readers could start reading the DESIR-cohort.
Baseline X-SIs were acquired according to a standardized method, provided in the DESIR 
protocol. All available digital baseline X-SIs of the DESIR-cohort (n=688) were read 
independently by the two trained central readers according to the mNY criteria, blinded 
for all clinical and laboratory data, as well as for the results of the local reads for the X-SIs. 
Agreement on fulfilllment of the mNY criteria for radiographic sacroiliitis at the patient level 
between the two readers was calculated and in case the readers disagreed, a radiologist 
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experienced in the field of SpA (MR) served as adjudicator. A radiograph of the SI-joints was 
marked positive for sacroiliitis if 2/3 readers agreed on the fulfilllment of mNY criteria (ie: at 
least unilateral grade 3 sacroiliitis, or at least bilateral grade 2 sacroiliitis), hereafter called 
‘central reading’. Furthermore, the two central readers marked the type of lesions they 
recognized (erosions, sclerosis, joint space widening/narrowing and (partial) ankylosis).
Local radiologists or rheumatologists who might have access to all clinical information and 
lab test results at each study center, read all available baseline radiograph of the SI-joint in 
their own center, hereafter called ‘local reading’. Since the local readers, who are working in 
regular clinical practice, were not trained experts it was considered more appropriate to use 
a scoring system that better resembles common clinical practice than the mNY criteria do: 
local readers were asked to rate each SI-joint either as ‘normal’ or as ‘doubtful sacroiliitis’ 
or as ‘obvious sacroiliitis’ or as ‘SI-joint fusion’ 13. No specification of the type of lesions 
was provided by the local readers. In this scoring method, at least a unilateral rating of 
’obvious sacroiliitis’ was considered sufficient to fulfill the imaging criterion of sacroiliitis. 
This was our primary analysis with regard to the comparison with the fulfilllment of the 
mNY by central reading. In a second analysis, we have further compared a rating of ‘bilateral 
‘obvious sacroiliitis’ or unilateral ‘fusion’’ with the fulfilllment of the mNY criteria by central 
reading. Finally, we have also used a stricter definition of the mNY criteria of the central 
reading: at least bilateral grade 3 or unilateral grade 4.
To compare the grading of the individual SI-joints of the central readers to the scoring of 
the individual SI-joints by the local readers, central mNY grades 2 and 3 were combined 
and compared to local ‘obvious sacroiliitis’ and mNY grade 4 was compared to local ‘SI-
joint fusion’ for each central reader separately. Moreover, central mNY grades 3 and 4 were 
combined and compared to the local read ‘fusion’ again for each central reader separately.
Statistical analysis
Agreement was calculated using cross-tabulation expressed in Cohen’s Kappa (κ) or linear 
weighted kappa (κW) as appropriate, agreement on the positive cases (positive agreement) 
and agreement on the negative cases (negative agreement) for the following comparisons 14, 15: 
interreader agreement on the presence/absence of radiographic sacroiliitis between the 
two central readers, between local reading and central reading using the various definitions 
for sacroiliitis explained above, and interreader agreement on the type of lesion (erosions, 
sclerosis, joint space narrowing/widening and ankylosis) between the two central readers 
and on the grading of the SI-joints between the two central readers and between local 
reading and central reading as explained above. Sensitivity, specificity, positive predictive 
values (PPV), negative predictive values (NPV) as well as the number of false-positive and 
false-negative classifications by local reading versus central reading as external standard 
were calculated.
Among the patients with a positive X-SI according to local reading, it was investigated which 
type of lesion was most frequently scored by the central readers separately.
All kappas were interpreted according to the standards proposed by Landis and Koch; 
values <0 as indicating no agreement and 0-0.20 as slight, 0.21-0.40 as fair, 0.41-0.60 as 
moderate, 0.61-0.80 as substantial, and 0.81-1 as almost perfect agreement 16. SPSS 
software version 20.0 was used for the statistical analysis.
Results
The mean age of the 688 included patients was 31.6 (SD 8.6) years, the mean symptom 
duration was 17.7 (SD 10.5) months, 368 (53.5%) patients were men and 405 (58.9%) 
patients were HLA-B27 positive. In 648/688 patients imaging data was complete; in 40 
additional patients data on MRI-SI was missing. In 582/648 patients with available imaging 
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data the ASAS axSpA criteria could be applied. The remaining 66 patients had an onset of IBP 
>45 years of age. Based on local scoring of imaging for sacroiliitis, 408/582 patients (70.1%) 
fulfilled the ASAS axSpA criteria (84.1% HLA-B27 positive). One hundred sixty-one fulfilled 
the ASAS axSpA criteria based on the presence of radiographic sacroiliitis (at least unilateral 
’obvious sacroiliitis’; 75.8% HLA-B27 positive); 83/408 based on inflammatory sacroiliitis on 
MRI as judged by the local reading (67.5% HLA-B27 positive) and the remaining 164/408 
patients fulfilled the ASAS axSpA criteria based on HLA-B27 positivity.
Table 1: Interreader agreement between central reader 1 and central reader 2 in SI-joints 









modified New York + modified New York –
modified New York + 96 58
modified New York – 50 484
 κ (95% CI): 0.54 (0.46-0.62) Positive agreement: 64.0% Negative agreement: 90.0%
Erosions + Erosions – 
Erosions + 132 131
Erosions – 133 980
κ (95% CI): 0.38 (0.32-0.44) Positive agreement: 50.0% Negative agreement: 88.1%
Sclerosis + Sclerosis – 
Sclerosis + 182 144
Sclerosis – 133 917
κ (95% CI): 0.44 (0.38-0.49) Positive agreement: 56.8% Negative agreement: 86.9%
Joint space widening + Joint space widening –
Joint space widening + 13 137
Joint space widening – 10 1216
κ (95% CI): 0.13 (0.06-0.19) Positive agreement: 15.0% Negative agreement: 94.3%
Joint space narrowing + Joint space narrowing –
Joint space narrowing + 14 127
Joint space narrowing – 21 1214
κ (95% CI): 0.12 (0.05-0.20) Positive agreement: 15.9% Negative agreement: 94.3%
Ankylosis + Ankylosis –
Ankylosis + 27 63
Ankylosis – 67 1219
κ (95% CI): 0.24 (0.15-0.33) Positive agreement: 29.3% Negative agreement: 94.9%
Not possible to evaluate: n=27 for right SI-joint and n=29 for left SI-joint. Positive agreement is the 
agreement on positive cases. Negative agreement is the agreement on negative cases.
Agreement between the two central readers
Agreement between the two central readers regarding absence/presence of radiographic 
sacroiliitis (mNY) is moderate (κ=0.54; table 1). The adjudicator needed to read 108/688 
X-rays (15.7%) because of disagreement between the 2 central readers.
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Agreement regarding the grading of the SI-joints is also moderate (κW=0.56 for both left 
and right SI-joints; table 2). Most disagreement is seen in grade 0 versus grade 1, followed 
by grade 0 versus grade 2, and followed by grade 1 versus grade 2. Similar numbers of 
disagreement are seen for grade 2 versus grade 3 as for grade 1 versus grade 2. Depending 
on the grade of the other SI-joint, this could cause a different classification of a patient. 
The remaining numbers of disagreement are seen in grade 0 versus grade 3 and, and in 
grade 1 versus grade 3. With these types of disagreement, a patient is classified differently 
regardless of the grade of the other SI-joint of the patient.
Table 2: Interreader agreement of the grading of the SI-joints (mNY) between central reader 1 and 
central reader 2.
Central reader 2
Central reader 1 Right SI-joint Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Grade 0 345 51 35 4 0
Grade 1 28 14 17 5 0
Grade 2 26 16 40 15 0
Grade 3 7 6 19 45 0
Grade 4 0 0 0 5 2
κW (95% CI): 0.56 (0.50-0.61) 
Central reader 2
Central reader 1 Left SI-joint Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Grade 0 369 48 22 6 0
Grade 1 15 13 14 10 0
Grade 2 24 26 33 20 0
Grade 3 8 7 23 34 0
Grade 4 0 0 0 1 5
κW (95% CI): 0.56 (0.51-0.62)
Not possible to evaluate: n=27 for right SI-joint and n=29 for left SI-joint.
Agreement between local reading and central reading 
According to local reading (at least unilateral ’obvious sacroiliitis’) 183/688 patients (26.6%) 
had radiographic sacroiliitis and according to central reading 145/688 patients (21.1%) had 
radiographic sacroiliitis. Agreement between local reading and central reading was very 
similar to the interreader agreement between the two central readers (κ=0.55). Comparing 
local reading to the scores of the individual central readers revealed very similar levels of 
agreement (table 3).
In the comparison of local reading to central reading, 76 out of the 183 patients (41.5%) 
with a positive radiograph of the SI-joints according to local reading were read negative by 
central reading; 38 patients out of 505 (7.5%) negative radiographs of the SI-joints according 
to local reading were read positive by central reading (table 3). In daily practice, where local 
readers judge the X-SIs, this would mean that 41.5% of the AS patients are overclassified 
compared to central reading as external standard (45.9% compared to reader 1 and 42.1% 
compared to reader 2) and that AS (according to central reading) is not recognized in 7.5% of 
the patients compared to central reading as external standard (10.9% compared to reader 1 
and 7.9% compared to reader 2).
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Seventy-six of the 183 patients with ’obvious sacroiliitis’ according to local reading had 
unilateral ‘obvious sacroiliitis’; thirty of these were rated as ‘negative’ by central reading. 
If only patients with at least bilateral ‘obvious sacroiliitis’ or at least unilateral ‘fusion’ were 
considered ‘positive’ by local reading, still 32/109 patients (29.4%) were rated as ‘negative’ 
by central reading (according to the original mNY; κ=0.52). The proportion of negative ratings 
according to this definition of local reading that were rated ‘positive’ by central reading 
increased to 11.7% (68/579).
Thereafter we compared this more stringent definition of positivity by local reading with 
a more stringent definition of positivity by central reading (at least grade 3 bilateral or 
grade 4 unilateral involvement). This resulted in reduced agreement (κ=0.44 for reader 1 
and κ=0.43 for reader 2), showing even a higher number of patients being overclassified 
as AS according to local reading compared to the central readers (62.4% and 65.1% reader 
1 and 2 respectively). The interreader agreement between the two central readers for this 
stricter mNY definition of sacroiliitis was again only moderate (κ=0.56), but better than the 
agreement between local reading and the individual central readers. Even with the most 
stringent definition of sacroiliitis (‘positivity‘ defined as bilateral fusion in the local reading 
and bilateral grade 4 in the central reading) still huge disagreement between local reading 
and the individual central readers was seen (table 3).
Table 4 shows the comparison of the individual ratings of local reading and the mNY 
gradings per SI-joint of central reading on a individual reader basis. For the determination 
of agreement, we have both combined mNY grades 2 and 3 (for ‘positivity’) as well as mNY 
grades 3 and 4, and compared these with ‘obvious sacroiliitis’ from the local read. The kappas 
were only moderate (range 0.36-0.51) with regard to both readers and both definitions.
Table 3: Agreement between local reading and central reading of presence/absence of sacroiliitis, for 
the various definitions of sacroiliitis. 
Central reader 1




Sacroiliitis + Sacroiliitis -
Sacroiliitis + 99 84
Sacroiliitis - 55 450
κ (95% CI): 0.46 (0.38-0.53) Pos. agreem.: 58.8% Neg. agreem.: 86.6%
Central reader 2
Sacroiliitis + Sacroiliitis -
Sacroiliitis + 106 77
Sacroiliitis - 40 465
κ (95% CI): 0.53 (0.46-0.61) Pos. agreem.: 64.4% Neg. agreem.: 88.8%
Central reading (2/3 readers)
Sacroiliitis + Sacroiliitis -
Sacroiliitis + 107 76
Sacroiliitis - 38 467
κ (95% CI): 0.55 (0.47-0.62) Pos. agreem.: 65.2% Neg. agreem.: 89.1%










Sacroiliitis + Sacroiliitis -
Sacroiliitis + 74 35
Sacroiliitis - 80 499
κ (95% CI): 0.46 (0.38-0.55) Pos. agreem.: 56.3% Neg. agreem.: 89.7% 
Central reader 2
Sacroiliitis + Sacroiliitis -
Sacroiliitis + 76 33
Sacroiliitis - 70 509
κ (95% CI): 0.51 (0.42-0.59) Pos. agreem.: 59.6% Neg. agreem.: 90.8%
Central reading (2/3 readers)
Sacroiliitis + Sacroiliitis -
Sacroiliitis + 77 32
Sacroiliitis - 68 511
κ (95% CI): 0.52 (0.44-0.60) Pos. agreem.: 60.6% Neg. agreem.: 91.1%
Reader 1, strict definition (≥3 bilaterally, or 4 
unilaterally)






Sacroiliitis + Sacroiliitis -
Sacroiliitis + 41 68
Sacroiliitis - 15 564
κ (95% CI): 0.44 (0.34-0.53) Pos. agreem.: 49.7% Neg. agreem.: 93.1%
Reader 2, strict definition (≥3 bilaterally, or 4 
unilaterally)
Sacroiliitis + Sacroiliitis -
Sacroiliitis + 38 71
Sacroiliitis - 10 569
κ (95% CI): 0.43 (0.33-0.53) Pos. agreem.: 48.4% Neg. agreem.: 93.4%
Reader 1, strict definition (≥4 bilaterally)
Local reading 
(bilateral ‘fusion’)
Sacroiliitis + Sacroiliitis -
Sacroiliitis + 2 3
Sacroiliitis - 3 680
κ (95% CI): 0.40 (0.01-0.78) Pos. agreem.: 40.0% Neg. agreem.: 99.6%
Reader 2, strict definition (≥4 bilaterally)
Sacroiliitis + Sacroiliitis -
Sacroiliitis + 0 5
Sacroiliitis - 1 682
κ (95% CI): 0.00 (0.00-0.00) Pos. agreem.: 0.00% Neg. agreem.: 99.6%
Pos. agreem. is the agreement on positive cases. Neg. agreem. is the agreement on negative cases. 
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Sensitivity, specificity, NPV (negative predictive value) and PPV (positive predictive value) applies to 
the comparison of the local reading (at least unilateral ‘obvious sacroiliitis’) to the central reading (≥2 
bilaterally, or ≥3 unilaterally, 2/3 readers).








Right SI-joint Grade 0 Grade 1 Grade 2* Grade 3*^ Grade 4^
Normal 321 36 37 15 0
Doubtful sacroiliitis 80 16 28 10 1
Obvious sacroiliitis 34 10 31 49 3
Fusion 0 2 1 3 3
* Grade 2 and 3 of central reader 1 combined: κW (95% CI): 0.40 (0.34-0.46) 







Left SI-joint Grade 0 Grade 1 Grade 2* Grade 3*^ Grade 4^
Normal 336 21 36 15 0
Doubtful sacroiliitis 77 12 24 9 1
Obvious sacroiliitis 31 18 42 44 1
Fusion 0 1 2 4 4
* Grade 2 and 3 of central reader 1 combined: κW (95% CI): 0.45 (0.38-0.51)  







Right SI-joint Grade 0 Grade 1 Grade 2* Grade 3*^ Grade 4^
Normal 324 46 32 10 0
Doubtful sacroiliitis 64 27 33 10 1
Obvious sacroiliitis 21 14 45 50 0
Fusion 1 1 1 5 1
* Grade 2 and 3 of central reader 2 combined: κW (95% CI): 0.48 (0.42-0.54) 







Left SI-joint Grade 0 Grade 1 Grade 2* Grade 3*^ Grade 4^
Normal 330 50 23 7 0
Doubtful sacroiliitis 60 29 25 12 1
Obvious sacroiliitis 28 17 45 48 1
Fusion 0 0 0 8 3
* Grade 2 and 3 of central reader 2 combined: κW (95% CI): 0.51 (0.45-0.57) 
^ Grade 3 and 4 of central reader 2 combined: κW (95% CI): 0.44 (0.39-0.49) 
Not possible to evaluate: n=27 for right SI-joint and n=29 for left SI-joint. Positive agreement is the 
agreement on positive cases. Negative agreement is the agreement on negative cases.
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Types of lesions
Regarding the type of lesion, agreement between the two central readers varied from 
κ=0.12 for joint space narrowing to κ=0.44 for sclerosis (table 5). The prevalence of joint 
space alterations and ankylosis is low in this cohort of recent onset IBP patients; among the 
SI-joints graded as at least grade 3 the prevalence of joint space widening was 8.7% (reader 
2) and 24.6% (reader 1) and the prevalence of ankylosis was 13.7% (reader 1) and 27.3% 
(reader 2). The frequency of erosions and sclerosis in SI-joints graded as 2 was very similar 
to the frequency of erosions and sclerosis in SI-joints graded as 3, for both readers.
Among the patients with a positive radiograph of the SI-joints according to local reading (at 
least unilateral ’obvious sacroiliitis’), sclerosis was the most frequently reported lesion by 
the central readers (56.8% according to reader 1 and 72.7% according to reader 2), followed 
by erosions (50.3% according to reader 1 and 61.2% according to reader 2) (table 5).
Table 5: Frequency of lesions read by the central reader 1 and central reader 2 among patients with a 
positive radiograph of the SI-joints according to local reading (at least unilateral ’obvious sacroiliitis’) 
(n=183).
Type of lesion (%) Reader 1 Reader 2
Erosions 50.3 61.2
Sclerosis 56.8 72.7
Joint space widening 24.6 8.7
Joint space narrowing 24.0 11.5
Ankylosis 13.7 27.3
Discussion 
In the DESIR-cohort, the interreader agreement between two trained central readers and 
between local reading and central reading of X-SIs is moderate at best. The two central 
trained readers showed only moderate agreement with regard to presence/absence of 
radiographic sacroiliitis, grading of the SI-joints and about type of lesion, yet comparable to 
levels of agreement reported in previous studies where central readers were also trained 
(κ=0.12-0.69 for absence/presence of sacroiliitis; κ=0.22 for erosions; κ=0.26 for sclerosis 
and κ=0.19 for joint space alterations) 6, 12, 17. Furthermore, interreader agreement was at a 
similar level as the agreement between local reading and central reading about presence/
absence of radiographic sacroiliitis and grading of the SI-joints.
As it was not specified which X-SIs were judged by local radiologists and which by local 
rheumatologists, it was not possible to compare the readings of radiologists and 
rheumatologists separately to the central reading. However, we did not expect a difference 
in number of misclassified patients between radiologists and rheumatologists based on the 
findings of van Tubergen et al., and based on our own findings regarding presence/absence 
of sacroiliitis on MRI in the DESIR-cohort 7, 18. Moreover, the results of an unpublished ASAS 
survey pointed out that more than 55% of the rheumatologists rely on both the judgement 
of the radiologist as well as their own judgement in assessing sacroiliitis on radiographs 
(M. Rudwaleit, personal communication, January 18 2014, unpublished data from an ASAS 
survey).
Misclassifications could have major implications for a patient, as the presence/absence of 
sacroiliitis is the only difference in the classification of AS (mNY) versus nr-axSpA or even 
no SpA. This is indeed what the results show; 41.5-45.9% of the patients classified as AS by 
the local readers are falsely classified with the central read as external standard and 7.5-
10.9% of the AS patients according to the central read is not recognized in daily practice. 
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The percentages of misclassified patients are somewhat higher than reported in another 
study where 11.4% of AS patients according to local readers were reclassified as nr-axSpA 
by central trained readers, and 15.5% of nr-axSpA patients according to local readers were 
reclassified as AS by central readers 19. However, these lower percentages can probably be 
explained by the fact that this study also included patients with longstanding AS (>10 years) 
showing more severe lesions which are easier to recognize, the fact that the presence/
absence of syndesmophytes in the spine was taken into account as well, and by the fact that 
both readers had to agree on the absence/presence of sacroiliitis thereby not looking at a 
possible reclassification of patients in whom the two central readers disagreed regarding 
the presence/absence of sacroiliitis 19.
As our aim was to compare the diagnostic performance of readers in daily clinical practice 
to the performance of trained expert readers using the mNY grading system for the 
classification of patients in studies, we have applied a “daily practice definition” of sacroiliitis: 
in daily clinical practice, a rheumatologist will consider a diagnosis of axial SpA when there is 
‘obvious sacroiliitis’ at least unilaterally, but obviously the rheumatologist is more convinced 
of a diagnosis of axial SpA in case of bilateral involvement. Here we have examined both 
definitions of ‘positivity’: one more lenient and one more stringent definition. If ‘at least 
unilateral ‘obvious sacroiliitis’’ in the local read was required for positivity, 41.5% of the 
patients with radiographic sacroiliitis could not be confirmed by central reading (using 
the original mNY definition). However, even if ‘bilateral ‘obvious sacroiliitis’ or at least 
unilateral ‘fusion’’ by the local reading was required for positivity, still 29.4% of the patients 
with a local diagnosis of AS could not be confirmed by central reading. This percentage of 
misclassification increased to 62.4% (reader 1) and 65.1% (reader 2) if we compared the 
local rating of either ‘bilateral ‘obvious sacroiliitis’ or unilateral ‘fusion’’ with a similarly strict 
definition of sacroiliitis by central reading (at least grade 3 bilaterally or unilateral grade 4).
As the local and central reading are not identical, the true percentage of misclassified 
patients must be between 29.4% and 65.1%, and likely around 40-45% as the use of ‘at least 
unilateral ‘obvious sacroiliitis’’ by the local reader is what is required in clinical practice to 
classify a patient as having AS. While this study has been performed in the DESIR centers 
in France, and generalizability is formally restricted, there is no valid reason to assume that 
clinical rheumatologists in other countries apply different diagnostic reasoning.
As the local readers did not mark a specification of the type of lesions, the reads of the 
central readers were used to gain insight in which type of lesion was best recognized by 
the local readers. However, because of the low prevalence of joint space alterations and 
ankylosis it is difficult to investigate the agreement on recognizing this type of lesion. Yet, if 
joint space alterations are present, the two central readers recognized ankylosis more easily 
than widening or narrowing of the joint space. The prevalence of sclerosis and erosions, on 
the other hand, is higher and both types of lesions are more easily recognized than joint 
space alterations as shown by the higher kappas.
Although the question whether training improves recognition of radiographic sacroiliitis was 
not addressed directly in this study, the fact that the agreement between local reading and 
central reading is so similar to the interreader agreement between the two trained central 
readers seems to confirm the findings of van Tubergen et al. 7 that training does not improve 
recognition of radiographic sacroiliitis. This arises the question whether it is necessary for 
DESIR and similar cohorts to have a central reading of the radiographs of the SI-joints instead 
of a local reading. It could be argued based on the discovered levels of agreement that there 
is no preference for central readers over local readers since both trained central readers 
and local readers can only poorly recognize radiographic sacroiliitis. Nonetheless, central 
reading consisting of a judgement of 2 out 3 agreeing readers suggests being more robust 
than a local reading based on the opinion of a single reader. Depending on the research 
question, a choice could be made which reads to use: either the reads that would have been 
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used in clinical practice as well, or the reads of the central reading based on a majority read 
of 2 out of 3, which are closer to the truth.
For both local and trained central readers, the recognition of radiographic sacroiliitis remains 
challenging. Nevertheless, the only difference between AS and nr-axSpA is the presence of 
radiographic sacroiliitis. A patient can be classified as AS if only IBP is present in addition to 
radiographic sacroiliitis while in the absence of radiographic sacroiliiitis and in the absence 
of a positive MRI (ASAS definition) a minimum of 3 other SpA-features must be present 
in order to classify the patient as axSpA 3. The fact that a patient is classified differently, 
based on a different read of the same radiograph of the SI-joints - which is shown to happen 
frequently - arises the question how ‘gold’ this distinction between AS and nr-axSpA is. It 
is worrisome that such a small factor can have major consequences for a patient, not only 
in terms of diagnosis but also in terms of treatment as based on the presence/absence of 
radiographic sacroiliitis TNFi can be administered or not. Moreover, inclusion of patients 
in clinical trials is based on the presence/absence of radiographic sacroiliitis as judged by 
either local or central readers. Rereading the radiographs by different readers or even 
blinded rereading of the same radiographs by the same readers could lead to significant 
change in classification of the patients 6.
A limitation of this study is the lack of a gold standard as CT, to confirm the presence/absence 
of sacroiliitis 20. Furthermore, this study focussed on sacroiliitis on conventional radiographs 
only. The role of MRI in the diagnosis and classification of axSpA should be investigated in 
more detail as well as its correlation to conventional radiographs.
In conclusion, in patients with recent onset IBP, individually trained central readers disagree 
as much as clinical practice local rheumatologists/radiologists in recognizing radiographic 
sacroiliitis. While the two central readers disagree with each other in a balanced manner 
(disagreement in both directions, reflecting measurement error), the local readers primarily 
overrate sacroiliitis in comparison with central readers, which results in an unacceptably high 
percentage of false-positive diagnoses of AS. A small minority of patients with a classification 
of AS according to central reading is not recognized in daily clinical practice. Independently 
of the precise definition of sacroiliitis, the disagreement regarding the presence/absence of 
sacroiliitis is so significant that the role of radiographic sacroiliitis as a diagnostic criterion 
for axSpA should be re-evaluated.
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Abstract
Objective
Investigating changes in patient classification (ASAS axSpA criteria) based on evaluation of 
images of the sacroiliac joints (MRI-SI and X-SI) by local and central readers.
Methods
The DESIR-cohort included patients with inflammatory back pain (IBP; ≥3 months, but <3 
years), suggestive of axSpA. Local radiologists/rheumatologists (local reading) and two 
central readers (central reading) evaluated baseline images. Agreement regarding positive 
MRI (pos-MRI) between central readers and between local reading and central reading was 
calculated (kappas). Number of patients classified differently (ASAS criteria) by using local 
reading instead of central reading was calculated.
Results
Interreader agreement between the two central readers and between local reading and 
central reading was substantial (κ=0.73 and κ=0.70, respectively). In 89/663 MRI-SIs (13.4%) 
local reading and central reading disagreed; 38/223 patients (17.0%) with pos-MRI (local 
reading) were negative by central reading; 51/440 patients (11.6%) with neg-MRI (local 
reading) were positive by central reading.
In 163/582 patients eligible for applying ASAS criteria (28.0%), local reading and central 
reading disagreed on positive imaging (MRI-SI and/or X-SI; κ=0.68). In 46/582 patients 
(7.9%) a different evaluation resulted in a different classification; 18/582 patients (3.1%) 
classified no SpA (central reading) were axSpA by local reading; 28/582 patients (4.8%) 
classified axSpA (central reading) were no SpA by local reading. Among axSpA patients 
(central reading), 16/419 patients (3.8%) fulfilling imaging arm by central reading fulfilled 
clinical arm by local reading; 29/419 patients (6.9%) fulfilling clinical arm by central reading 
fulfilled also imaging arm by local reading.
Conclusion 
In patients with recent onset IBP, trained readers and local rheumatologists/radiologists 
agree well on recognizing a pos-MRI. While disagreeing in 28% of the patients on positive 
imaging (MRI-SI and/or X-SI), classification of only 7.9% of the patients changed based on a 
different evaluation of images, showing the ASAS axSpA criteria’s robustness.
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Introduction 
The 2009 classification criteria for axial spondyloarthritis (axSpA) by the Assessment 
of SpondyloArthritis international Society (ASAS) are gaining more awareness and are 
increasingly being used to guide daily practice and include patients in clinical trials 1-3. 
According to the ASAS axSpA criteria it is possible to classify patients with chronic back 
pain as axSpA via the clinical arm based on the presence of at least two SpA-features in 
addition to HLA-B27 positivity, or to classify patients via the imaging arm. In the presence 
of sacroiliitis on plain radiographs (modified New York (mNY) criteria) and/or MRI (ASAS 
definition of a positive MRI (pos-MRI)), a patient can be classified as axSpA if at least one 
additional SpA-feature should be present 1, 4, 5. However, recognition of sacroiliitis on MRI and 
especially on plain radiographs is challenging 6-8. It is known that interpretation of findings 
vary according to the expertise of the physician interpreting the image 7. In daily practice, 
local radiologists and/or rheumatologists judge MRIs and radiographs of the SI-joints, 
frequently with knowledge of the clinical signs and symptoms, while in research cohorts 
and clinical trials ≥1 trained reader - blinded for clinical information - judge the images. As 
the classification as axSpA is heavily based on sacroiliitis, the classification of a patient could 
change as another reader judges the same MRI and/or radiographs differently. The ABILITY-1 
trial included patients with non-radiographic axSpA (nr-axSpA), based on readings of the 
pelvic radiographs by local radiologists or rheumatologists. A post-hoc central reading (for 
another purpose) was performed and based on this reading, 37% of the patients classified 
as nr-axSpA by local sites were reclassified as fulfilling the mNY criteria 3, 9. In another trial, 
the RAPID-axSpA trial, a similar analysis was performed resulting in reclassification of 36% of 
the patients (26% reclassified as fulfilling the mNY criteria, and 10% reclassified as nr-axSpA, 
based on the central reading in contrast to the local reading) 2, 10.
As sacroiliitis by two imaging methods as well as HLA-B27 positivity play an important role 
in the ASAS axSpA criteria, a patient will not necessarily be classified differently based on 
another reading of the radiograph and/or MRI of the SI-joints. Therefore, we investigated 
the change in classification of patients according to the ASAS axSpA criteria based on 
the evaluation of local and central readers of the same set of images. We performed this 
investigation in the DESIR (DEvenir des Spondylarthropathies Indifférenciées Récentes)-
cohort, which has information on MRIs and radiographs of the SI-joints scored by the local 
rheumatologist or radiologist and also by two trained central readers. 
Methods
Patients
Baseline data from the DESIR-cohort was used for this analysis. The DESIR-cohort is 
described extensively before 11. In short, consecutive patients aged 18-50 with Inflammatory 
Back Pain (IBP) in the thoracic and/or lumbar spine and/or the buttock area (≥3 months, 
but <3 years) fulfilling either the Calin (4/5 criteria) or the Berlin (2/4 criteria) for IBP and 
a suspicion of SpA by the rheumatologist with a score of ≥ 5 on a scale of 0 to 10 (where 
0 was not suggestive of axSpA and 10 was very suggestive of axSpA) from 25 centers in 
France were included in this prospective longitudinal cohort 12, 13. In total, 708 patients were 
included between December 2007 and April 2010. The study is approved by the appropriate 
medical ethical committee and fulfilled Good Clinical Practice Guidelines. Before patients 
were included in the study, they gave written informed consent. 
A detailed description of the study protocol is available at the website (http://www.
lacohortedesir.fr/desir-in-english/). The research proposal for this particular analysis was 
approved by the scientific committee of the DESIR-cohort. 
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Data collection
With the use of a standardized CRF a database was built. According to the DESIR protocol 
the following data, among others, were collected: physical examination, ongoing treatment, 
co-morbidities, laboratory tests and questionnaires 11. The database for the baseline data 
used for this analysis was locked on October 30th 2012. 
Images and scoring methods
In each participating center MRIs of the SI-joints (MRI-SIs) were performed at baseline, with 
magnetic fields between 1.0 and 1.5T, using T1-FSE and STIR sequences with 12-15 semi-
coronal slices of 4 mm thickness, parallel to the long axis of the sacrum, without the use of a 
contrast agent. All initial MRI-SIs were checked on quality by a central reader in Montpellier, 
and regular calibration by the manufacturer was required. Plain radiographs of the pelvis 
(X-SI) were performed in anteroposterior view at baseline. 
All available baseline MRI-SIs (n=663) were scored by a local radiologist/rheumatologist who 
might have had access to all clinical and laboratory data at each participating center (local 
reading) 14. Each SI-joint on MRI was assessed on the presence/absence of inflammation 
by answering the following question on the CRF ‘Are there characteristic acute/active 
inflammatory lesions compatible with axial spondyloarthritis of the sacroiliac joints or 
entheses, outside the sacroiliac joints? Normal (score 0), doubtful (score 1) or abnormal 
(score 2).’ On the CRF, inflammatory lesions were defined as ‘Bone edema/contrast product 
uptake in or adjacent to the sacroiliac joints or entheses (compatible with active lesions 
observed in cases of ankylosis spondylitis/axial spondyloarthritis; STIR and/or T1 sequences 
with gadolinium injection are required).’ In this reading, a pos-MRI was defined as a score of 
2 in at least one of the SI-joints. 
Two central readers (RvdB and FT), experienced in scoring MRI-SIs, participated in a 
calibration training on reading MRI-SIs according to the ASAS definition. MRI-SIs were 
considered positive according to the ASAS definition if BME lesions highly suggestive of 
SpA were present if ≥1 BME lesion on ≥2 consecutive slices, or if several BME lesions are 
visible on a single slice. The presence of only synovitis, enthesitis or capsulitis without BME 
is not sufficient for a positive MRI-SI 5. During the calibration session, executed by two senior 
radiologists (MR and AF) and two senior rheumatologists (PC and MD), supervised by an 
expert in AS and imaging scoring (DvdH), definitions of lesions, examples and pitfalls were 
discussed, followed by a supervised reading of training cases by the two readers. After this 
calibration session, 30 blinded MRI-SIs were read independently by the two readers (κ=0.30; 
positive agreement 73.7%; negative agreement 54.5%). A consensus meeting followed 
with the same group. Six weeks later, a second set consisting of 20 blinded MRI-SIs, were 
read independently by the two readers, again followed by a consensus meeting with the 
same group. After this second training session, agreement between the two readers was 
considered sufficient  so the readers could start reading the DESIR-cohort (κ=0.74; positive 
agreement 80.0%; negative agreement 93.3%). 
All available baseline MRI-SIs were read independently by the two readers, blinded for 
all clinical and laboratory data, the other imaging modality, as well as the local readings. 
Agreement on presence/absence of a pos-MRI was calculated and in case of disagreement, 
one of the senior radiologists involved in the calibration session (MR) served as adjudicator 
and scored the MRI-SI blinded to the information of the primary readers. An image was 
marked as pos-MRI (central reading) if 2/3 readers agreed. 
The evaluation of X-SIs (n=688) by both local readers and central readers has been described 
before 8. In short, the calibration of the two central readers (RvdB and GL) was performed 
in a similar way as for MRI-SI. Based on the mNY criteria, sacroiliitis was defined as grade ≥2 
bilaterally or grade 3-4 unilaterally by central reading (pos-X-SI) 4. The local readers evaluated 
X-SIs according to a method derived from the mNY. Since the local readers, who are working 
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in regular clinical practice, were not trained experts it was considered more appropriate use 
a scoring system that better resembles common clinical practice than the mNY criteria do. 
Local readers were asked to rate each SI-joint either as ‘normal’ or as ‘doubtful sacroiliitis’ 
or as ‘obvious sacroiliitis’ or as ‘SI-joint fusion’. In this analysis at least a unilateral rating of 
‘obvious sacroiliitis’ was considered a pos-X-SI for local reading. This has been explained in 
more detail before 8.
Statistical analysis
Agreement was calculated using cross-tabulation expressed in Cohen’s Kappa (κ), agreement 
on positive cases (positive agreement) and on negative cases (negative agreement) for the 
following comparisons (online supplementary text 1) 15-18: interreader agreement between 
the two central readers, agreement between local reading and central reading and between 
local reading and the two individual central readers on the presence/absence of a pos-MRI. 
Central reading was considered the external standard. 
Next, the number of patients with a different MRI-SI and/or X-SI read using local reading 
instead of central reading was calculated, followed by the number of patients classified 
differently according to the ASAS axSpA criteria. This was done both for overall fulfillment 
and fulfillment of the imaging versus clinical arm. 
SPSS software version 20.0 was used for the statistical analysis.
Results
The mean age of patients with available MRI-SI (n=663) was 31.7 (SD 8.7) years, mean 
symptom duration was 17.8 (SD 10.5) months, 309 (46.6%) patients were men and 387 
(58.4%) were HLA-B27 positive. 
Finally, in 15 patients X-SI was missing resulting in 648 patients with complete imaging. In 
66/648 patients with complete imaging, IBP onset was >45 years and therefore the ASAS 
axSpA criteria could not be applied, leaving 582 patients (figure 1). Patient characteristics 
of these 582 patients were very similar to the patients with complete MRI-SI; mean age 
was 31.5 (SD 7.2) years, mean symptom duration was 18.3 (SD 10.6) months, 277 (47.7%) 
patients were men and 350 (60.1%) were HLA-B27 positive. 
Agreement on a positive MRI
Interreader agreement between the two central readers regarding a pos-MRI is substantial 
(κ=0.73; table 1); 84/663 MRI-SIs (12.7%) were adjudicated because of disagreement. 










 1 MRI-SI+ (ASAS) MRI-SI- (ASAS)
MRI-SI+ (ASAS) 200 56
MRI-SI - (ASAS) 28 379
κ (95% CI): 0.73 (0.67-0.78) Positive agreement: 82.6% Negative agreement: 90.0%
Positive agreement is the agreement on positive cases. Negative agreement is the agreement on 
negative cases.
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IBP onset >45 
years N=66
Figure 1: Flowchart of patients included in the DESIR-cohort and included in this analysis.
According to central reading, 236/663 patients (35.6%) had a pos-MRI; according to local 
reading, 33.6% had a pos-MRI. Agreement between local reading and central reading 
was also substantial (κ=0.70). In 13.4% of the MRI-SIs, local reading and central reading 
disagreed; 38/223 patients (17.0%) with a pos-MRI according to local reading, were read 
negative by central reading; 51/440 patients (11.6%) without a pos-MRI according to local 
reading, were read positive by central reading (online supplementary text 2). Comparisons 
of local reading versus the individual central readers show very similar results (table 2). 
There was no difference in agreement between local reading and central reading if MRI-SIs 
were read by local rheumatologists (n=174) or by local radiologists (n=457) (n=32 read by 
both a radiologist and a rheumatologist; data not shown).
Classification of patients according to the ASAS axSpA criteria
In this paragraph we focus only on the 582 patients in which the ASAS axSpA criteria could 
be applied. In 28.0% of the patients there was a disagreement on pos-imaging, MRI-SI and/
or X-SI (κ=0.68). In 15.6% of the patients the disagreement was caused by a different X-SI 
read only (agreement on MRI-SI); in  10.1% the read of MRI-SI was different only (agreement 
on X-SI); and in 2.2% both X-SI and MRI-SI were read differently. 
In total, 409 patients (70.2%) fulfilled the ASAS axSpA criteria based on local reading and 
419 patients (72.0%) based on central reading. In 7.9% of the patients a different evaluation 
of imaging (MRI-SI and/or X-SI) resulted in a different classification. Eighteen patients were 
classified no SpA based on central reading but were classified axSpA based on local reading; in 
28 patients it was the other way around (figure 2). In 14/18 and 13/28 patients, respectively, 
the different classification was the result of a different X-SI evaluation, consequently these 
patients changed from AS to no SpA and vice versa (table 3). The results of the comparison 
of local reading versus the individual central readers are similar (online supplementary table 
S2). 
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Table 2: Agreement between local reading and central reading, and between local reading and the 









g MRI-SI+ (ASAS) MRI-SI- (ASAS)
MRI-SI+ 185 38
MRI-SI - 51 389









g MRI-SI+ (ASAS) MRI-SI- (ASAS)
MRI-SI+ 180 43
MRI-SI - 76 364









g MRI-SI+ (ASAS) MRI-SI- (ASAS)
MRI-SI+ 177 46
MRI-SI - 51 389
κ (95% CI): 0.67 (0.62-0.73) Positive agreement: 78.5% Negative agreement: 88.9%
Positive agreement is the agreement on positive cases. Negative agreement is the agreement on 
negative cases.
Additional discrepancies were seen when interested in whether patients fulfill the imaging 
arm or the clinical arm within the ASAS axSpA criteria. By definition, patients fulfilling the 
clinical arm will always fulfill the clinical arm as HLA-B27 status will not change, but could 
fulfill the imaging arm as well, or not anymore, if a different evaluation of the same imaging 
set is used. Among the patients classified as axSpA based on central reading (n=419), 16 
axSpA patients fulfilled the imaging arm based on central reading but fulfilled the clinical 
arm only based on local reading (in 8 patients due to a different X-SI read) (figure 2). When 
solely interested in whether patients fulfilled the imaging arm of the ASAS axSpA criteria or 
not, 44 patients fulfilled the imaging arm by central reading but not by local reading. Vice 
versa, 29 axSpA patients fulfilled the clinical arm only based on central reading but fulfilled 
the imaging arm based on local reading (in 13 patients due to a different X-SI read). Again, 
when interested in whether patients fulfill the imaging arm or not, 47 patients fulfilled the 
imaging arm by local reading but not by central reading (table 3). Comparisons of local 
reading versus the individual readers show similar results (online supplementary table S1).
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Figure 2: Bar graphs representing patients with SpA (ASAS+) according to one reading (local or cen-
tral) but without SpA (dark grey) or a different arm of the ASAS criteria (light grey) according to the 
other reading (local or central) (total n=582, in 163 patients the imaging read was different between 
local and central reading). 
Table 3: Classification of patients according to the ASAS axSpA criteria using Local reading instead of 
Central reading or the individual central readers.
Patients in which local 
and central reading (2/3 
readers) differed, n=163
Central reading (2/3 readers)
























MRI+ 0 4 29 3
mNY+
MRI- 8 0 0 10
mNY-




MRI+ 0 1 13 4
mNY+
MRI- 3 0 1 10
mNY-
MRI+ 4 0 0 4
Clinical arm+ 1 7 8
No SpA (ASAS-) 3 10 15
Both arms; patients fulfil both the imaging arm and the clinical arm. Imaging arm; patients fulfil the 
imaging arm only. Clinical arm; patients fulfil the clinical arm only. MRI+; sacroiliitis on MRI. mNY+; 
sacroiliitis on radiograph. Boxes in grey are empty as a patient fulfilling the clinical arm by definition 




In the DESIR-cohort, agreement between two trained central readers as well as between 
central reading and local reading on pos-MRI was substantial, thereby comparable to levels 
of agreement reported in a study designed to test inter- and intrareader agreement between 
experienced radiologists on a pos-MRI (κ=0.79-0.85) 19. Though, it should be noted that at 
the start of the DESIR-cohort, the ASAS definition of a positive MRI-SI was not published 
yet. The levels of agreement of pos-MRI in the DESIR-cohort were higher than levels of 
agreement on pos-X-SI in the same cohort (κ=0.46-0.55). In addition, where misclassification 
by local reading regarding X-SIs almost exclusively consisted of overclassification of positive 
cases, the disagreement regarding MRI-SI is more balanced (as many positive as negative 
misclassifications) 8. 
Our data provide interesting information of what would happen in case of testing eligibility 
of patients for clinical trials. Potentially 163/582 patients in which MRI-SI and/or X-SI 
reading was different between local reading and central reading could have a different 
classification according to the ASAS axSpA criteria. If patients in the DESIR-cohort would 
have been included in a clinical trial requiring fulfillment of mNY criteria based on local 
reading, 76/183 (41.5%) of the patients would not have fulfilled the mNY criteria by central 
reading. Similarly, 38/505 (7.5%) of the patients would be included based on central reading 
but not based on local reading 8. Assuming a requirement of sacroiliitis on MRI according to 
local reading, 38/223 (17.0%) of the patients included would not be eligible based on central 
reading; the other way around, 51/440 patients (11.6%) not eligible for inclusion based on 
local reading would be included based on central reading. However, if inclusion would have 
been based on fulfillment of the imaging arm of the ASAS axSpA criteria the total percentage 
of reclassified patients would be 15.6% (91/582); 44 patients (7.6%) eligible based on central 
reading would not be included based on local reading and 47 patients (8.1%) the other way 
around. Based on the fulfillment of the entire axSpA criteria this percentage is 7.9% (46/582 
patients); 28 patients (4.8%) would be included based on central reading but not on local 
reading and 18 patients (3.1%) the other way around.
The effect of local versus central reading regarding fulfillment of mNY criteria became 
recently evident by data provided to the Food and Drug Administration (FDA). In both the 
ABILITY-I and RAPID-axSpA trial, over 25% of the patients were reclassified as fulfilling mNY 
criteria based on central reading while they were entered as nr-axSpA based on local reading 
2, 3, 9, 10. The DESIR-cohort confirms this disagreement between local and central readers in 
the largest cohort addressing this issue. Moreover, there are no data on this aspect for MRI-
SI this far, so the data presented in this study are the first data on MRI-SI in a large group 
of patients. As X-SI reading is so unreliable, the question arises whether it would be an 
option to only conduct MRI-SI and leave out X-SI completely, especially if structural lesions 
on MRI-SI are considered as well. More data from other cohorts, including patients with 
long-standing disease, are necessary to address this question in more detail. 
Without knowing the truth of the result of imaging, central reading based on a consensus 
score of 2/3 readers, is the best approximation of the truth, followed by the reading of one 
central reader trained in the scoring, followed by local reading, (readers not specifically 
trained for this purpose). The choice for local reading or central reading for inclusion in 
clinical trials depends also on the purpose: if the aim is to test a drug in the way it will be 
applied in clinical practice, local reading would be preferred; if the aim is testing efficacy 
in the purest population, central reading would be preferred. The latter is mostly required 
by registration agencies. Furthermore, the European Medical Agency has approved TNF-
inhibitors for patients with nr-axSpA only if additional signs of objective inflammation 
such as elevated CRP and/or a pos-MRI are present, while in patients fulfilling the mNY no 
additional sign of objective inflammation is required. Looking at all axSpA patients (including 
patients fulfilling the clinical arm) in the DESIR-cohort and assuming eligibility of all patients 
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for treatment with TNF-inhibitors (i.e. assuming that patients in the clinical arm had signs 
of objective inflammation and that all patients had active disease), 18 patients could have 
had inappropriate treatment with TNF-inhibitors and 28 patients were not treated with 
TNF-inhibitors based on false classification by local reading in comparison to the external 
standard of central reading. It should be noted that this situation implies an intrinsic 
dissimilarity in requirements to start with TNF-inhibitors based on the potentially fallible 
judgement on the presence or absence of radiographic sacroiliitis. 
This study has several strengths we would like to address. The DESIR-cohort consists of a 
high number of patients, and in every patient both local reading and central reading of 
the same baseline set of images is available, thereby offering the unique opportunity to 
investigate the effect of local reading versus central reading. As patients were recruited in 
25 centers where several rheumatologists and radiologists are working, local reading is a 
wide representation of clinical practice. Furthermore, central reading was performed by two 
independent trained readers and included an adjudication score, ensuring the robustness 
of central reading. 
The main limitation of this study is that the DESIR-cohort only comprises patients with short 
disease duration. Patients with short symptom duration usually do not show extensive 
lesions, thereby making recognition of lesions in patients in the DESIR-cohort probably more 
difficult than in patients with established disease. Thus the results regarding agreement on 
positive imaging presented in this study might be slightly worse than could be expected 
in more established diseased patients. Another limitation is the fact that all sites were in 
France. It is unknown if this is generalizable to other countries. However, the two RCTs with 
similar percentages of disagreement in X-SI scores included many international sites across 
the world. Lastly, the role of structural damage on MRI-SI has not been taken into account. 
It would be interesting to know how the agreement between local and central reading is 
for this aspect, and if these structural changes could be taken into account in addition to or 
instead of the X-SI.
In conclusion, substantial levels of agreement between the two central readers and between 
local reading and central reading indicate that both local rheumatologists/radiologists and 
trained readers performed well in recognizing a pos-MRI in patients with recent onset 
IBP. However, when taking into account the reading of X-SI as well, levels of agreement 
between local reading and central reading are decreasing, yet it is reassuring that only 7.9% 
of the patients in the DESIR-cohort were classified differently using the full ASAS axSpA 
criteria, based on a different reading of the same set of images by local reading and central 
reading. These results point out the robustness of the ASAS axSpA classification criteria to 
differences in reading of the images, showing that these criteria can be applied reliably in 
clinical practice.
Supplementary data
Additional material is published online only. To view please visit the journal online (http://
dx.doi.org/10.1136/annrheumdis-2014-205432).
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Abstract
Objectives
To evaluate metric properties of the SPARCC-score of the sacroiliac joints. 
Methods
Patients ≥16 years with back pain (≥3 months, ≤2 years, onset <45 years) were included 
in the SPondyloArthritis Caught Early (SPACE)-cohort. Patients with (possible) axial 
spondyloarthritis (axSpA) had follow-up visits after 3 and 12 months. Patients were treated 
according to usual clinical practice. MRI-SIs were scored in two independent campaigns (1: 
baseline to 3 months and 2: baseline to 3 months to 12 months) by two different blinded 
reader pairs, applying the ASAS definition (positive versus negative MRI-SI) (discordant cases 
were adjudicated by a third reader) and the SPARCC-score (mean of two agreeing readers) 
was obtained. Agreement (kappa; positive/negative agreement) between SPARCC-score 
cut-off values and a consensus judgment of a positive MRI (ASAS definition) as external 
standard, change in SPARCC-score and smallest detectable changes (SDCs) over 3 and 12 
months were calculated. 
Results
SPARCC-score ≥2 showed best agreement with a positive MRI (both campaigns). In campaign 
1, SPARCC-score changed (increased/decreased) in 70/151 patients; 26/70 change >SDC 
(3.4) of which 20 on stable treatment. In campaign 2, 20/68 patients changed in SPARCC-
score; 11/20 change >SDC (2.1) of which 8 patients on stable treatment (3 months). Over 1 
year, 23/74 patients changed in SPARCC-score; 14/23 change >SDC (2.4) of which 7 on stable 
treatment. 
Conclusions 
SPARCC-score ≥2 can be used as a surrogate for a consensus judgment of a positive MRI 
(ASAS definition) in clinical trials. The SDCs ranged from 2.1-3.4 dependent on reader pair 
and these are close to the proposed minimum important change of 2.5. 
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Introduction
A positive MRI of the sacroiliac joints according to the ASAS definition (‘positive-MRI’) 1 is 
part of the ASAS axial spondyloarthritis (axSpA) criteria 2 and is increasingly used to test 
eligibility of axSpA patients for clinical trials 3-5. Within clinical trials, MRI-SI is often repeated 
over short periods of time (e.g. 12 weeks) to test efficacy of (especially biological) treatment 
in terms of changes in inflammation. For this efficacy read, the SPondyloArthritis Research 
Consortium of Canada (SPARCC)-score is frequently used as it measures inflammation on a 
continuous scale with good sensitivity to change 6, 7. It is unknown what SPARCC-score cut-
off value the equivalent is of a ‘positive-MRI’, which is needed to link the read for eligibility 
and the efficacy reading. This information would be useful for example to define groups with 
MRIs scored according to SPARCC-scores as having either or not a ‘positive-MRI’, to study 
differences in treatment response over time 3.
Treatment with biologicals may dramatically influence inflammatory signs on MRI 8-11 but 
inflammation may also spontaneously change over time in patients without treatment 
and in patients on stable non-biological treatment 12-14. However, it is not clear how many 
SPARCC-score units these spontaneous changes represent 12-14. Moreover, these spontaneous 
changes are likely to be different with variable lengths of follow-up. A minimally important 
change (MIC) of 2.5 SPARCC-units is proposed based on the patient global assessment as 
external anchor 15. It is known that interreader reliability of SPARCC-scores at a fixed time 
point is acceptable to high (ICC 0.69-0.96) 16, 17, but reliability on change in SPARCC-scores 
over time has sparsely been reported and appeared to be moderate (ICC 0.52) in one small 
study with 20 patients 7. Therefore, it would be of additional value to have knowledge about 
interreader reliability in terms of smallest detectable change (SDC), in order to be able to 
judge whether the SDC is sufficiently small to detect the proposed MIC.
The aim of this study is threefold: first, to define which SPARCC-score best approximates a 
‘positive-MRI’ judgment; second, to establish an SDC for a 3-month period and for a 1-year 
period; third, to describe which variation in SPARCC-score over a 3-month and 1-year period 
can be expected in patients without (change in) treatment.
Methods
Study population
Data from the SPondyloArthritis Caught Early (SPACE)-cohort is used for this analysis. An 
extensive description of the SPACE-cohort is given elsewhere 18. In short, the SPACE-cohort 
is an ongoing cohort started in January 2009, including patients aged 16 years and older 
with back pain (≥3 months, ≤2 years, onset <45 years) visiting the rheumatology outpatient 
clinics of five participating centers. Patients were not included if they had other painful 
conditions (not related to SpA) that could interfere with the evaluation of the disease. After 
signing informed consent, all patients underwent a diagnostic work-up at baseline, including 
MRI and plain radiographs of the SI-joints, HLA-B27 testing and examining for other SpA-
features. Patients fulfilling the ASAS axSpA criteria or patients with possible axSpA were 
included for follow-up visits after 3 and 12 months. Possible axSpA was defined as the 
presence of at least one specific SpA-feature with a high positive likelihood ratio (LR+ above 
6) or at least two less specific SpA-features (LR+ below 6), but not fulfilling the ASAS axSpA 
criteria 19. 
MRI-SI
MR imaging was performed on a 1.5T scanner, acquiring T1-weighted Turbo Spin Echo 
(T1TSE) (TR 550/TE 10) and Short Tau Inversion Recovery (STIR) (TR 2500/TE 60) sequences, 
obtaining slices of 4mm thickness in coronal oblique view of the SI-joints. 
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All readers in this study were extensively trained in reading MRIs according to the ASAS 
definition and the SPARCC-score during a calibration session, supervised by a senior 
radiologist (MR) and a senior rheumatologist (DvdH), discussing definitions of lesions, 
examples and pitfalls. Next, all readers independently read 30 blinded MRIs to calculate 
agreement (κ=0.75 to κ=0.87 for the different pairs of readers), followed by a consensus 
meeting in which the supervising rheumatologist and radiologist of the calibration session 
participated too. The agreement was considered sufficiently high to start scoring the SPACE-
cohort.
Two reading campaigns were performed, at different moments in time, by different pairs of 
readers (RvdB and MdH in campaign 1; PB and MdH in campaign 2) with partly overlapping 
patients and images. Patients in the first reading campaign were included between January 
2009 and November 2012 in five different centers and patients in the second reading 
campaign were included between January 2009 and October 2013 in one center. In campaign 
1, baseline and 3-month MRI-SIs were evaluated; in campaign 2, baseline, 3-month and 
1-year MRI-SIs were evaluated. In both campaigns, MRI-SIs were independently read by the 
two trained readers on the fulfilllment of the ASAS definition 1 and according to the SPARCC-
score 6, blinded for the time sequence of the MRI-SIs as well as for clinical and laboratory 
data.
An MRI-SI can be marked positive according to the ASAS definition if ≥1 bone marrow edema 
(BME) lesion highly suggestive of SpA is present on ≥2 consecutive slices, or if several BME 
lesions highly suggestive of SpA are visible on a single slice. The presence of only synovitis, 
enthesitis or capsulitis without BME is not sufficient for a positive MRI-SI 1. In case the two 
readers disagreed on the presence of a ‘positive-MRI’, a third trained reader served as 
adjudicator (VNC in campaign 1; RvdB in campaign 2). 
According to the SPARCC-score, the presence of increased signal corresponding to BME 
lesions highly suggestive of SpA is marked on the six middle slices of an MRI-SI, representing 
the largest proportion of the synovial compartment of the SI-joints. Each SI-joint is divided 
into four quadrants (upper iliac, lower iliac, upper sacrum and lower sacrum). The maximum 
score for two SI-joints on each slice is eight. In addition, a score for ‘intensity’ may be 
assigned to each SI-joint if an ‘intense signal’ is seen in any quadrant on each slice resulting 
in a maximum score of 12. The signal from presacral blood vessels defined a lesion that is 
scored as intense. Furthermore, a score for ‘depth’ may be assigned to each SI-joint if an 
homogeneous and unequivocal increase in signal is extending over a depth of at least 1 
cm from the articular surface on each slice resulting in a maximum score of 12. A lesion is 
graded as deep if there is a homogeneous and unequivocal increase in signal extending over 
at least 1 cm from the articular surface. The total maximum SPARCC-score is 72 6. The mean 
SPARCC-scores of the two readers were used; in case there was a third reader involved, the 
mean of the SPARCC-scores of the two readers in agreement of a ‘positive-MRI’ for that 
particular case were used. 
Treatment
Patients in the SPACE-cohort are not treated according to a fixed protocol, but according 
to usual clinical practice by their rheumatologist. Treatment with NSAIDs was recorded 
according to the ASAS recommendations, resulting in a 0-100 score whereby 0 means no 
NSAID intake at all, and 100 means a daily intake at a full dose over the whole period of 
interest 20. Treatment with DMARDs and anti-TNF therapy was recorded as present or absent.
To investigate variation in SPARCC-scores over time, patients were categorized according 
to their treatment over the period of interest: no treatment, stable NSAID and/or DMARD 
intake, and change in NSAID and/or DMARD intake. Patients receiving anti-TNF therapy 
during the period of interest were excluded from the analysis on variation in SPARCC-scores.
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Statistical analysis 
Baseline characteristics of patients in both groups were investigated using descriptive 
statistics. Agreement (Cohen’s kappa) between MRI-positivity based on several SPARCC-
score cut-off values (≥1, ≥2, ≥3 and ≥4) and the consensus judgment of a ‘positive-MRI’ , 
as external standard, was calculated using cross-tabulation. Agreement on positive cases 
(positive agreement) and on negative cases (negative agreement) was also calculated 21.
Changes in SPARCC-score over the period of interest (baseline - 3 months (both campaigns); 
baseline - 1 year (campaign 2)), were visualized in cumulative probability plots in which 
patients were grouped based on treatment. Next, SDCs were calculated based on a 95% 
level of agreement (95%LoA) between the two readers on the change scores for both 
baseline to 3-month and baseline to 1-year intervals, using the following formula: SDC = 
(1.96 * SD∆change-scores) / (√2 *√k), whereby k represents the number of readers (equals 2 in 
this study) 22. The SDCs are also displayed in Bland Altman plots, that plot the mean SPARCC-
score changes of the two readers (X-axis) and the inter-reader differences in SPARCC-score 
changes (Y-axis). In addition, the mean of the inter-reader differences in SPARCC-score 
changes (which is a reflection of the systematic error between the two readers) and the 
95% levels of agreement (LoA) are presented in these plots. SPSS software version 20.0 was 
used for statistical analysis.
Results
Patients with available baseline MRI-SI were included in the analysis of the agreement 
between the SPARCC-score cut-off value and ‘positive-MRI’ (n=294 (campaign 1) and n=249 
(campaign 2)). There is a partial overlap (49.1%) between patients included in campaign 2 
and those included in campaign 1. In both campaigns the population is young, with short 
symptom duration, around 1/3 of the patients is male and around 1/3 fulfilled the ASAS 
axSpA criteria (table 1).
A 3-month follow-up MRI-SI was available in 154 patients in campaign 1. However, 3/154 
patients received anti-TNF therapy during this period and were therefore excluded from the 
follow-up part of the analysis of the SPARCC-score changes over time and SDCs. In campaign 
2, a 3-month follow-up MRI-SI was available in 70 patients and in 76 patients a 1-year 
follow-up MRI-SI was available. Two patients received anti-TNF therapy, leaving MRI-SIs of 
68 (campaign 1) and 74 patients (campaign 2) for follow-up analyses.
SPARCC-score cut-off 
In both campaigns, there was a high level of agreement between MRI-positivity based on all 
tested SPARCC-score cut-off values and the consensus judgment of a ‘positive-MRI’ as external 
standard  (table 2). A cut-off value of ≥2 showed the highest kappa values (0.94 in campaign 
1 and 0.98 in campaign 2) and provided the best balance in terms of misclassifications in 
comparison to the external standard; 5 false-positive and 1 false-negative classifications in 
campaign 1; zero false-positive and 1 false-negative classification in campaign 2. 
Smallest detectable change of SPARCC-score
Of the patients with available follow-up MRI, the mean SPARCC-score at baseline was 4.0 
(SD 8.3) and 2.3 (SD 5.7) (campaign 1 and 2, respectively). At 3 months, the mean SPARCC-
score was 3.4 (SD 6.7) and 1.6 (SD 3.8) (campaign 1 and 2, respectively), and at 1 year the 
mean SPARCC-score was 1.4 (SD 4.0) (campaign 2).
Bland and Altman plots show the mean of the two readers in SPARCC-score changes over the 
3-month (campaign 1 and 2) and 1-year period (campaign 2) against the difference between 
the two readers in SPARCC-score changes over those periods (figure 1). 
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Table 1: Baseline characteristics of patients in reading campaign 1 and patients in reading campaign 
2. A proportion (49.1%) of the patients was included in both campaigns.
Reading campaign 1, 
n=294
Reading campaign 2, 
n=249
Age (years) at inclusion, mean ± SD 31.2 ± 10.4 31.1 ± 11.5
Male, n (%) 102 (34.7) 81 (32.5)
Duration of back pain (months), mean ± SD 13.1 ± 7.1 13.3 ± 7.4
HLA-B27 positive, n (%) 113 (38.4) 79 (31.7)
Pos. Fam. History SpA, n (%) 113 (38.4) 89 (35.7)
IBP, n (%) 195 (66.3) 142 (57.0)
Psoriasis, n (%) 28 (9.5) 26 (10.4)
Dactylitis, n (%) 16 (5.4) 8 (3.2)
Enthesitis, n (%) 49 (16.7) 24 (9.6)
Uveitis, n (%) 24 (8.2) 18 (7.2)
IBD, n (%) 20 (6.8) 19 (7.6)
Good response to NSAIDs, n (%) 112 (38.1) 69 (27.7)
Elevated CRP/ESR, n (%) 58 (19.7) 42(16.9)
Asymmetric lower limb arthritis, n (%) 48 (16.3) 26 (10.4)
Radiographic sacroiliitis*, n (%) 23 (7.8) 24 (9.6)
Sacroiliitis MRI**, n (%) 67 (22.8) 31 (12.4)
SPARCC-score, mean ± SD 2.9 ± 7.7 1.3 ± 4.4
CRP, mean ± SD 6.9 ± 13.0 7.3 ± 11.6
ASDAS, mean ± SD 2.6 ± 1.1 2.7 ± 0.8
BASDAI, mean ± SD 4.6 ± 2.5 4.6 ± 2.1
BASFI, mean ± SD 3.0 ± 2.3 3.2 ± 2.4
ASAS axSpA criteria positive, n (%) 119 (40.5) 83 (33.3)
*Radiographic sacroiliitis according to the modified New York criteria 25. **Sacroiliitis on MRI 
according to the ASAS definition (consensus judgment) 1. HLA-B27, Human Leukocyte Antigen; IBP, 
Inflammatory Back Pain; IBD, Inflammatory Bowel Disease; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate. 
The plots show that a large number of observations is clustered around the mean difference 
of 0, and that differences between readers occur with similar amplitude across the entire 
range of the SPARCC-score (a homoscedastic pattern). To visualize the high number of 
overlapping observations, series of ranges were defined in which all observations were 
grouped into their corresponding range, exponentially displayed on the X-axis. The SDC in 
campaign 1 over the 3-month period is 3.4 SPARCC-units, depicted in figure 1a as the dark 
grey area reflecting the SDC of both increased and decreased SPARCC-scores over time. The 
SDC in campaign 2 over the 3-month period is 2.1 SPARCC-units (figure 1b) and over the 



























Figure 1: Bland Altman plots showing 
the mean SPARCC-score change of 
the two readers (X-axis) versus the 
delta SPARCC-score changes of the 
two readers (Y-axis). The large num-
ber of overlapping observations clus-
tered around the mean difference of 
zero are displayed in series of ranges 
increasing exponentially on the posi-
tive side of zero and decreasing expo-
nentially on the negative side (X-axis). 
The ‘n’ above the X-axis show the 
number of observations per group. 
The solid grey line represent the over-
all mean of the delta SPARCC-score 
changes (equivalent to systematic 
error between the two readers). The 
light grey area represents  the 95% 
levels of agreement (LoA), and the 
dark grey area represents the smal-
lest detectable change (SDC) in both 
directions (increase in SPARCC-score 
and decrease in SPARCC-score over 
time). The reader is referred to the 
text for further clarification.
Figure 1a: mean of the delta SPARCC-
scores 0.1 (95% LoA -6.8 to 7.0); SDC 
3.4. Observations are clustered in the 
range -0.5 to 0.5 (n=89) and the range 
-1 to -0.5 (n=16).
Figure 1b: mean of the delta SPARCC-
scores 0.2 (95% LoA -4.0 to 4.4); SDC 
2.1. Observations are clustered in the 
range -0.5 to 0.5 (n=52).
Figure 1c: mean of the delta SPARCC-
scores -0.1 (95% LoA -5.0 to 4.8); SDC 
2.4. Observations are clustered in the 
range -0.5 to 0.5 (n=52).
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Table 2: Various SPARCC cut-off values tested against the ASAS definition of a positive MRI, in reading 
campaign 1 and reading campaign 2.
 Reading campaign 1 (n=294)
positive MRI (ASAS) negative MRI (ASAS)
SPARCC ≥1 67 21
SPARCC <1 0 206
Kappa: 0.82 PA: 95.2% NA: 86.5%
SPARCC ≥2 66 5
SPARCC <2 1 222
Kappa: 0.94 PA: 98.7% NA: 95.7%
SPARCC ≥3 57 1
SPARCC <3 10 226
Kappa: 0.89 PA: 97.6% NA: 91.2%
SPARCC ≥4 47 1
SPARCC <4 20 226
Kappa: 0.77 PA: 95.6% NA: 81.7%
Reading campaign 2 (n=249)
positive MRI (ASAS) negative MRI (ASAS)
SPARCC ≥1 31 5
SPARCC <1 0 213
Kappa: 0.91 PA: 98.8% NA: 92.5%
SPARCC ≥2 31 1
SPARCC <2 0 217
Kappa: 0.98 PA: 99.8% NA: 98.4%
SPARCC ≥3 25 0
SPARCC <3 6 218
Kappa: 0.88 PA: 98.6% NA: 89.3%
SPARCC ≥4 21 0
SPARCC <4 10 218
Kappa: 0.79 PA: 97.8% NA: 80.8%
PA, positive agreement is the agreement on positive cases. NA, negative agreement is the agreement 
on negative cases.
Change in SPARCC-scores over 3 months and 1 year
Eighty-one out of 151 patients in campaign 1 (53.6%) showed no change in SPARCC-
score over the 3-month period of which 75/81 (92.6%) had a SPARCC-score of 0 at both 
time points. In the 70 out of 151 patients (46.4%) showing a change in SPARCC-score, 27 
increased and 43 decreased (mean change -1.1 (SD 6.3); median change -0.5 (range -16.5 to 
16.0)) (figure 2a & table 3). In 26 out of 70 patients (37.1%) with SPARCC-score changes, the 
change was more than the SDC (3.4); 16 patients decreased (2 patients without treatment, 
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Cumulative probability of delta SPARCC score
baseline - 1 year
No treatment
Stable NSAID and/or DMARD intake
Change NSAID and/or DMARD intake
Campaign 2
Figure 2c
Figure 2: Cumulative probability plots of all delta SPARCC-scores over a 3-month period 
(2a and 2b) and a 1-year period (2c) with different symbols indicating the treatment over the investi-
gated period.
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Table 3: All changes in SPARCC-score in patients grouped according to treatment.






Campaign 1 – baseline to 3 months
No SPARCC-score change N=13 N=56 N=7 N=5
Increase in SPARCC-score 























Campaign 2 – baseline to 3 months
No SPARCC-score change N=4 N=31 N=8 N=5
Increase in SPARCC-score




















Campaign 2 – baseline to 1 year
No SPARCC-score change N=10 N=28 N=7 N=6
Increase in SPARCC-score























NSAIDs intake) and 10 patients increased (2 without treatment, 7 with stable NSAIDs 
intake, 1 started NSAIDs intake). In the remaining 44 patients (62.9%) the SPARCC-score 
changes were within the area still compatible with measurement error. intake but continued 
NSAID intake). In the remaining 9 patients (39.1%) SPARCC-score changes were not beyond 
measurement error. 
In campaign 2, two follow-up intervals for the same patients are available. Over the 3-month 
period, SPARCC-score did not change in 48 out of 68 patients (70.6%); 46/48 patients 
(95.8%) had a SPARCC-score of 0 at both time points. In the remaining 20 patients (29.4%) 
the SPARCC-score changed; 14 patients showed a decrease and 6 patients an increase (mean 
change -3.1 (SD 4.6); median change -1.5 (range -12.5 to 5) (figure 2b & table 3). Eleven out 
of 20 patients (55.0%) showed a SPARCC-score change >SDC (2.1); 10 patients decreased (1 
without treatment, 6 with stable NSAIDs intake, 2 with stable NSAIDs and DMARD intake, 
1 started NSAIDs intake) and 1 patient increased (started NSAIDs intake). The remaining 9 
patients (45.0%) had SPARCC-score changes still compatible with measurement error.
The results over the 1-year period in campaign 2 are similar to the results over the 3-month 
period in campaign 2, although more variation between patients is seen; 51/74 patients 
(68.9%) did not show a change in SPARCC-score, of which 50 patients (98.0%) had a SPARCC-
score of 0 at both time points. The remaining 23 patients (31.1%) showed a change in 
SPARCC-score; 16 patients decreased and 7 increased (mean change -2.9 (SD 7.5); median 
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change -1.0 (range -18.0 to 12.0)) (figure 2c & table 3). Fourteen out of the 23 patients 
(60.9%) showed a SPARCC-score change of more than the SDC (2.4); 10 patients decreased 
(2 without treatment, 4 with stable NSAID intake, 2 with stable DMARD intake, 1 stopped 
NSAID intake, 1 started but stopped again NSAID intake) and 4 patients increased (1 with 
stable NSAID intake, 1 stopped NSAID intake, 1 started NSAID intake, 1 stopped DMARD
The majority of the patients showing changes in SPARCC-score of more than the SDC in both 
campaigns (20/26 (76.9%; campaign 1), 8/11 (72.7%; 3-month period campaign 2) and 7/14 
(50.0%; 1-year period campaign 2)) were on stable NSAID and/or DMARD intake.
Discussion
This study performed in the SPACE-cohort has shown in two campaigns that a cut-off 
value of 2 SPARCC-units is best compatible with a consensus judgment of a positive versus 
negative MRI according to the ASAS definition. These results were not unexpected as the 
ASAS definition of a positive MRI-SI includes - apart from a qualitative part (BME lesions 
highly suggestive of spondyloarthritis) - a quantitative part that requires at least one BME 
lesion visible on at least 2 consecutive slices or several lesions on a single slice 1. However, 
in theory, a SPARCC-score can be high because of the presence of several small lesions 
(highly suggestive of SpA), scattered over several slices (e.g. one lesion on slice 1, another 
lesion on slice 4 and another lesion on slice 6) but still not fulfilling the ASAS definition. A 
SPARCC-score can also be high if one lesion is assigned as ‘intense’ or ‘deep’, while it is only 
visible on 1 slice. Moreover, the SPARCC-score prescribes that lesions are scored in the six 
middle slices, while the ASAS definition takes all slices into account 1, 6. Occasionally, part 
of a lesion may be visible on only one of the six middle slices, while the remaining part of 
the lesion is visible outside those six middle slices, or a slice outside those middle six shows 
several lesions. However, these considerations are mainly theoretical and do not appear 
very frequently. Therefore, a SPARCC cut-off level of 2 units may serve as a surrogate for 
the ASAS definition of a positive MRI and could be used in clinical trials with central efficacy 
reading in order to derive a dichotomy (positive versus negative) for prognostic reasons. 
The SDCs in campaign 2 (2.1 SPARCC-units over 3 months and 2.4 over 1 year) are close to 
the proposed MIC of 2.5 SPARCC-units, which was calculated using pooled changes over 12 
and 52 weeks 15, but the SDC of campaign 1 (3.4) is slightly higher. This suggests that the 
previously proposed MIC is close to measurement error in our study based on two different 
reader pairs and different periods of follow-up.
A large proportion of the SPARCC-score changes seen in the patients in both reading 
campaigns could be considered as noise as these changes are smaller than the SDCs (62.9% 
and 45% (3-months, campaign 1 and 2) and 39.1% (1-year in campaign 2). To investigate the 
influence of non-biological treatment on inflammation on MRI-SI, only patients with SPARCC-
score changes greater than the SDC were taken into account. Somewhat surprisingly, the 
majority of patients with a change in SPARCC-score were on stable NSAID and/or DMARD 
treatment. Some patients taking stable doses of NSAIDs increased in SPARCC-score while 
others who were also on stable NSAIDs intake decreased in SPARCC-score. These results 
are in line with the results found in trials where patients using NSAIDs – either in an open 
label trial or in a placebo group – showed also both increased and decreased inflammation 
scores on MRI-SI over 6 and 16 weeks, respectively 14, 23. Moreover, also patients with stable 
background treatment in the placebo group of the ABILITY-1 trial slightly decreased in 
SPARCC-score at group level, like we found in this study 3. 
Although too few patients in the SPACE-cohort used DMARDs to draw conclusions on 
the effect of DMARDs, comparable effects can be expected. The comparator group in the 
ESTHER trial using sulfasalazine showed a mean decrease of 1.7 and 1.9 SPARCC-units over 
24 and 48 weeks, respectively 13. In the comparator group of another trial where patients 
used methotrexate, a mean of 1.4 (95%CI -0.8 to 3.5) inflammatory lesions resolved over 
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30 weeks 24. Although an overall decrease in inflammation score was seen in these trials, 
some patients increased in inflammation score on MRI-SI when looking at the individual 
level 13, 24. These results indicate that in patients on stable treatment changes in BME on 
MRI-SI that are beyond measurement error may occur, which may point to true fluctuation 
in inflammatory activity over time. 
The direct comparisons of our results with the results of drug efficacy trials is difficult as 
the SPACE-cohort is an observational cohort including unselected patients with back pain 
of short duration resulting in a heterogeneous patient population, with low numbers of 
a ‘positive-MRI’ and low baseline mean SPARCC-scores, while drug efficacy trials select 
patients with high levels of disease activity. In patients selected because of a high level of 
disease activity a decrease in scores is more likely (regression to the mean) in comparison 
to an unselected group of patients. Thus, the patients in the SPACE-cohort will likely not be 
representative of patients in trials. Nevertheless, we have also observed an overall decrease 
in the SPACE-cohort, just as in the trials. This might be due to the fact that patients preferably 
seek help in case of maximum complaints, which is by default the time point of inclusion in 
the SPACE-cohort. It is possible that the results would have been different if this study had 
been performed in a long-standing or severely diseased group of patients. Furthermore, 
the SPACE-cohort is not designed to investigate the effects of treatment on inflammation 
on MRI. For example, and in contrast to drug efficacy trials, there is not a good relation 
between the start date of therapy and the date of the MRI. 
Another possible limitation is that the readers have given their judgement based on the 
ASAS definition immediately after the evaluation according to the SPARCC-score. Since the 
quantitative part of the ASAS definition resembles a SPARCC-score of 2, the choice of the 
value of 2 as the best SPARCC-score to serve as cut-off level for negative and positive MRI 
may not be entirely independent. It would have been better if different scores were acquired 
independently, or even by different readers, as is frequently the case in clinical trials. 
In conclusion, a SPARCC-score of 2 as cut-off value best reflects the caesura between a 
positive and negative MRI according to the ASAS definition. This cut-off can be used (in 
clinical trials) in order to create a dichotomous MRI variable of potential prognostic interest. 
The SDCs we have obtained in our two experiments are close enough to the proposed MIC 
of 2.5 SPARCC-units, which adds credibility to a cut-off level of 2.5 units in that it represents 
a true difference rather than only measurement error. Surprisingly, while patients are on 
stable treatment, true (>SDC) changes in SPARCC-score over time (both increases and 
decreases) were frequently observed. This observation strongly suggests that MRI-activity 
fluctuates over time.
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Abstract
Objective
To give an overview of the recommendations for the use of anti-TNF-α therapy in AS in 23 
countries worldwide 
Methods
The recommendations were collected, translated and a summary was checked by Assessment 
of SpondyloArthritis International Society (ASAS) members from the respective countries. 
The recommendations were compared with the ASAS recommendations (2006) on three 
aspects: patient selection for initiation of treatment (diagnosis, disease activity, previous 
treatment and contraindications), assessment of disease and assessment of response.
Results
The majority of the recommendations are similar to the ASAS recommendation with regard 
to patient selection, assessment of disease and treatment response. Additional objective 
assessments of disease activity are required in eight countries, leading to a more strict 
indication to start anti-TNF-α therapy.
Conclusion
Most national recommendations follow the international ASAS recommendations, 
suggesting that the latter are widely implemented. This might contribute to comparable 
access with anti-TNF-α treatment across countries. This article shows that general consensus 
exists about the use of anti-TNF-α therapy in AS across the world, although some countries 
require additional objective signs of inflammation and/or more pre-treatment, which limits 
access.
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Introduction
AS is a chronic, progressive inflammatory, rheumatic disease that generally starts in the 
second or third decade of life 1-3. The most characteristic features of AS are inflammatory 
back pain (IBP) due to sacroiliitis and spondylitis, and the formation of syndesmophytes 
leading to ankylosis of the spine 1, 4. In addition, AS is frequently associated with enthesitis, 
acute anterior uveitis, inflammatory bowel disease (IBD), psoriasis, peripheral (oligo)
arthritis predominantly of the lower extremities, and cardiovascular and pulmonary 
abnormalities 1, 5, 6.
For decades, AS was mainly treated with NSAIDs, physiotherapy and to a lesser extent 
with DMARDs 3, 4. And this is still the basis for treatment according to the Assessment of 
SpondyloArthritis International Society (ASAS)/European League Against Rheumatism 
(EULAR) recommendations for the management of AS 1. Even though NSAIDs often give 
quick symptomatic relief 7, the effects on the longterm outcome are limited and there 
are reservations with safety in relation to long-term use 2, 7, 8. Moreover, DMARDs are 
largely ineffective in axial AS and have limited efficacy on peripheral arthritis in AS 3, 7, 8. 
The treatment armamentarium is broadened since the discovery of anti-TNF-α agents as 
an effective therapy. The anti-TNF-α agents infliximab 8, 9, etanercept 10, 11, adalimumab 12 
and golimumab 13 have shown to be effective in the treatment of AS in short-term as well 
as intermediate to long-term evaluations 2, 14. Anti-TNF-α agents are very effective in the 
treatment of AS; nevertheless, they are associated with high costs and risks of side effects 
and might not be suitable for all patients.
Therefore, it is important that recommendations are available to support the appropriate 
use of anti-TNF-α agents within individual countries.
In 2003, the ASAS proposed recommendations for the use of anti-TNF-α treatment in AS for 
rheumatologists and other experts in the management of AS, as well as payers 3, 14. There 
was an update of the recommendations in 2006 15. Many countries developed national 
guidelines, whether or not based on the ASAS recommendations. The aim of the present 
report is to give an overview of the recommendations for the use of anti-TNF-α therapy in 
AS in 23 countries worldwide, with a focus on the similarities and differences compared with 
the ASAS recommendations.
In concordance with the advice of EULAR, we use the general term of recommendations 
throughout the manuscript, although some countries publish their recommendations as 
guidelines.
Methods
The recommendations of the following countries (presented alphabetically grouped by 
continent) were presented and translated: Australia, Hong Kong, Korea, Canada, Colombia, 
Mexico, Belgium, Czech Republic, Finland, France, Germany, Greece, Hungary, Italy, the 
Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland and the UK.
A summary of the translated recommendations was sent to ASAS members from the 
specific countries included in this overview. They were asked to check the correctness of 
the summary. The recommendations were compared with the 2006 version of the ASAS 
recommendations 15 as a standard to be able to easily compare discrepancies.
ASAS recommendations
The ASAS recommendations are divided into the following three parts: patient selection 
for initiation of treatment including diagnosis, disease activity, previous treatment and 
contraindications; assessment of disease; and assessment of response (table 1).
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Table 1: International ASAS consensus statement for the use of anti-TNFα agents in patients with AS.
PATIENT SELECTION
Diagnosis Patients normally fulfilling modified New York criteria for definitive ankylosing spon-
dylitis
Modified New York criteria 1984:
Radiological criterion: Sacroiliitis, grade > II bilaterally or grade III to IV unilaterally
Clinical criteria (two of the following three): low back pain and stiffness for more than 
three months which improves with exercise but is not relieved by rest; limitation of 
motion of the lumbar spine in both the sagittal and frontal planes; limitation of chest 
expansion relative to normal values correlated for age and sex
Active 
disease
Active disease for >4 weeks
BASDAI >4 (0-10) and an expert* opinion**
*The expert is a physician, usually a rheumatologist, with expertise in inflammatory 
back pain and the use of biological agents. Expert should be locally defined.
**The expert should consider clinical features (history and examination), serum acu-
te phase reactant levels and/or imaging results, such as radiographs demonstrating 
rapid progression or MRI indicating ongoing inflammation.
Treatment 
failure
All patients should have had adequate therapeutic trials of at least two NSAIDs. An 
adequate therapeutic trial is defined as:
Treatment for at least 3 months at maximum recommended or tolerated anti-inflam-
matory dose unless contraindicated
Treatment for <3 months where treatment was withdrawn because of intolerance, 
toxicity, or contraindications
Patients with pure axial manifestations do not have to take DMARDs before anti-TN-
Fα treatment can be started
Patients with symptomatic peripheral arthritis should have an insufficient response 
to at least one local corticosteroid injection if appropriate
Patients with persistent peripheral arthritis must have had a therapeutic trial of 
sulfasalazine*
Patients with symptomatic enthesitis must have failed appropriate local treatment
*Sulfasalazine: treatment for at least four months at standard target dose or maxi-
mally tolerated dose unless contraindicated or not tolerated. Treatment for less than 




Women who are pregnant or breast feeding; effective contraception must be 
practiced
Active infection
Patients at high risk of infection including:
Chronic leg ulcer
Previous tuberculosis (note: please follow local recommendations for prevention or 
treatment)
Septic arthritis of a native joint within the past 12 months
Sepsis of a prosthetic joint within the past 12 months, or indefinitely if the joint 
remains in situ
Persistent or recurrent chest infections
Indwelling urinary catheter
History of lupus or multiple sclerosis
Malignancy or pre-malignancy states excluding:
Basal cell carcinoma
Malignancies diagnosed and treated more than 10 years previously (where the 








Physical function (BASFI or Dougados functional index)
Pain (VAS, past week, spine at night, from ankylosing spondylitis and VAS, past week, 
spine, from ankylosing spondylitis)
Spinal mobility (chest expansion and modified Schober and occiput to wall distance 
and lateral lumbar flexion)
Patient’s global assessment (VAS, past week)
Stiffness (duration of morning stiffness, spine, past week)
Peripheral joints and entheses (number of swollen joints (44 joints count), enthesitis 
score such as developed in Maastricht, Berlin, or San Francisco)
Acute phase reactants (ESR or CRP) 
Fatigue (VAS)
BASDAI VAS overall level of fatigue/tiredness, past week
VAS overall level of ankylosing spondylitis neck, back, or hip pain, past week
VAS overall level of pain/swelling in joints other than neck, back or hips, past week
VAS overall discomfort from any areas tender to touch or pressure, past week
VAS overall level of morning stiffness from time of awakening, past week





BASDAI: 50% relative change or absolute change of 20 mm (on a scale between 0 and 
100) and
expert opinion in favour of continuation
Time of 
evaluation
Between 6 and 12 weeks
ASAS, Assessment of Spondyloarthritis International Society; BASDAI, Bath Ankylosing Spondylitis 
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; VAS, visual analogue 
scale; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NSAID, non-steroidal anti-
inflammatory drugs; DMARD, disease modifying anti-rheumatic drugs; TNF, tumour necrosis factor; 
MRI, magnetic imaging resonance.
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Results
Table 2 gives an overview of the recommendations of the 23 countries (references of 
the recommendations in appendix 1, available as supplementary data at Rheumatology 
Online). They are presented alphabetically grouped by continent. The recommendations of 
Canada, Mexico, France, Italy, Portugal, Spain and Sweden (n=7) (table 2) were developed 
by the professional rheumatologic community as treatment recommendations. In Australia, 
Hong Kong, Korea, Colombia, Belgium, Finland, Greece, Norway, Poland and Switzerland 
(n=10) (table 2), the recommendations were developed for reimbursement purposes. The 
recommendations of the Czech Republic, Germany, Hungary, the Netherlands, the UK and 
Slovakia (n=6) (table 2) were developed for both purposes.
Diagnosis
According to the ASAS recommendations, patients should normally fulfill the modified 
New York criteria for AS (table 1) 15. Most recommendations (n=16) follow the ASAS 
recommendations and qualify patients for treatment if they fulfill the modified New York 
criteria 16. In five recommendations, MRI and/or CT, instead of X-rays, are approved to reveal 
sacroiliitis 16. In Hong Kong and Colombia, a diagnosis of SpA according to the Amor or ESSG 
criteria is sufficient for the diagnostic part for initiation of anti-TNF-α therapy (table 2).
Disease activity
The ASAS recommendations define active AS as having active disease for >4 weeks based 
on a BASDAI score ≥4 (scale 0-10) and an expert opinion of active AS (table 1) 15. According 
to all recommendations, except the Finnish recommendation, disease activity should be 
measured with the BASDAI. In 19 recommendations, the disease activity is qualified as high 
when the BASDAI is ≥4. In two other recommendations (Hong Kong and Norway), the BASDAI 
is also used to measure disease activity, but no qualification of active disease is given.
An expert opinion to determine disease activity is required in 13 countries (table 2).
In eight recommendations, additional assessments of disease activity are required, such 
as laboratory parameters for inflammation (CRP and/or ESR), (spinal) pain [visual analogue 
scale (VAS)] (n=4), patient and physician global health (n=2 and n=1, respectively), and/or 
inflammation on MRI (n=1), or limitation in spinal mobility (n=1) (table 2). In particular, the 
request for additional elevated acute-phase reactants or inflammation on MRI increases the 
threshold to start a TNF-blocker substantially. In one instance (Hong Kong), a large increase 
is required (ESR >50 mm/h or CRP >50 mg/l). Moreover, the requirement for limitation in 
spinal mobility is remarkable, as this can be caused by the severity of the disease without 
active inflammation.
Failure of standard treatment
ASAS offers a description of conventional treatment failure specified for the predominant 
localization of the disease (axial, peripheral arthritis and enthesitis) (table 1).
Most recommendations follow the ASAS recommendations and give specified descriptions 
of treatment failure.
In general, the recommendations describe failure of conventional treatment for 
predominantly axial localization as failure of two or more NSAIDs administered for a period 
of 1-3 months (n=18). In Hong Kong, Canada and France, patients should fail at least three 
NSAIDs. Conventional treatment failure for a predominantly peripheral localization is in 18 
recommendations described as a failure of one or two DMARDs (in most recommendations 
specified as MTX and/or SSZ) administered for a period of 2-3 months, and as a failure of 
IA injections of CSs (n=16). Conventional treatment failure of CS injections for enthesitis is 
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To minimize treatment risks, ASAS has specified a list of contraindications (table 1) basically 
similar to contraindications of the treatment of anti-TNF-α therapy for other indications 15. 
Almost all recommendations (n=17) list active infections, especially tuberculosis (TB), as 
contraindications.
Several recommendations mention some types of malignancy or pre-malignancy (n=10), 
a history of lupus (n=8), multiple sclerosis or other demyelinating diseases (n=11) 
and pregnancy/breastfeeding (n=9) as contraindications, in accordance with the ASAS 
recommendations.
A frequently mentioned contraindication (n=11) not referred to in the ASAS 
recommendations 15 is heart failure stages 3-4 as defined by the New York Heart Association 
(NYHA) 17.
Remarkably, the recommendations of the Czech Republic and Slovakia report that an 
advanced or terminal radiographic stage of the disease is a contraindication for applying 
anti-TNF-α therapy. Four recommendations do not mention contraindications at all.
Monitoring and withdrawal
ASAS recommends using the ASAS core set for daily practice 18 and the BASDAI to assess the 
activity of the disease (table 1) 15. Most countries (n=19) recommend the ASAS core set for 
daily practice as well, or at least a part of the ASAS core set. However, four countries do not 
specify how to assess the disease (table 2).
An assessment of the treatment response should be conducted 6-12 weeks after the start of 
the treatment, according to ASAS (table 1) 15. In 16 recommendations, the same time frame 
is advised. However, in seven recommendations the response is assessed after >12 weeks 
(range 14-16 weeks).
At this assessment point, a decision should be made about either continuation or 
discontinuation of anti-TNF-α therapy. ASAS advises considering discontinuation in patients 
not showing a 50% relative or absolute change of 2cm (scale 0-10 cm) in the BASDAI score 15. 
Eighteen recommendations use these criteria to determine a good treatment response. In 
some recommendations other criteria to assess response to treatment are obligatory, such 
as normalized or improved lab tests (n=3) and improvement in pain (n=2) or BASDAI <4 
(n=1). Furthermore, ASAS advises a positive opinion by the expert to continue treatment. 
This criterion is used in 14 recommendations as well.
Discussion and Conclusion
This report provides an overview of the recommendations developed in 23 countries 
across the world. ASAS developed recommendations for the management of anti-TNF-α 
therapy in patients with AS 3, 15. As internationally developed recommendations, the ASAS 
recommendations might contribute to comparable access with anti-TNF-α treatment across 
countries 19.
Indeed, this aim is (largely) reached, since the recommendations in AS are quite similar 
worldwide, in contrast to the recommendations in RA, which vary greatly between 
countries in Europe 19. This can be explained by the lack of European guidance for initiation 
of anti-TNF-α therapy in RA 19, unlike the situation in AS 15. Another explanation might be 
the considerably varying goals of RA treatment with anti-TNF-α agents 19. Other possible 
explanations for the differences in recommendations across countries that apply to both RA 
and AS are variations regarding different methods for funding health-care provision and the 
level of recognition of recommendations 19.
Despite the similarities between the recommendations in AS across countries, differences 
exist. These differences are mostly based on the fact that some countries use objective 
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assessment, such as acute-phase reactants, to measure disease activity for initiation and 
to monitor treatment response. This puts a major limitation on access to TNF-a blockers 
for patients in these countries, as only about half of the patients with active disease have 
elevated acute-phase reactants 20. Although patients with elevated acute-phase reactants 
have a higher likelihood to show response, this difference is too small to withhold patients 
with a normal acute-phase reactant treatment with TNF-a blockers. Other differences exist 
in the required pre-treatment for NSAIDs (more and/or longer) and DMARDs (also required 
in axial disease and not only SSZ in peripheral disease). Moreover, several countries evaluate 
the efficacy of treatment after ≥12 weeks.
In conclusion, it can be said that despite some differences, there is general consensus about 
the recommendations to use anti-TNF-a therapy in AS across the world, except for the 
stricter requirement of objective signs of inflammation in some countries. The observation 
that most national recommendations follow the international ASAS recommendations 
seems to indicate that the latter are widely accepted and implemented. The information 
acquired by this comparison will also be taken into account in the next update of the ASAS 
recommendations.
Supplementary data
Supplementary data are available at Rheumatology Online. 
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Abstract
Objective
To perform a systematic literature review as a basis for the update of the Assessment 
in SpondyloArthritis International Society and European League Against Reumatism 
(ASAS/EULAR) recommendations for the management of AS with non-pharmacological 
interventions and non-biologic drugs.
Methods
The search was performed in PubMed, EMBASE, PEDro and Cochrane between 1 January 
2005 and 1 December 2009, and in abstracts of EULAR and ACR meetings (2007-09). Effect 
sizes for outcomes on pain, disease activity, spinal mobility and physical function and level 
of evidence were presented.
Results
Of 2383 papers, 35 with complete data were included. Physical therapy exercises in various 
modalities have positive effects on BASFI, BASDAI, pain and mobility function. Various 
NSAIDs including coxibs improve BASDAI, disease activity and BASFI. No effect of SSZ and 
MTX on any variable was found. Surgical interventions of the spine and the hip can give 
excellent results by restoring function.
Conclusion
This concise summary of current evidence for non-pharmacological interventions and non-
biologic drugs formed the basis for the update of the ASAS/EULAR recommendations for the 
management of AS.
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Introduction
AS is a chronic, inflammatory rheumatic disease, generally starting early in life 1-4. 
Inflammatory back pain due to sacroiliitis and spondylitis, and formation of syndesmophytes 
leading to ankylosis of the spine, characterize AS 4, 5. Although AS is difficult to treat, the 
treatment armamentarium of AS has been broadened since the discovery of anti-TNF-α 
agents as effective treatments 6-8.
Clinicians need to be aware of the relative benefits and risks of the available treatments, and 
need to have evidence-based information about the most efficacious strategies in particular 
patient settings 4.
In 2005 Zochling et al. 4 performed a systematic literature search for evidence based 
recommendations by the Assessment in SpondyloArthritis International Society and 
European League Against Reumatism (ASAS/EULAR) for the management of AS. In 2010 
an update of this systematic literature search was performed to serve as a base for the 
development of an update of the ASAS/EULAR recommendations 9. The details and results 
of the performed systematic review on non-pharmacological interventions and non-biologic 
drugs are presented in this article. The results on biologics are presented in the article by 
Baraliakos elsewhere in this journal. 
Methods
Participants and outcome measures
Participants were defined as patients with a diagnosis of AS or axial spondyloarthritis. The 
required treatments were non-pharmacological interventions and non-biologic drugs. There 
were no restrictions with regard to type of non-pharmacological intervention, or to dose, 
duration or route of administration of non-biologic drugs.
The primary outcomes of interest include pain, disease activity (including BASDAI), spinal 
mobility (including BASMI) and physical function (including BASFI).
Inclusion/exclusion criteria
Randomized controlled trials (RCTs) and controlled trials are the ideal study designs for 
inclusion in this review.
However, the aim of this review is to provide evidence of all types of non-pharmacological 
interventions and non-biologic drugs. Since not all types of treatment can be studied within 
RCTs alone, the main focus of interest was also on systematic reviews, uncontrolled trials/ 
cohort studies, case-control studies and cross-sectional studies. Studies about non-axial 
spondyloarthritides and other inflammatory joint conditions, animal studies, non-clinical 
outcome studies and non-treatment studies, narrative review articles, commentaries, 
guidelines, case reports, letters and editorials and studies in other languages than English, 
Dutch and German were excluded.
Studies about biologic drugs were also excluded because those studies will be included in a 
search performed by Baraliakos.
Systematic literature search
A search strategy was built in collaboration with an experienced librarian, based on the 
previous search of Zochling et al. 4. The systematic literature search for published papers 
was performed in the electronic databases PubMed, EMBASE, PEDro and Cochrane 
between 1 January 2005, which is the end date of the literature search by Zochling et al. 4, 
and 1 December 2009. The complete search strategies for the databases are provided in 
supplementary appendix S1, available as supplementary data at Rheumatology Online. 
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Abstracts of rheumatology scientific meetings (EULAR, ACR) from the years 2007, 2008 
and 2009 were searched by hand to ensure that all potential studies were identified for 
this review. Furthermore, references of relevant reviews and included papers were hand 
searched for information on any other relevant studies.
Selection of studies
One reviewer (RvdB) assessed each title and abstract on suitability for inclusion in the review, 
according to the inclusion and exclusion criteria described above. Papers not addressing 
the topic of interest were excluded and reasons recorded. The full-text paper was assessed 
when further information was required to determine if the inclusion criteria were met.
Data extraction and categorizing evidence
The included papers were assessed using the full-text paper by one reviewer (RvdB) to 
extract relevant data, including patient characteristics and details of treatment.
If necessary, authors were contacted to provide any required additional information. 
The results were reported to the ASAS/EULAR expert committee at the beginning of the 
recommendation development process. All included papers were categorized according to 
their level of evidence (see legend in table 1) 3. The assigned levels are shown in table 1.
Data analysis
Since different types of studies are included about various types of treatments, the results 
are very heterogeneous and therefore the results cannot be pooled. Yet, the results are 
analysed and presented per type of treatment.
Estimation of effectiveness
Per treatment group, the Cohen’s effect size (Cohen’s ES; mean change in score divided by 
the baseline SD) was calculated, and the standardized response mean (SRM; mean change 
divided by the SD of the change) was calculated where possible 36. To compare the effect 
between treatment groups, treatment ES was calculated (mean change in the index group 
minus the mean change in the comparator group divided by a pooled baseline SD). For each 
ES, the corresponding 95% CI was constructed. An ES of 0.2 or 0.3 is considered a small 
change, around 0.5 as moderate and >0.8 as a large change, and a negative ES indicates 
worse.
Results
Treatment modalities and types of research evidence
The general search revealed 3179 papers; 1638 in PubMed, 1486 in EMBASE, 14 in PEdro, 34 
in Cochrane and 7 abstracts. After eliminating duplicates, 2383 papers remained. Of those, 
2347 papers were excluded (supplementary appendix S2, available as supplementary data 
at Rheumatology Online) and 35 papers were included, of which 3 are Cochrane reviews and 
1 abstract (supplementary appendix S3, available as supplementary data at Rheumatology 
Online). An overview of the included papers is shown in the supplementary appendix S4, 
available as supplementary data at Rheumatology Online.
Non-pharmacological treatment
No studies on treatments about diet, education, self-help groups or lifestyle modification 





























































































































































































































































































































































































































































































































































Review of non-biologic treatment of AS |































































































































































































































































































































































































































































































































































































































































































































































































































































































































Review of non-biologic treatment of AS |


















































































































































































































































































































































































































































































































































































































































































































































































































































The effect of physiotherapy has been reviewed in a Cochrane review in 2008 37. The results 
of this review show that individual home-based or supervised exercise programmes are 
better than no intervention at all on pain, physical function, spinal mobility and patient 
global assessment, and that supervised group physiotherapy is better than home exercise 37.
Besides the Cochrane review, nine papers were identified 10-15, 38-40 of which three were 
already included in the Cochrane review 38-40. In the six additional papers, the effects of 
various exercises in AS patients are compared (supplementary appendix S4, available as 
supplementary data at Rheumatology Online). The results of these six studies confirm the 
results of the Cochrane review. Various types of exercise [supervised group, home and 
Global Posture Reeducation (GPR) method exercise] have moderate to good effects on 
BASFI, BASDAI, pain and mobility, as shown by the calculated Cohen’s ES and SRM (table 1 
and figure 1). The calculated treatment ES showed that supervised group physiotherapy is 
better than home exercise on BASFI, pain and mobility, and slightly better on BASDAI. Home 
exercise is better than no exercise at all on BASFI and BASDAI (table 2).
Although most papers had level 1b evidence, the studies investigated various exercises with 
variable durations and had small patient samples. Therefore, many ES are not statistically 
significant, showing only a trend (table 1).
Balneotherapy, spa therapy and rehabilitation
The same Cochrane review also revealed that combined inpatient spa exercise therapy 
followed by group physiotherapy is better than group physiotherapy alone 37. In addition 
to the Cochrane review, four RCTs 16, 17, 42, 43 about various types of balneotherapy and spa 
therapy in AS patients were identified (level 1b evidence), of which two were already 
presented in the Cochrane review 42, 43.
As in the exercise therapy studies, the studies about balneotherapy included only small 
patient numbers in various therapies, resulting in not statistically significant ES.
However, the trend shows that balneotherapy in all its modalities is (moderate) effective on 
BASFI, BASDAI and pain, as shown by the calculated Cohen’s ES and treatment ES (tables 1 
and 2). The effect of balneotherapy on pain is equal to the effect of NSAIDs (either mono 
or combined) 17. Stangerbath therapy combined with exercises is effective on BASFI and 
BASDAI, only directly after therapy 16 (figure 1). One level 3 evidence study about the effect 
of inpatient rehabilitation was identified that showed a strong effect on BASFI, pain and 
OWD (table 1) 18.
NSAIDs
Three studies about the effects of different NSAIDs in AS patients were identified 19, 20, 41. 
The effect of celecoxib (200 and 400mg daily) in comparison with diclofenac (150mg daily) 
(level 1b evidence) 19, the effect of etoricoxib (90mg daily) (level 3 evidence) 20 and the 
effect of NSAIDs in continuous usage in comparison with NSAID usage on demand (level 1b 
evidence) 41 were investigated.
The latter study is a follow-up study of a double-blind RCT about the effect of celecoxib 
200mg versus ketoprofen 200mg versus placebo after 6 weeks 44. This study was already 
included in the review of Zochling et al. 4, showing a significant improvement in pain and 
function after 6 weeks of use of both NSAIDs in comparison with placebo 44. The follow-up 
study showed that measures of disease activity, including pain and BASDAI, were stable 
over a time period of 24 months in both the continuous and on-demand groups and not 
statistically significant between the groups 41. Although the clinical effects of both treatment 
strategies are similar, inhibition of structural damage progression in the spine is better with 
continuous use than with on-demand use 41.
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Figure 1: SRM of differe t outcome parameters.
The calculated Cohen’s ES and SRM of the other two studies showed that all NSAIDs have 
statistically significantly moderate to good effect on BASFI, BASDAI, disease activity and pain 
(table 1 and figure 1). Various NSAIDs have a similar effect as assessed by treatment ES 
(table 2). Furthermore, no new signs of toxicity were discovered.
127
DMARDs
In 2005 and 2006, two Cochrane reviews summarized the effects of MTX and SSZ, 
respectively 45, 46. The MTX review showed that there is no evidence to support any benefit 
of MTX in the treatment of AS. One additional open-label study about the effect of MTX 
was found besides the Cochrane review. The calculated Cohen’s ES did not show any 
improvement on BASFI, BASDAI, pain or mobility (table 1 and figure 1) 24.
The SSZ Cochrane review showed some benefit of SSZ in reducing ESR and easing morning 
stiffness, yet no benefit in physical function, pain, spinal mobility and disease activity 46. 
These results are confirmed by three additional identified SSZ studies (level 1b and 3 
evidences) not included in the SSZ Cochrane review 21-23 (supplementary appendix S4, 
available as supplementary data at Rheumatology Online). Although the calculated Cohen’s 
ES revealed moderate to good effect on BASDAI and pain (table 1, figure 1), the calculated 
treatment ES showed that the effect of SSZ on these outcome parameters is not better 
than the effect of placebo, as shown in one study, and that the effect of SSZ was statistically 
significantly worse than the effect of etanercept (ETN) (table 2). No new signs of toxicity for 
SSZ and MTX were found.
Other therapies
Two studies about other types of therapy were identified. One study investigated the effect 
of probiotics compared with placebo (level 1b evidence) 47 (supplementary appendix S4, 
available as supplementary data at Rheumatology Online). The calculated ES showed that 
probiotics do no better on global well-being and functional index than placebo (tables 1 
and 2). The other study investigated the effect of radium chloride on BASFI, BASDAI, pain 
and disease activity in an uncontrolled design (level 3 evidence) (table 1). The calculated 
ES demonstrated a moderate effect on BASFI and good effect on BASDAI, pain and disease 
activity (table 1 and figure 1) 25.
Surgical interventions
Total hip replacement
Total hip replacement (THR) is a frequently used procedure in AS patients with hip 
involvement. This search revealed one study about hip surgery and resurfacing of the hip 
(Zimmer, Wintherthur, Switzerland). The authors proposed that hip resurfacing might be 
an option instead of THR for young AS patients with hip involvement. They compared the 
effects of resurfacing with THR on pain relief, function and mobility in 38 resurfaced hips 
(23 AS patients) and 41 THRs (25 AS patients) over a mean follow-up time of 34.5 months. 
Both groups showed significant pain relief and good restoration of function and mobility 26 
(table 1).
Spine
Although spinal surgery to resolve fixed kyphotic deformity is accompanied by severe risks, 
it can give excellent functional results by restoring balance and horizontal vision, as shown 
by all nine included papers in this search 27-35. These papers review the different available 
techniques. All included papers are case series, and therefore low-quality studies (level 
of evidence 3) (supplementary Appendices S4 and S5, available as supplementary data at 
Rheumatology Online).
One study compared open wedge osteotomy (OWO) of the cervical spine with closed wedge 
osteotomy (CWO).
No difference in correction of kyphosis between the two techniques was found 28. 
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Another study compared the conventional technique of cervical extension osteotomy with a 
new technique in which the patients have a modified larger lateral resection area than with 
the conventional technique. Again, no differences between the two techniques were found 
concerning functional improvement, satisfaction or complications 30. Similarly, a prone or a 
sitting position during the procedure demonstrated no difference in correction 33.
For thoracolumbar deformities, polysegmental wedge osteotomy might be associated 
with lower risks. However, the correction is often insufficient in the case of calcified 
intervertebral discs. Theoretically, CWO is superior to OWO in terms of efficiency and 
minimal loss of correction and lower accompanied risks, although technically difficult 28, 34. 
For pseudoarthrosis, posterior correction is an effective treatment (posterior opening wedge 
osteotomy), as well as fixation without anterior fusion 27. The data from the included papers 
do not show whether a specific technique gives better results for any specific indication.
Discussion
This systematic review is an update of the review by Zochling et al. 4 and identified available 
nonpharmacological and non-biologic pharmacological treatments effective for symptomatic 
control of AS. The results of this search confirm the 2005 findings for physiotherapy 4; 
exercises in various modalities, individually at home or in a group and under supervision, 
land or water based, have positive effects on BASFI, BASDAI, pain and mobility function. 
However, the small numbers of participants, the heterogeneity of the interventions and 
outcome measures, and deficiency in reporting data result in wide intervals and lack of 
strong evidence.
Zochling et al. 4 revealed that different kinds of NSAIDs and coxibs improve spinal and 
peripheral joint pain and function. The current search confirmed these results by showing 
that various NSAIDs including coxibs improve BASDAI, disease activity and BASFI.
In 2005 no effect of SSZ or MTX on back pain and function was demonstrated 4, which is 
confirmed by new research. The current search revealed no effect of SSZ and MTX on pain, 
nor on BASFI and BASDAI.
THR is still the standard procedure in AS patients with hip involvement. Although a small 
study showed positive effects of hip resurfacing techniques 26, it must be carefully considered 
whether resurfacing techniques are indeed a good alternative for THR given the recent 
developments and accompanying problems with the resurfacing techniques from another 
brand. The articular surface replacement hip prosthesis from the manufacturer DePuy 
(Warsaw, IN, USA) has been recalled from the market because of failing of the prosthesis. 
Metal debris from wear of the implant led to a reaction that destroyed the soft tissues 
surrounding the joint, causing long-term disability and a high revision rate of 12% over 5 
years 48.
Surgical interventions of the spine give excellent results by restoring horizontal gaze and 
function yet are considered with high risks. Furthermore, it is still unclear which procedure 
of spine surgery is the best for any specific indication.
Conclusion
This review presents a concise summary of the current evidence available for therapeutic 
interventions for the management of AS, both non-pharmacological and pharmacological, 
excluding biologics. This overview formed the basis for the update of the ASAS/EULAR 
recommendations for the management of AS.
Supplementary data
Supplementary data are available at Rheumatology Online. 
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Abstract
Objective
To perform a literature review as basis for the update of the Assessment in SpondyloArthritis 
international Society/European League Against Rheumatism (ASAS/EULAR) treatment 
recommendations with biologics in AS. 
Methods
A literature search of all publications found in MedLine, Embase and Cochrane database 
between 2005 and 2009 and in the EULAR/ACR meetings between 2007 and 2009 was 
performed. The research evidence and strength of recommendation (SOR) for biologics 
were provided.
Results
Out of 247 reports on AS treatment with biologics, 98 contained efficacy data and 25 had 
complete data for analysis. The treatment effect sizes (95% CI) for anti-TNF versus placebo 
varied between 0.34 (0.08, 0.6) and 1.5 (0.45, 2.5) for BASDAI and 0.33 (0.07, 0.59) and 2.5 
(1.3, 3.7) for BASFI. The calculation of the numbers needed to treat all the different outcomes 
varied between 2.3 and 3.0 patients for all ASAS outcomes and between 2.7 and 6.5 patients 
for ASAS partial remission. Data on biologics other than anti-TNF and for TNF blockers on 
juvenile SpA were limited. The incidence rates of uveitis during anti-TNF treatment varied 
between 4.4/100 patient-years (pys) and 15.6/100 pys during placebo (p<0.05). The 
incidence rates of IBD flares were significantly less during infliximab treatment (0.2/100 
pys). The rate of infections was higher in patients treated with anti-TNF as compared with 
placebo, but there was no difference in the incidence of serious infections for treatment 
with anti-TNF versus placebo.
Conclusions
The overall evidence was very high for anti-TNF treatment (1b, SOR: A) with respect to 
efficacy and safety, while it was low for biologic treatment other than anti-TNF (3, SOR: C).
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Introduction
Treatment with anti-TNF has shown short- and long-term efficacy without major safety issues 
in clinical trials of patients with active AS. At the moment, four different anti-TNF agents are 
available and approved for the treatment of AS (infliximab, etanercept, adalimumab and 
golimumab).
In 2003, the Assessment in SpondyloArthritis international Society (ASAS) proposed 
recommendations for the use of anti-TNF agents in patients with AS, based on a Delphi 
questionnaire, published data, clinical expertise and a consensus meeting among 
experts 1, 2. In 2006, the ASAS/European League Against Rheumatism (EULAR) management 
recommendations of AS were published.
These include guidance on non-pharmacological and pharmacological treatment including 
the use of TNF blockers. The recommendations for the use of anti-TNF agents and the ASAS/
EULAR management recommendations are complimentary.
The recommendations for the use of anti-TNF agents were updated in 2006 3, since it was 
felt that the research had rapidly evolved in this area after the first publication. In the first 
update, several aspects of treatment with anti-TNF agents, such as the initiation, use and 
withdrawal of anti-TNF treatment, based on data on the efficacy and safety of those agents 
were taken into account. In 2009 it was decided that a second update of both the ASAS/
EULAR recommendations for the management of AS and the recommendations for the use 
of anti-TNF agents should be performed. Two systematic literature reviews were performed 
to search for the underlying evidence: one on biologics and one on non-pharmacological 
and pharmacological (excluding biologics) treatment.
The primary outcome of interest for this systematic literature review was the evidence on the 
long-term efficacy and safety of TNF blockers in AS. This includes information on a possible 
distinction between the different TNF blockers, information about switching between TNF 
blockers in case of inefficacy or safety concerns, efficacy and safety of other biologics than 
TNF blockers and the efficacy of biologics including TNF blockers in patients fulfilling the 
ASAS classification criteria for axial SpA but not yet the modified New York criteria for AS.
Methods
Included study designs
Randomized controlled trials (RCTs) were considered as the ideal study design for calculation 
of the intended analyses.
However, since a low number of RCTs was anticipated, all possible studies (quasi-randomized 
studies, non-randomized studies, case-control studies) as well as abstracts from the EULAR 
and ACR annual meetings for the years 2007-09 were included.
Systematic literature search
A systematic literature search for published articles was performed for the time period 1 
January 2005 (which represents the date after the end of the last systematic literature review 
on this topic 4) to 1 December 2009, using the PubMed, Embase and Cochrane databases 
with the assistance of an experienced librarian. Furthermore, a search of published abstracts 
in the online abstract libraries of the EULAR and the ACR annual meetings for the years 
2007-09 for additional relevant but still unpublished studies was performed by hand. The 
terms that were used for each search were ‘ankylosing spondylitis’, ‘spondyloarthritis’, ‘anti-
TNF’, ‘biologics’, ‘infliximab’, ‘etanercept’, ‘adalimumab’, ‘anakinra’, ‘abatacept’, ‘rituximab’ 
in all possible combinations of at least two of the terms and up to all terms together. The 
complete search strategies for the database searches are provided in supplementary 
appendix 1, available as supplementary data at Rheumatology Online.
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Selection of studies
All reports (published papers and abstracts of meetings) had to deal with patients fulfilling 
the modified New York criteria for AS 5 or the ASAS classification criteria for SpA 6.
Data extraction, data analysis and quality appraisal
From the studies that could be included in the analysis, all relevant efficacy and safety data 
were extracted and entered into standard data extraction forms in a Microsoft Excel- file 
according to the key components of the PICO (Participants, Interventions, Comparisons 
and Outcomes) method (supplementary appendix 1, available as supplementary data at 
Rheumatology Online). Calculations were made for the effect sizes (ESs, mean change in 
score divided by the baseline SD) for treatment [treatment effect (TE), the mean change 
in the index group minus the mean change in the comparator group divided by a pooled 
baseline SD] and for the Guyatt’s ES (mean change in the index group divided by the SD 
of the change in the placebo group) according to all reported measures: disease activity 
(BASDAI 7), metrology (BASMI 8) and function (BASFI 9, CRP, ESR), but also the number 
needed to treat (NNT) for response to treatment according to the ASAS definitions (ASAS 
response 10). The latter is used for assessment of the efficacy of study drugs by using the 
ASAS group core set of criteria for symptomatic improvement in AS 10 and is measured 
by a 20 and 40% response according to the ASAS criteria 10 and an improvement in the ‘5 
out of 6 criteria’ 11. ASAS 20 response is defined as an improvement of not <20% and an 
absolute improvement of at least 1U (on a scale of 0-10) in at least three of the following 
Figure 1: Flowchart of the selection of references in MedLine and 
Embase database as well as in the abstract books of the EULAR and 
ACR meetings, which served as the basis for this literature search. 
During the process, duplicates of papers, incomplete data, reports 
with longer follow-ups available in other papers, case reports without 
follow-up information and publications or reports with ‘wrong outco-
me’ were excluded.
After collection, each 
title and abstract was 
examined for suitability 
in the review by excluding 
these studies that met 
the following exclusion 
criteria: duplicates of 
papers, incomplete data, 
reports that had longer 
follow-ups available in 
other papers than the 
ones found (in this case, 
the longer follow-up 
papers were included in 
the final analysis), case 
reports without follow-
up information and 
publications or reports 
with ‘wrong outcome’ 
(e.g. listing AS or SpA 
as keywords but not 
reporting about these 
diseases in particular) 
(figure 1). The full papers 
that were excluded 
from the analyses are 
listed in supplementary 
appendix 2, available as 
supplementary data at 
Rheumatology Online.
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four domains: patient’s global assessment, pain, function (represented by the BASFI score) 
and inflammation [represented by the mean of the two morning stiffness-related BASDAI 
numeric rating scale (NRS) scores]. Furthermore, there must be an absence of deterioration, 
which is defined as worsening of not >20% and net worsening of not >1U (on a scale of 
0-10), in the remaining domain. Similarly, ASAS 40 response is defined as an improvement 
of not <40% and an absolute improvement of at least 1U (on a scale of 0-10) in at least three 
of the four domains mentioned above, while there should be no worsening in any of the 
domains. To meet the ‘5 out of 6 criteria’, a 20% improvement in any five of the following 
six domains is required: the four domains used for ASAS 20 plus the CRP value and spinal 
mobility (assessed by the BASMI score).
Since we decided to include not only RCT alone, but also other types of studies (see above) 
in this review, a greater heterogeneity of the results was expected for all analyses.
A further assessment was made for each included study according to the Oxford Center for 
Evidence-based Medicine (CEBM) level of evidence, which gives studies a score for ‘level of 
evidence’ (1a-5) and a score for ‘grade of recommendation’ (A-D 12). Analysis of safety data 
and adverse events (AEs) was done in a descriptive way in summary tables.
The results were finally presented to the ASAS/EULAR expert committee during the process 
of the update of the ASAS/EULAR management recommendations of AS and the update of 
the recommendations for the start of TNF-blocking agents.
Results
Process of the literature review
Overall, 409 reports were identified in MedLine and 630 reports were identified in the 
Embase database, while no report was found in the Cochrane database.
The search of the abstract meetings revealed 254 reports at EULAR and 202 reports at the 
ACR meeting. After exclusion of duplicates, 257 reports remained for validation, 64 reports 
were found to be dealing with efficacy and/or safety outcomes of patients and finally, 25 
papers were found to have useful data for analysis (figure 1).
Efficacy
Calculation of ESs for treatment outcomes
The comparison between anti-TNF treatment versus placebo showed superior outcome 
for the treatment effect in favour of the anti-TNF treatment [13-21]. For the evaluation of 
the BASDAI, the ES (95% CI) varied between studies from 0.34 (0.08, 0.6) to 1.5 (0.45, 2.5) 
(table 1).
For evaluation of the BASFI, the ES (95% CI) varied between 0.07 (-0.21, 0.34) and 2.5 (1.3, 
3.7), whereas for evaluation of the BASMI, the ES (95% CI) was only available for golimumab 
[0.08 (-0.20, 0.31)] (table 1).
Furthermore, data for different other outcomes such as occiput-to-wall measurements, 
chest expansion, physician’s global and patient’s global were only available in some of the 
studies 18, 20. The treatment effect for patient’s global assessment was 0.53 (0.17, 0.89), 
for physician’s global assessment 1.3 (0.67, 1.9), for chest expansion zero (-0.35, 0.35), for 
occiput-to-wall it varied between -0.22 (-0.52, 0.09) and 0.01 (0.34, 0.37) and for modified 
Schober’s test between 0.06 (-0.29, 0.42) and 0.28 (-0.03, 0.58).
The treatment effect for continuous versus on-demand anti-TNF treatment could only be 
calculated for infliximab, with an ES (95% CI) of 0.76 (0.44, 1.1) for BASDAI and 0.74 (0.42, 
1.1) for BASFI, 0.53 (0.22, 0.84) for patient’s global assessment, 0.03 (-0.28, 0.34) for the 
physical component of the short form 36 (SF-36) questionnaire and 0.19 (-0.12, 0.5) for the 
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mental component of SF-36.
The Guyatt’s ES could only be calculated for golimumab in AS 19 and infliximab in non-
radiographic SpA 21.
Calculation of numbers needed to treat
The calculation of the NNT for achieving all different treatment outcomes revealed only 
minor variations between the TNF blockers but superiority as compared with placebo 14, 18-26, 
with NNTs of 2.3-2.7 for ASAS 20, 2.9-3.7 for ASAS 40, 2.4-2.8 for ASAS 5/6, 2.5 for BASDAI 
50 and 4.7-5.9 for ASAS partial remission.
Similar NNTs were found for patients with nonradiographic axial SpA, with 2.3 for ASAS 20, 
1.6-2.4 for ASAS 40, 3.2 for ASAS 5/6 and 2.3-2.7 with ASAS partial remission (table 2).
In the comparison of continuous versus on-demand treatment with TNF blockers, the 
NNTs for ASAS 20 response were 4.2 versus 9.1 patients, for ASAS 40 response 6.7 versus 
8.3 patients and for ASAS partial remission 5.9 versus 20.0 patients, respectively. For the 
differentiation between patients with versus without total spinal ankylosis, the NNTs varied 
between 2.4 for ASAS partial remission and 9.1 for ASAS 5/6 (table 3).
Efficacy of TNF blockers on extraspinal manifestations of the disease
One study from patients diagnosed as SpA according to the Amor criteria 27 provided data on 
the efficacy of TNF blockers in peripheral manifestations of the disease.
Patients with refractory disabling heel enthesitis were treated with etanercept or placebo. 
Patient’s global assessment, heel pain and WOMAC improved significantly in the etanercept 
group as compared with placebo, already after 2 weeks of treatment.
Treatment with biologics other than TNF blockers
Overall, only small studies on biologics other than TNF blockers were available, and all 
of these studies included patients with advanced disease 28-32. None of the studies was 
placebo-controlled. The compounds used were rituximab, anakinra or abatacept. All of the 
compounds showed only minor improvement in disease-related indices, and because there 
are no control groups, the level of improvement is difficult to interpret.
For rituximab in anti-TNF naïve patients 28, there were significant within-group improvements 
in BASDAI (p=0.047), pain as reported by the patient (p=0.021) and improvement in CRP 
(p=0.017). Further data published in the full paper of this abstract in 2010 showed a good 
improvement of all assessed parameters (50% in BASDAI50, 40% in ASAS 40) as compared 
with a poor response in those patients who had failed TNF blocker therapy before rituximab 
treatment (10% in ASAS40, none in BASDAI 50). For anakinra 31, the rate of patients showing 
sufficient ASAS response was reported as 25% for ASAS 20 and 20% for ASAS 40, while 
BASDAI improved from 5.8 to 4.6 and there was no change in CRP, as compared with 
baseline. The data of this study were included in abstract form in the first version of the 
recommendations 4, whereas the full paper is now available for the current report. For 
abatacept, there was only minor response of single patients 30.
TNF blockers in juvenile SpA
Only one small study published in abstract form 33 including patients with juvenile SpA 
patients with established AS (n=5 patients) and undifferentiated SpA (n=19) treated with 
infliximab could be used for data analysis. In this study, the amount of active joints, tender 
entheses, pain, CRP and HAQ showed significant decrease after 1 year in all patients. The 
mean amount of active joints decreased from 4.7 (1.7) to 0, the mean amount of tender 
entheses from 11.9 (10.7) to 0, the mean CRP from 24.8 (10) to 1.3 (3.1), the pain (mean of 
NRS) from 7.2 (2.0) to 1.7 (2.7), while the mean score in the childhood HAQ did not show 
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changes in the patients who were initially treated with infliximab and remained on this 
treatment.
Level of evidence and strength of recommendations for treatment with biologics in AS
The overall research evidence for all TNF blockers is rated with 1b+ (table 4), including two 
studies with patients with non-radiographic axial SpA 18, 21, which showed similar outcomes 
as compared with studies of patients with established AS.
Furthermore, the research evidence for the use of infliximab on demand and for the use of 
etanercept in a dose of 1x25 mg/week in patients with low disease activity was also rated 
with 1b+. There are no data on dose adjustment for adalimumab at the current time point. 
The strength of recommendation (SOR) for the use of all available TNF blockers in AS in the 
recommended dose is rated with A, with the exception of treatment with etanercept 1x25 
mg/week, where the SOR is rated with B (table 4).
The research evidence for the treatment of patients with DMARDs concomitant to TNF 
blockers as well as switching between TNF blockers is 3+, while the SOR was rated with 
C. Although the analyses for switching between anti-TNF compounds have been based on 
patients treated with infliximab after failure of treatment with etanercept, it is expected 
that other combinations among other TNF blockers would reveal similar outcomes.
For treatment with biologics other than TNF blockers, the available data showed a research 
evidence of 3 for anakinra based on the same study as already included in the previous 
review; however, this result remains to be confirmed by further studies. Data for abatacept 
and rituximab are scarce and did not allow for any conclusions, while no data for tocilizumab 
were available within the period of analysis in this update. The SOR for the use of anakinra 
in AS was rated with C.
For the use of biologics in patients with juvenile onset of SpA, only data on infliximab were 
available. The research evidence was 3, which can be translated to SOR rated with C (table 4).
Incidence of concomitant extra-articular manifestations in AS during treatment with TNF 
blockers
TNF blockers showed beneficial effect on the treatment of extra-articular manifestations 
(EAMs) of AS as compared with treatment with placebo. Data were available for infliximab, 
etanercept and adalimumab, while data from studies with golimumab were not available at 
this time point.
Two main concomitant EAMs were recognized: anterior uveitis (AU) and IBDs.
As suggested in a meta-analysis for the treatment of AU, which included only patients 
with infliximab and etanercept (adalimumab data were not available at this time point), 
the incident rates during anti-TNF treatment were 4.4 (range 1.1-8.0) per 100 patient-years 
(pys) as compared with 15.6 (7.8-27.9)/100 pys during placebo treatment (all p<0.05) 34, 35. In 
a more recent paper 35, the incidence of AU flares under open-label adalimumab treatment 
was 7.4/100 pys and statistically significantly lower than the incidence rate of AU during the 
previously performed placebo-controlled period of the same trial with 15.0 AU flares/100 
pys (p=0.001).
Another follow-up study with patients treated open label with etanercept showed similar 
superiority of etanercept (13 AU flares/100 pys), as compared with the numbers known 
from the placebo-controlled period of the same trial 36. Similar data were shown in a meta-
analysis that was available in abstract form 37 (the full paper was published in 2010). 
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A summary of the studies dealing with the 
occurrence of AU in patients with anti-TNF 
during the time period analysed in this update 
is shown in table 5.
For the incidence of IBD, other differences 
between the TNF blockers were found, with 
significantly lower incidence rates during 
treatment with infliximab, as compared with 
etanercept or adalimumab 38 (table 6).
Safety
AEs
The incidence of AEs between treatment 
with TNF blocker and placebo, between 
TNF blockers in different treatment doses or 
during treatment with TNF blockers with or 
without concomitant treatment with other 
compounds is shown in table 7. Overall, the 
incidence of AEs as reported in the present 
updated review is in line with those reported 
in the first version of the recommendations 4.
Infections
In a meta-analysis comparing the risk 
difference between TNF blockers and 
placebo 39, the incidence rate of non-
serious infections was 84.5 (58.4)/100 pys in 
patients treated with TNF blockers during the 
randomized control phases of the trials (RCTs) 
and reduced to 64.4 (56.7)/ 100 pys during 
the open-label phases. The latter was similar 
to the incidence of non-serious infections 
registered in the placebo arm of the RCTs, 
with an incidence of 63.6 (63.0) non-serious 
infections/100 pys.
In contrast, the analysis of serious infections 
showed an incidence of 2.3 (4.0) under TNF 
blockers during the RCTs and of 1.4 (2.8) 
during the open-label phases, as compared 
with an incidence of 1.4 (2.83) serious 
infections under placebo. An overview on the 
available data of the relative risk for infections 
in patients with AS is shown in table 7.
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Formation of antibodies against TNF blockers
Only a few studies were dealing with the issue of antibody formation during treatment with 
TNF blockers in AS. In one study with infliximab 40 - patients who discontinued and re-started 
TNF blockade in the same treatment regimen - immunogenicity had no influence on the 
response to re-treatment or on safety outcomes in the long-term follow-up. While antibody 
formation due to immunogenicity was not detected during and after treatment with 
etanercept 41, antibody formation correlated well with undetectable serum trough levels, 
with inefficacy and infusion or injection reactions in patients treated with infliximab 42 or 
adalimumab 43 in two small studies.
Table 4: Research evidence for treatment with different biologic compounds and dosages in 
patients with AS and SpA for the years 2006 - 2010, compared to the last published version of the 





INF 5mg/kg cont. (only AS) 1b+
1b+
A
INF 5mg/kg cont. (non-
radiographic SpA) NA
INF 5mg/kg on dem. NA A




ETN 2x25mg 1b+ A
ETN 1x25mg NA B
ADA 1x40mg
3+ 1b+ A
(only AS) (both AS and non-radiographic SpA)
GOL 1x50mg/100mg NA 1b+ A




(anakinra only) 3± C
INF 5mg/kg in JuvSpA -- 3 C
+ = supportive, - = not supportive, ± = uncertain. SOR = strength of recommendations; NA = no data 
available.
Discussion
This report is a systematic literature review that was performed in order to obtain the detailed 
data for the second update of the ASAS/EULAR recommendations for the management 
of AS, with a special topic of interest being the treatment with biologics. After the first 
version of the recommendations published by ASAS in 2003 2 and a first update in 2006 3, a 
substantial number of new publications with long-term data on TNF blockers and reports on 
other biologics made this second update necessary.
On the basis of the published data on efficacy and safety, the research evidence is determined 
and the SOR is provided.
More data on all TNF blockers approved for the treatment of AS were available for the 
time January 2005-December 2009, as compared with the time before 2005, where the first 
version and the first update of the recommendations were available. Overall, all anti-TNF 
blockers proved to be efficacious in AS and SpA with a high level of research evidence (1b+).
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Table 6: Incidence of acute inflammatory bowel disease (IBD) in AS patients treated with anti-TNF. 
P values were p<0.001 for infliximab versus. etanercept, 0.02 for infliximab versus. adalimumab and 
1.0 for etanercept versus. adalimumab 39.
Treatment Incidence of IBD  / 100 patient years
Total number of 
treated patients Numbers of IBD cases
Placebo 1.3 434 2
Infliximab 0.2 366 1
Etanercept 2.3 419 14
Adalimumab 2.3 295 3
Table 7: Calculation of relative risk (RR) and 95% confidence intervals (95% CI) for infections in patients 
with AS, as pooled relative risk for the placebo-controlled trials and for trials with comparators other 
than placebo.
Type of study Adverse event Study RR (95% CI)
Studies comparing 




anti-TNF vs. placebo 
treatment 40
Risk difference: 0.4%
(95% CI -8% to 1.6%)
Studies comparing 
TNF treatment with 
other comparators 
than placebo
All adverse events 
(for comparison)
Etanercept 1x50mg vs. 
2x25mg 23 0.84 (0.39 - 1.81)
Infusion reactions
Infliximab continuous 
vs. on demand 20 2.23 (1.00 - 4.94)
Infliximab on demand, 
without vs. with MTX 20 3.04 (0.64 - 14.52)
In comparison, the data of the last recommendations were only based on patients with 
established disease, proposing a research evidence level of 1b+ for continuous infliximab (5 
mg/kg/6 weeks) and for etanercept (2-25 mg/week) but a research evidence level of 3+ for 
adalimumab (40 mg/2 weeks), while there were no data for the treatment with etanercept 
in the dose of 1-50 mg/week or for golimumab. In this update, also a research level evidence 
of 1+ can be given to adalimumab and golimumab in the approved doses.
The SOR for the use of all available TNF blockers in AS in the dose recommended by the 
label of each compound is rated with A. However, the present calculations also support 
treatment with infliximab on demand and treatment with etanercept in the decreased dose 
of 1-25mg for patients with established AS who remain on low disease activity (research 
evidence 1b+). For the latter, the SOR is rated with B. There are no data on dose adjustment 
for adalimumab at the current time point.
In contrast to the previous version of the recommendations, data on the treatment with 
DMARDs concomitant to TNF blockers as well as switching between TNF blockers are now 
available. The calculated research evidence is 3+, while the SOR was rated with C. Although 
the analyses for switching between anti-TNF compounds have been based on patients 
treated with infliximab after failure of etanercept treatment, it is expected that other 
combinations among other TNF blockers would reveal similar outcomes.
Data from new biologic compounds other than TNF blockers were also available this time. 
However, only studies with anakinra provided information that could be used for calculations, 
showing a research evidence of 3 (SOR rated with C). Data for abatacept, rituximab and 
tocilizumab were scarce and did not allow for any conclusions.
For the use of biologics in patients with juvenile onset of SpA, only limited data were 
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available. There, infliximab showed research evidence on a level of 1b+, which can be 
translated to a SOR rated with A.
Finally, the available data indicate a beneficial effect of TNF blockers for the treatment of the 
two main EAMs in the same patients, AU and inflammatory bowel diseases, with only minor 
differences between the available compounds.
With respect to safety, the overall incidence of AEs was not different to what had been 
reported previously.
However, treatment with TNF blockers showed a somewhat higher infection rate as compared 
with placebo, although there was no difference between the treatments in the comparison 
for serious infections. Nevertheless, it seems that the overall incidence of infections during 
treatment with TNF blockers decreased with longer duration of the studies, which might 
be due to selection of patients who stay in the study. In the short-term follow-up studies 
with patients treated with biologics other than TNF blockers, no major safety issues were 
reported. Finally, the formation of antibodies against TNF blockers has been reported in 
some studies and has correlated with low serum levels of the compounds, mainly in studies 
with mAbs. Nevertheless, immunogenicity had no influence on the response to re-treatment 
or on safety outcomes in one small study. More data are necessary to determine the clinical 
relevance of the formation of anti-drug antibodies.
In conclusion, the analysis of all available literature data support the use of the currently 
available TNF blockers for the treatment of patients with advanced AS who are fulfilling the 
ASAS recommendations for such treatment.
Furthermore, data from first studies from patients with non-radiographic SpA show a 
similar response to TNF blockers. Overall, biologics other than TNF blockers cannot be 
recommended at the current time because of lack of sufficient evidence. DMARDs do not 
add to efficacy or safety as concomitant treatment with anti-TNF in patients with AS. TNF 
blockers show good evidence in patients with juvenile onset of SpA, but these data are 
based on a limited number of studies.
Supplementary data
Supplementary data are available at Rheumatology Online.
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Abstract
This first update of the ASAS/EULAR recommendations on the management of 
ankylosing spondylitis (AS) is based on the original paper, a systematic review of existing 
recommendations and the literature since 2005 and the discussion and agreement among 
21 international experts, 2 patients and 2 physiotherapists in a meeting in February 2010. 
Each original bullet point was discussed in de tail and reworded if necessary. Decisions 
on new recommendations were made - if necessary after voting. The strength of the 
recommendations (SOR) was scored on an 11-point numerical rating scale after the meeting 
by email. These recommendations apply to patients of all ages that fulfill the modified NY 
criteria for AS, independent of extra-articular manifestations, and they take into account all 
drug and non-drug interventions related to AS. Four overarching principles were introduced, 
implying that one bullet has been moved to this section. There are now 11 bullet points 
including 2 new ones, one related to extra-articular manifestations and one to changes in 
the disease course. With a mean score of 9.1 (range 8-10) the SOR was generally very good.
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Introduction
The European League against Rheumatism (EULAR) has developed management 
recommendations for various rheumatic conditions in the past decade 1–6 based on standard 
operating procedures published some years ago 7. The basis for the methodology is the 
AGREE instrument 8. A systematic literature review (SLR) serves as the basis for the expert 
discussions and the consensus process 9–11. The Assessments in Ankylosing Spondylitis 
International Society (ASAS), which published a core set of endpoints for the disease more 
than 10 years ago 12 has taken the lead in developing recommendations for anti-tumour 
necrosis factor (TNF) therapy in ankylosing spondylitis (AS) 13, which have already been 
updated twice 14, 15. The two organisations jointly developed the first set of recommendations 
for the management of AS together in 2005.
As this is a requirement of the EULAR standard operating procedures for management 
recommendations and as the field of spondyloarthritis is moving rapidly, an update of the 
first recommendations for the management of AS is needed after 5 years. 
While the first version of the management recommendations was initially developed without 
patients, and as discrepancies between patients’ and physicians’ perspectives are well 
known 16, on this occasion patients were involved in the project group from the beginning. 
Moreover, other stakeholders, such as physiotherapists, were also represented in the project 
group. A patient-specific version of the first recommendations has been developed with the 
active support of patients of many European and North American countries 17. The original 
and the patient version of the recommendations has been evaluated 18, 19 and disseminated 
in several countries 20–23. 
AS is the prototype 24, a subtype, and an outcome of spondyloarthritis, particularly of the 
axial form of spondyloarthritis. Recent new classification criteria have widened the spectrum 
of spondyloarthritis by including earlier forms in addition to AS 25, 26. This project has also 
led to a separation in the classification to predominantly axial and peripheral forms of 
spondyloarthritis. The term ‘axial spondyloarthritis’ covers patients with chronic back pain 
who have AS, which is defined by the presence of definite structural changes on radiographs 
in the sacroiliac joints, and patients with early or abortive forms of spondyloarthritis, which 
is defined by the presence of sacroiliac inflammation as detected by MRI or the presence 
of HLA-B27 in combination with the presence of features typical of spondyloarthritis 27, 28. 
It can be anticipated that future trials will increasingly target axial spondyloarthritis rather 
than AS. Some trials with that aim have already been performed and some have started. 
However, as the evidence from such trials is currently limited it has been decided to restrict 
the recommendations to AS, although the project group unanimously agreed that these 
recommendations can equally be applied to patients with axial spondyloarthritis.
As the number of clinical trials and publications on AS therapy has steadily increased over 
the first decade of the millennium, this provided a sound rationale for a SLR.
Methods
ASAS and EULAR agreed in 2009 to collaborate in the development of the first update 
of the recommendations. To facilitate the process, it was decided that the convenor (JB) 
and the epidemiologist (DvdH) would maintain the same role that they undertook in the 
development of the first recommendations. 
These original recommendations 1 formed the basis for the update. Two fellows performed 
the SLR, which needed an update since 2005 when the previous SLR was performed 11. The 
international expert group included 21 rheumatologists, two orthopaedic surgeons, four 
patients (two of them were also rheumatologists) and one physiotherapist - representing 16 
countries worldwide. The same group of international AS experts who participated in the 
development of the first recommendations was invited to participate.
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The experts met on 25/26 February 2010 in Zurich. During the meeting, the data from the 
SLR dating from the previous search in 2005 until December 2009 were presented to the 
international experts. Each bullet point was discussed in detail until consensus was reached 
as to whether rewording was necessary. New recommendations were considered if this was 
proposed by a member of the panel.
Scoring on an 11-point numerical rating scale for the strength of recommendation was done 
by email by each expert for each bullet point after the meeting.
The methodology and detailed results of the SLR are described elsewhere in two separate 
papers: one dealing with biological agents and the other with all other management aspects 
such as non-biological drugs, education and physiotherapy (submitted).
Results
General definitions
The target population was defined as follows: the recommendations were to apply to all 
patients fulfilling the modified New York criteria for AS, independent of extra-articular 
manifestations. Patients of all ages, including paediatric patients, were included, and all 
pharmacological and non-pharmacological interventions for AS were taken into account.
The first discussion addressed whether the terminology of the recommendations should be 
changed to ‘Recommendations for the management of axial spondyloarthritis’. The arguments 
in favour were mainly that the new classification criteria for axial spondyloarthritis 25, 26 
are now available and they should therefore be included in the recommendations. The 
arguments against this were rather pragmatic, such as ‘the world of rheumatology is not yet 
ready for that change’. Furthermore, there is a paucity of papers in early disease. The group 
finally decided to stick to the term ‘AS’ for the time being. However, every expert expressed 
the opinion that patients with early axial spondyloarthritis who do not yet fulfill the modified 
New York criteria are part of the same spectrum of disease and that these management 
recommendations most likely apply equally to those patients. Importantly, this patient 
population is already well recognised in the last update of the ASAS recommendations for 
anti-TNF therapy 15. However, it should also be clearly stated that not all patients who fulfill 
classification criteria for axial spondyloarthritis will necessarily develop structural damage 
with radiographic changes in the sacroiliac joints and/or spine, which is presently considered 
essential in order for patients to fulfill currently used criteria for AS 29, 30. This is actually 
similar to patients fulfilling the 2010 criteria for rheumatoid arthritis (RA) versus patients 
fulfilling the 1987 criteria for RA.
Although there are first hints that TNF blockers may be safer in AS compared with RA 31, 
a decision was made not to create a unique update on the safety of biological agents in 
AS/spondyloarthritis, but rather to rely on the extensive work done by Furst et al. 32 who 
have undertaken an annual consensus document on this topic from the ‘Targeted therapies’ 
meeting.
Results of the SLR
The detailed results will be published elsewhere (submitted).
However, the information that was obtained from the SLR was taken into account during the 
discussions of each bullet point.
Results of the discussions
The first change the expert group agreed on was, by analogy with other EULAR 
recommendations (e.g. management recommendations for RA, 6), to define overarching 
principles of management.
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Bullet point number 3 in the first published version of the recommendations 1 stating that the 
optimal management of patients with AS requires a combination of non-pharmacological 
and pharmacological treatment modalities has now been moved to this section.
Of note, the citations in this section are not the complete results of the SLR and they are 
not complete. They are just examples given to document the basis of the statements and 
notations made in the text.
An overview of the new recommendation is given in box 1.
The overarching principles of the management of patients with AS are:
ⱷ AS is a potentially severe disease with diverse manifestations, usually requiring 
multidisciplinary treatment coordinated by the rheumatologist.
ⱷ The primary goal of treating the patient with AS is to maximise long term health-related 
quality of life through control of symptoms and inflammation, prevention of progressive 
structural damage, preservation/normalisation of function and social participation.
ⱷ Treatment of AS should aim at optimal care and must be based on a shared decision 
between the patient and the rheumatologist.
ⱷ The optimal management of patients with AS requires a combination of non-
pharmacological and pharmacological treatment modalities.
Comment
Patients with AS present with different disease manifestations 24 and a high proportion 
may run a severe course of disease 33. The main health problems of patients with AS have 
recently been listed as part of an International Classification of Functioning, Disability and 
Health consensus process 34, 35. 
It is important to stress that the rheumatologist is the expert who should take the lead in the 
management of patients with AS. The major aim for the treatment of rheumatic diseases is 
the preservation and gain of short and long-term health-related quality of life. The general 
view is that this is best achieved through control of symptoms and inflammation—with 
the aim to prevent deformity and disability due to structural damage caused by new bone 
formation and the decline of function and social participation.
Strength of recommendation: 9.5±0.1.
Thereafter, the bullet points were discussed point by point in considerable detail, and 
agreement was achieved on 11 points.
The updated recommendations are:
General treatment
The treatment of patients with AS should be individualised according to:
ⱷ The current manifestations of the disease (axial, peripheral, entheseal, extra-articular 
symptoms and signs)
ⱷ The level of current symptoms, clinical findings and prognostic indicators
ⱷ The general clinical status (age, gender, comorbidities, concomitant medications, 
psychosocial factors).
Comment
This general bullet point was not changed. It stresses that there may be considerable 
variation in how AS patients may present to the rheumatologist. The aim of management 
and appropriate interventions may thus also differ substantially. This implies that these aims 
must be tailored to the unique features of the particular AS patient.
Strength of recommendation: 9.5±0.1.
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Disease monitoring
The disease monitoring of patients with AS should include:




All according to the clinical presentation as well as the ASAS core set.
The frequency of monitoring should be decided on an individual basis depending on:




This bullet point was not changed. It basically leaves the decision as to how frequently 
patients should be monitored to the rheumatologist in charge of management. This is 
mainly due to the fact that the course of disease may differ substantially between patients 
and different aspects, as stated in the bullet point, may need to be considered.
Importantly, experts agreed that, in general, spinal X-rays should not be repeated 
more frequently than every 2 years unless clearly indicated in individual cases. This 
recommendation is based on the experience from clinical studies 36, 37.
Strength of recommendation: 9.4±0.2.
Non-pharmacological treatment
ⱷ The cornerstone of non-pharmacological treatment of patients with AS is patient 
education and regular exercise.
ⱷ Home exercises are effective. Physical therapy with supervised exercises, land or water 
based, individually or in a group, should be preferred as these are more effective than 
home exercises.
ⱷ Patient associations and self-help groups may be useful.
For comparison, the old recommendation was: non-pharmacological treatment of AS should 
include patient education and regular exercise. Individual and group physical therapy should 
be considered. Patient associations and self-help groups may be useful.
Comment
This bullet point was changed according to the SLR and the recent Cochrane review on the 
subject 38, and was supported by the view of an experienced physiotherapist (HD) and the 
participating patients.
Strength of recommendation: 8.8±0.4.
Extra-articular manifestations and comorbidities
ⱷ The frequently observed extra-articular manifestations, e.g. psoriasis, uveitis, and 
chronic inflammatory bowel disease (IBD), should be managed in collaboration with 
the respective specialists.
ⱷ Rheumatologists should be aware of an increased risk of cardiovascular disease and 
osteoporosis.
Comment
This is a new bullet point, with agreement being achieved after considerable discussion. 
The main argument was that extraarticular manifestations are rather frequent in AS and 
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the entire spectrum of spondyloarthritis 39, and that they constitute a frequent challenge in 
management that clearly requires cooperation between specialities.
On the other hand, there are frequent comorbidities that require the attention of 
the managing rheumatologist. These include low bone mineral density, osteoporotic 
fractures 40, 41 and cardiovascular diseases 42, 43, which have been reported to occur in AS and 
spondyloarthritis at an increased rate compared with the general population. 
The rheumatologist is encouraged to identify patients at risk and the potential additional risk 
factors. At this time, it is difficult to make a clear-cut recommendation on the management 
of osteopaenia and osteoporosis for patients with AS in the absence of any studies on the 
subject.
Regarding the management of cardiovascular risk there are recent EULAR recommendations 
that propose an annual risk assessment related to national guidelines 44. Although this is 
mainly intended for patients with RA, these same guidelines should also be considered for 
patients with AS and psoriatic arthritis. Rheumatologists are referred to local guidelines 
for the management of cardiovascular risk and, if no local guidelines are available, the 
management should be carried out according to the systematic coronary risk evaluation 
(SCORE) function 45 (for overview see Cooney et al.) 46. In addition to appropriate 
cardiovascular risk management, aggressive suppression of the infl ammatory process is 
recommended to lower the cardiovascular risk further.
Strength of recommendation: 9.0±0.3.
Non-steroidal anti-inflammatory drugs
ⱷ Non-steroidal anti-inflammatory drugs (NSAID), including Coxibs, are recommended as 
first-line drug treatment for AS patients with pain and stiffness.
ⱷ Continuous treatment with NSAID is preferred for patients with persistently active, 
symptomatic disease.
ⱷ Cardiovascular, gastrointestinal and renal risks should be taken into account when 
prescribing NSAID.
For comparison, the old recommendation was: NSAID are recommended as first-line drug 
treatment for patients with AS with pain and stiffness. In those with increased gastrointestinal 
risk, non-selective NSAID plus a gastroprotective agent, or a selective COX-2 inhibitor with or 
without a gastroprotective agent could be used.
Comment
This bullet point was subject to some minor modifications but the significance of the 
statement remains unchanged.
The main issues are still that NSAID are recommended as the first-line drug therapy, that 
NSAID are recommended to be taken continuously in active patients, and that NSAID are 
considered relatively safe in the population of patients with AS, although the cardiovascular, 
gastrointestinal and renal risks may be somewhat increased in this population.
The main challenges are that it is unclear whether a cut-off such as a Bath ankylosing 
spondylitis disease activity index of 4 is valuable in classifying patients as responders or 
nonresponders with regard to NSAID therapy, whether NSAID should be taken continuously 
regardless of symptoms by all (even asymptomatic) patients to prevent new bone formation, 
whether long-term NSAID therapy is safe, whether patients at risk can be readily identified, 
and how this should be done in clinical practice.
There is evidence that NSAID are efficacious for the relief of pain and stiffness in patients 
with AS 47 for both short-term and prolonged periods of treatment 48, 49. The efficacy is, at 
least partly, dose related 48. There seems to be no effect on spinal inflammation as assessed 
by MRI in one small study 50, but continuous therapy may be superior in the prevention of 
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new bone formation 51. Coxibs may be safe for short-term therapy even in patients with 
IBD 52. One recent step forward for clinical trials in AS has been the ASAS proposal on how 
information on NSAID intake should be collected in studies 53.
Strength of recommendation: 9.3±0.3.
Analgesics
ⱷ Analgesics, such as paracetamol and opioid-(like) drugs, might be considered for residual 
pain after previously recommended treatments have failed, are contraindicated, and/
or poorly tolerated.
Comment
This bullet point has remained unchanged. This topic has been the source of frequent 
discussion and there are experts who have proposed eliminating this bullet point, but the 
majority still felt that inclusion of this bullet point was necessary because it was important 
to draw attention to the possibility that not all back pain in AS may derive from spinal 
inflammation.
Strength of recommendation: 8.0±0.5.
Glucocorticoids
ⱷ Glucocorticoid injections directed to the local site of musculoskeletal inflammation may 
be considered.
ⱷ The use of systemic glucocorticoids for axial disease is not supported by evidence.
Comment
This bullet point has remained unchanged. There have been no new studies and the available 
literature is still scarce.
Strength of recommendation: 8.9±0.4.
Disease modifying antirheumatic drugs
ⱷ There is no evidence for the efficacy of disease-modifying antirheumatic drugs (DMARD), 
including sulfasalazine and methotrexate, for the treatment of axial disease.
ⱷ Sulfasalazine may be considered in patients with peripheral arthritis.
Comment
This bullet point has remained unchanged. After the last Cochrane review 54 there were two 
new studies on sulfasalazine 55, 56, but the experts did not find that these provided sufficient 
new information to change this bullet point. The results of the first study, which was 
performed mainly in patients who had early spondyloarthritis, are conflicting 55, whereas in 
the head-to-head trial against etanercept there was no placebo group 56. Overall, a marginal 
positive effect of sulfasalazine with a rather limited effect size in AS cannot be excluded. 
Therefore, no strong recommendation can be given to support its use but the rheumatologist 
may decide on a trial of sulfasalazine for a limited period, usually not more than 4 months, 
after which further benefit is unlikely. The majority of the studies suggest some efficacy of 
sulfasalazine in patients with peripheral spondyloarthritis and in the prevention of anterior 
uveitis. However, etanercept was more efficacious in the active comparator trial 56. Finally, 
there is clearly no reason other than economic to recommend the obligatory use of a 
conventional DMARD in AS before anti-TNF therapy.
The data on methotrexate are still very limited and no positive recommendation can be 
given on an evidence basis. After the last Cochrane review 57 there was one new open-label 
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study with a high dose of methotrexate given subcutaneously 58, which again demonstrated 
no effect on patients with axial disease.
Most rheumatologists will try methotrexate in patients with predominant peripheral 
spondyloarthritis, but no evidence based recommendation can presently support this. 
Strength of recommendation: 9.4±0.2.
Anti-TNF therapy
ⱷ Anti-TNF therapy should be given to patients with persistently high disease activity 
despite conventional treatments according to the ASAS recommendations.
ⱷ There is no evidence to support the obligatory use of DMARD before or concomitant 
with anti-TNF therapy in patients with axial disease.
ⱷ There is no evidence to support a difference in efficacy of the various TNF inhibitors on 
the axial and articular/entheseal disease manifestations; but in the presence of IBD a 
difference in gastrointestinal efficacy needs to be taken into account.
ⱷ Switching to a second TNF blocker might be beneficial especially in patients with loss 
of response.
ⱷ There is no evidence to support the use of biological agents other than TNF inhibitors 
in AS.
For comparison, the old recommendation was: anti-TNF treatment should be given to 
patients with persistently high disease activity despite conventional treatments according to 
the ASAS recommendations. There is no evidence to support the obligatory use of DMARD 
before, or concomitant with, anti-TNF treatment in patients with axial disease.
Comment
This recommendation was substantially changed - based on extensive discussions related to 
the literature review, as the vast majority of new studies published in the past 5 years were 
related to anti-TNF therapy. The statement is of course strongly related to the recent update 
of the ASAS recommendations on anti-TNF therapy in AS. 15
Since the last systematic review 11 there were many new studies. In addition to infliximab 
and etanercept, adalimumab 59 and golimumab 60 have also been approved. There are 
substantial data on patient-reported outcomes 61. There is evidence that patients with 
advanced disease 62 also have some benefit, but patients with early 63 and very early 64 
disease seem to have even more benefit. The highest remission rate reported is up to 50% 
after 16 weeks 64 in patients with inflammatory back pain 65 of less than 3 years (mean 15 
months) and sacroiliitis on MRI but not on radiographs. Of note, the majority of the patients 
in these trials did not fulfill the modified New York criteria for AS.
The retention rate of patients with AS after 1 year of anti-TNF therapy was better than for 
patients with RA in a large registry 66. There is evidence that the efficacy of anti-TNF therapy 
lasts over several years 67–69.
Spinal inflammation, as assessed by MRI, improves substantially after anti-TNF therapy 70. 
Radiographic progression (mainly new bone formation) does not seem to be inhibited 
by anti-TNF therapy 71, but there is also no evidence that syndesmophyte formation is 
accelerated.
The major new aspect of the updated recommendations is the differential effect of anti-TNF 
therapy when available drugs have similar efficacy on musculoskeletal manifestations but 
differential efficacy in clinically symptomatic IBD 72. Here the monoclonal antibodies work 
better than the fusion protein (infliximab is approved for both Crohn’s disease (CD) and 
ulcerative colitis, adalimumab for CD, no data yet available for golimumab). The differences 
regarding acute anterior uveitis are less evident 73. The presence or absence of psoriasis 
does not seem to make a difference as regards efficacy on musculoskeletal symptoms 74. 
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There is evidence that anti-TNF agents improve the signs and symptoms of peripheral 
arthritis and enthesitis 75, 76.
Furthermore, a recommendation for switching is included for the first time since several 
studies have suggested high success rates 77–79. It was discussed that antibody formation 80, 81 
may be involved in the phenomenon of loss of response (secondary nonresponse) and that 
such patients seem to have an even higher potential for response to a second TNF blocker 
than primary non-responders.
The statement that there is no evidence for the efficacy of other biological therapies in AS is 
also new. It is based on two studies evaluating rituximab and abatacept, which both failed to 
show convincing response rates in patients who had failed TNF blockers 82, 83. The response 
rate to rituximab in TNF-naïve AS patients deserves further study 82.
Some experts stressed the importance of exercise and regular physiotherapy in patients 
with AS under treatment with TNF blockers, but the literature on this topic is still scarce 84.
Strength of recommendation: 9.4±0.2.
Surgery
ⱷ Total hip arthroplasty should be considered in patients with refractory pain or disability 
and radiographic evidence of structural damage, independent of age.
ⱷ Spinal corrective osteotomy may be considered in patients with severe disabling 
deformity.
ⱷ In patients with AS and an acute vertebral fracture a spinal surgeon should be consulted.
For comparison, the old recommendation was: total hip arthroplasty should be considered 
in patients with refractory pain or disability and radiographic evidence of structural 
damage, independent of age. Spinal surgery, such as corrective osteotomy and stabilisation 
procedures, may be of value in selected patients.
Comment
This bullet point was modified based on discussions with the two orthopaedic surgeons in 
the expert committee. The significance of hip involvement has been confirmed by a recent 
multinational study 85, 86. A statement related to that problem therefore remains important, 
and the first sentence on total hip arthroplasty remains unchanged. Cement is only rarely 
used in young patients 87, and heterotopic ossification does not seem to be a problem in 
patients with AS 88. The recommendation on spinal surgery was intensively discussed and a 
more detailed statement agreed on.
The second statement addresses an elective surgical procedure in the spine, which was 
shown to be beneficial for many patients with advanced AS and hyperkyphosis who have 
lost their horizontal vision ability. This technically challenging operation, which is only 
performed in experienced centres and is not available in some countries, leads to at least 
the partial correction of kyphosis. Triangular pieces of bone are removed from selected 
vertebral bodies (pedicle subtraction osteotomy) before the spine is re-stabilised by metallic 
bars and screws.
The third statement addresses spinal fractures that may lead to instability of the spine. 
These are often but not always rather acute clinical situations, which may or may not be 
associated with neurological symptoms 89–94. In addition, as mechanical stress may prevent 
discovertebral spinal lesions from fusion and lead to the development of pseudarthrosis, 
a spinal surgeon should at least be consulted in patients with symptomatic discovertebral 
lesions 95.
This has been regarded as so important that an extra bullet point, no 11, was added. Strength 
of recommendation: 9.2±0.3.
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The overarching principles of the management of patients with AS are: 
 Ҩ AS is a potentially severe disease with diverse manifestations, usually requiring multidisciplinary  
 treatment coordinated by the rheumatologist. 
 Ҩ The primary goal of treating the patient with AS is to maximise long term health-related quality  
 of life through control of symptoms and inflammation, prevention of progressive structural   
 damage, preservation/normalisation of function and social participation.
 Ҩ Treatment of AS should aim at the best care and must be based on a shared decision between   
 the patient and the rheumatologist. 
 Ҩ The optimal management of patients with AS requires a combination of non-pharmacological   
 and pharmacological treatment modalities.  
1. General treatment 
The treatment of patients with AS should be tailored according to: 
 Ҩ The current manifestations of the disease (axial, peripheral, entheseal, extra-articular symptoms  
 and signs). 
 Ҩ The level of current symptoms, clinical findings, and prognostic indicators. 
 Ҩ The general clinical status (age, gender, comorbidity, concomitant medications, psychosocial   
 factors).  
2. Disease monitoring 
The disease monitoring of patients with AS should include: 
 Ҩ Patient history (e.g. questionnaires) 
 Ҩ Clinical parameters 
 Ҩ Laboratory tests 
 Ҩ Imaging 
 ⱷ All according to the clinical presentation as well as the ASAS core set 
The frequency of monitoring should be decided on an individual basis depending on: 
 Ҩ Course of symptoms 
 Ҩ Severity 
 Ҩ Treatment  
 
3. Non-pharmacological treatment 
 Ҩ The cornerstone of non-pharmacological treatment of patients with AS is patient education and  
 regular exercise. 
 Ҩ Home exercises are effective. Physical therapy with supervised exercises, land or water based,   
 individually or in a group, should be preferred as these are more effective than home exercises. 
 Ҩ Patient associations and self-help groups may be useful.  
 
4. Extra-articular manifestations and comorbidities 
 Ҩ The frequently observed extra-articular manifestations, for example, psoriasis, uveitis and IBD,  
 should be managed in collaboration with the respective specialists. 
 Ҩ Rheumatologists should be aware of the increased risk of cardiovascular disease and   
 osteoporosis.  
 
5. Non-steroidal anti-inflammatory drugs 
 Ҩ NSAID, including Coxibs, are recommended as first-line drug treatment for AS patients with pain  
 and stiffness. 
 Ҩ Continuous treatment with NSAID is preferred for patients with persistently active, symptomatic  
 disease. 
 Ҩ Cardiovascular, gastrointestinal and renal risks should be taken into account when prescribing   
 NSAID. 
 
Box 1: First update of the ASAS/EULAR recommendations for the management of AS.
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6. Analgesics 
 Ҩ Analgesics, such as paracetamol and opioid (like) drugs, might be considered for residual pain   




 Ҩ Corticosteroid injections directed to the local site of musculoskeletal inflammation may be   
 considered. 
 Ҩ The use of systemic glucocorticoids for axial disease is not supported by evidence. 
 
8. Disease-modifying antirheumatic drugs 
 Ҩ There is no evidence for the efficacy of DMARD, including sulfasalazine and methotrexate, for  
 the treatment of axial disease. 
 Ҩ Sulfasalazine may be considered in patients with peripheral arthritis.  
 
9. Anti-TNF therapy 
 Ҩ Anti-TNF therapy should be given to patients with persistently high disease activity despite   
 conventional treatments according to the ASAS recommendations. 
 Ҩ There is no evidence to support the obligatory use of DMARD before or concomitant with anti-  
 TNF therapy in patients with axial disease. 
 Ҩ There is no evidence to support a difference in efficacy of the various TNF inhibitors on the   
 axial and articular/entheseal disease manifestations; but in the presence of IBD a difference in   
 gastrointestinal efficacy needs to be taken into account. 
 Ҩ Switching to a second TNF blocker might be beneficial especially in patients with loss of   
 response. 
 Ҩ There is no evidence to support the use of biological agents other than TNF inhibitors in AS. 
 
10. Surgery 
 Ҩ Total hip arthroplasty should be considered in patients with refractory pain or disability and   
 radiographic evidence of structural damage, independent of age. 
 Ҩ Spinal corrective osteotomy may be considered in patients with severe disabling deformity. 
 Ҩ In patients with AS and an acute vertebral fracture a spinal surgeon should be consulted.  
 
11. Changes in the disease course 
 Ҩ If a significant change in the course of the disease occurs, other causes than inflammation, such  
 as a spinal fracture, should be considered and appropriate evaluation, including imaging, should  
 be performed.
Changes in the disease course
ⱷ If a significant change in the course of the disease occurs, causes other than inflammation, 
such as a spinal fracture, should be considered and appropriate evaluation, including 
imaging, should be performed.
Comment
This is a new recommendation. The major point is that changes in the course of the disease 
should be carefully evaluated and MRI performed - especially in situations in which the 
nature of back pain changes. An experienced spinal surgeon may need to be consulted. It 
seems important to stress that not all AS patients with spinal fractures have neurological 
symptoms (and not all need to be operated on).
There are other important differential diagnoses such as spinal infections.
Strength of recommendation: 9.0±0.3.
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Discussion
The ASAS/EULAR recommendations were successfully updated. The introduction of 
overarching principles led to some changes, e.g. one bullet point and one sentence was 
moved to this section. There are now 11 bullet points including two new points: one for 
extra-articular manifestations and one for changes in the clinical course of AS.
A patient version of the recommendations will be developed. We encourage translation of 
these recommendations into various languages in a collaboration between rheumatologists 
and patients. After presentation at the EULAR 2010 meeting in Rome and publication in the 
EULAR journal, individual countries can now take on dissemination.
The collaboration between ASAS and EULAR has again been very successful and should be 
continued for the next update that may be renamed according to the new classification 
criteria for axial spondyloarthritis. There will be a need for further discussion as to 
whether the new criteria for peripheral spondyloarthritis 96 should give rise to separate 
recommendations for these patients.
Although it was decided that these recommendations concentrate on AS, the authors are 
well aware that the treatment of patients with non-radiographic axial spondyloarthritis is 
also a very important topic. There are now data of clinical trials available that address this 
question in a controlled manner 63, 64. They provide evidence that anti-TNF agents work in 
early disease in at least the same but probably in an even superior way. 
The original publication has already set a standard for the management of patients with 
AS. As we feel that this update has even improved the original set we are confident that 
these recommendations will be useful for patients and healthcare workers, including 
rheumatologists and other physicians treating patients with AS, as well as physiotherapists.
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Although our understanding of the expressions and mechanisms of SpA is far from complete, 
major advances have been made over the past decades. The need for earlier diagnosis was 
addressed by including MRI in the diagnostic process as well as by putting more emphasis on 
HLA-B27 in the diagnostic process. The development of new classification criteria, with the 
major objective to ensure the identification of non-radiographic types of SpA, is a further 
aid in classifying patients in early phases of the disease. The recently by ASAS proposed 
classification criteria sets for SpA included MRI for the first time 1, 2. With the help of MRI, 
patients can be classified earlier in the disease stage since MRI can provide evidence of 
inflammatory sacroiliitis. Furthermore, in 2006 ASAS/EULAR published management 
recommendations to provide guidance for monitoring and treatment of AS patients. 
However, the performance of the ASAS classification criteria, including (the role of) imaging 
(both MRI and radiographs), required thorough evaluation. Moreover, as the number of 
clinical trials and publications on AS therapy has steadily increased over the first decade of 
the millennium, the ASAS/EULAR recommendations for the management of AS needed an 
update. The performed studies described in this thesis have contributed to the continuously 
developing field of SpA. The main results and conclusions are summarized and discussed in 
this chapter. 
Part I: Early recognition and classification criteria of spondyloarthritis
The performance of the various developed classification criteria for SpA (mNY, Amor, ESSG, 
ASAS axial SpA, ASAS peripheral SpA, and the CASPAR criteria (for PsA only)) 1-6 was tested 
in a group of patients with predominantly axial complaints included in the SPondyloArthritis 
Caught Early (SPACE)-cohort (chapter 2) and in a group of patients with predominantly 
peripheral complaints (chapter 4) included in the Leiden Early Arthritis Clinic (EAC)-
cohort 7. In the EAC-cohort, patients diagnosed with PsA and peripheral SpA by the treating 
rheumatologist, and a control group matched on age, gender and symptom duration were 
selected and studied. In this group of PsA and peripheral SpA patients, the ASAS peripheral 
SpA criteria and CASPAR criteria had substantial overlap by classifying the same patients. 
In the peripheral SpA subgroup, the ASAS peripheral SpA criteria outperformed all other 
classification criteria, and in the PsA subgroup, the CASPAR criteria outperformed all other 
criteria. The diagnosis by the rheumatologist served as external standard. However, this 
setting is neither representative for all peripheral SpA patients nor for the whole concept of 
SpA since the EAC-cohort does not include patients with dactylitis or enthesitis or patients 
with predominantly axial complaints. This is reflected in the modest sensitivities of all 
classification criteria found in this analysis. Thus, in daily practice rheumatologists include 
a wider group of patients in the SpA disease spectrum than defined in the classification 
criteria, thereby underscoring the fact that classification criteria are not diagnostic criteria. 
Yet, it is very reassuring that the specificities of all criteria sets are in accordance with the 
reported specificities in the original validation cohorts 1-6. This is especially of importance for 
the ASAS peripheral SpA criteria as these criteria are quite new and there was a fear that they 
might be insufficiently specific. Moreover, the results of chapter 4 were recently confirmed 
in the ESPERANZA-cohort, which is developed in Spain to facilitate early diagnoses of SpA by 
creating early SpA units with standard operating procedures, and to improve the knowledge 
and practical skills of GPs and specialists in the field of SpA. Patients with complaints (IBP 
or asymmetrical arthritis (preferably in the lower limbs) or spinal/joint pain in combination 
with one other SpA-feature) were included. Thereby, a slightly different population is 
created than the population in the EAC-cohort and the ASAS validation cohort, but the 
sensitivity and specificity of the ASAS peripheral SpA criteria were very similar (sensitivity of 
56%, specificity of 85%) 8. 
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We also tested the existing classification criteria in patients with predominantly axial 
complaints included in the SPACE-cohort. The SPACE-cohort is an ongoing prospective 
longitudinal observational cohort including patients with back pain ≥3 months but ≤2 years 
with the onset of symptoms <45 years, which is extensively described in chapter 2. At 
baseline, all patients in the SPACE-cohort undergo a diagnostic work-up including imaging 
(MRI and radiographs of the SI-joints and spine), laboratory tests (including HLA-B27 testing) 
and physical examination and history taking. In chapter 2 we showed that at baseline almost 
60% of the patients in the SPACE-cohort fulfilled any classification criteria set (mNY, Amor, 
ESSG, ASAS axial SpA criteria) 2-5; almost 40% fulfilled the ASAS axial SpA criteria 2. The ASAS 
axial SpA criteria outperformed all other sets (including modifications of Amor and ESSG by 
adding MRI) with respect to sensitivity, specificity, positive and negative likelihood ratio (LR+ 
and LR-). Again, the diagnosis by the rheumatologist served as external standard. As the 
percentage of patients with axSpA according to the ASAS axSpA criteria in the SPACE-cohort 
appears to be high, it could be argued that our observed prevalence of axSpA is influenced 
by referral bias; e.g. that due to increased awareness among referring physicians about the 
SPACE cohort over time, patients from areas other than the Leiden area are referred to the 
LUMC or that only patients with a high suspicion of axSpA are referred.
However, the percentage of axSpA among all referred patients over the years was similar, 
and the percentage of referrals from outside the Leiden area was also similar over time. 
Moreover, 33 of the 157 patients (21.0%) included at baseline had none or only one less 
specific SpA feature. This indicates, but does not prove, that there is no referral bias, thereby 
suggesting that the observed prevalence of axSpA could be generalized to primary care 
(chapter 2). Moreover, very similar results regarding the performance of the ASAS axial 
SpA criteria are recently found in another study, also including patients with back pain ≥3 
months, onset <45 years, conducted by Moltó et al. among rheumatologists working in 
office-based and hospital-based practices in France 9. 
As there are indications that not all rheumatologists as well as registration authorities (U.S. 
Food and Drug Administration (FDA)) 10, 11 do appreciate the validity of the clinical arm of 
the ASAS axial SpA criteria as similar to the imaging arm, we compared patients fulfilling the 
clinical arm to patients fulfilling the imaging arm (both patients with radiographic sacroiliitis 
and patients with inflammatory sacroiliitis on MRI) in chapter 2. Noteworthy, patients in 
both arms were remarkably similar with respect to the presence of most SpA-features and 
level of disease activity (BASDAI and ASDAS). Similar comparisons were made in the DESIR-
cohort and in the ABILITY-1 trial. The latter is a randomized controlled trial performed in 
patients with nr-axSpA (fulfilling the ASAS axSpA criteria but not fulfilling the mNY criteria) 
to evaluate the efficacy and safety of adalimumab in those patients 12. The results of these 
studies were comparable to the results we found in the SPACE-cohort that patients fulfilling 
the clinical arm and patients fulfilling the imaging arm are very similar 12, 13. Nevertheless, 
the level of confidence about the diagnosis indicated by the rheumatologist in the SPACE-
cohort is lower in patients fulfilling the clinical arm than in patients fulfilling the imaging 
arm (chapter 2). This seems to indicate that rheumatologists heavily base their diagnosis on 
positive imaging. This concept is confirmed in the study by Moltó et al. mentioned above, 
pointing out that (radiographic) sacroiliitis has the highest LR+ on the diagnosis of SpA 
according to rheumatologists 9. 
For further analyses in the SPACE-cohort, patients are classified as no-SpA or axial SpA 
based on the ASAS axSpA criteria (the best performing classification criteria) as classification 
criteria are by definition exactly defined and therefore reproducible while the diagnosis 
of the rheumatologist is not. Of the axSpA patients, approximately 80% have IBP, and the 
other way around, 56.7% of the patients without SpA have IBP, thereby showing that - at 
least in the SPACE-cohort - IBP is not a very useful feature to discriminate between axSpA 
patients and patients without SpA (chapter 2). These results are in line with results reported 
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before 14, 15. Nevertheless, IBP history taking is cheap and can be useful in the diagnostic 
process in combination with other SpA-features (the more clinical items suggestive of SpA, 
the more likely the diagnosis) 16. Moreover, some items of IBP, like age at onset ≤35 years, 
are more important than other items by having a higher calculated LR+ on the diagnosis 
of axial SpA 17. However, the interpretation of (items) of IBP differ from person to person, 
reflected in low agreement on whether a patient is suffering from IBP or not 14, 18.
Nonetheless, in the previously developed ESSG criteria but also in the diagnostic Berlin 
algorithm, IBP was used as (one of the) entry criteria 4, 19. As the Berlin algorithm is the 
only available diagnostic tool, this challenged us to propose two modifications of the 
Berlin algorithm, presented in chapter 3. In modification 1, the first step of the algorithm – 
fulfillment of the ASAS IBP criteria – was slightly changed. Instead of ≥4 out of the 5 criteria, 
patients need to fulfill ≥3 out 5 criteria. Modification 2 slightly changed the structure and 
the set of SpA-features by deleting IBP as obligatory entry criterion and adding it as a SpA-
feature. This resulted in three entry groups based on the requirement of ≥4, 2-3 and 0-1 
SpA-features. The performance of the (modified) algorithms, was tested against fulfillment 
of the ASAS axSpA criteria, the disease probability based on the likelihood ratio product 19, 20 
and the diagnosis by the rheumatologist as external standard due to the lack of a true 
gold standard. Modification 1 resulted in a major increase in sensitivity, at the cost of little 
specificity. With modification 2, the number of missed axSpA diagnoses by the algorithm 
even further decreased. Additional adjustments that might improve the diagnostic 
algorithm even more could be contemplated; rheumatologists could consider performing 
an MRI in HLA-B27 negative patients who do have 2-3 other SpA-features, especially male 
patients 21, 22. As it is now stated in the algorithm, those patients leave the algorithm (‘consider 
other diagnosis’), however, if the MRI is positive they would fulfill the ASAS axSpA criteria. 
Moreover, as this algorithm is developed to guide rheumatologists in the diagnostic process, 
it will often be applied in patients with relatively short symptom duration. The usefulness 
of performing conventional radiographs of the SI-joints as a first step could therefore be 
challenged, reflected by the high number of negative radiographs in both the SPACE-cohort 
and the ASAS-cohort. Nevertheless, modification 2 of the algorithm might be a useful tool 
for rheumatologists in daily practice. The Dutch Society for Rheumatology (Nederlandse 
Vereniging voor Reumatologie (NVR)) recently published new guidelines for the diagnosis 
and treatment of axSpA in which the modified algorithm is included 23. 
Although the tools available to rheumatologists for classification and diagnostic purposes 
improved a lot over the last years, one of the unmet needs is the referral of the most 
appropriate patients by physicians and health professionals to the rheumatologist. 
Referring physicians have only limited knowledge of manifestations belonging to SpA 24, 
illustrated by the poor agreement regarding the evaluation of IBP by referring physicians 
and rheumatologists (κ=0.04 to κ=0.20) 14, 18. Therefore, it is a challenge for referring 
physicians to recognize patients with a suspicion of having SpA who should be referred to a 
rheumatologist. Several (complex) referral strategies have been developed in order to early 
identify patients with possible SpA. All strategies performed well in research settings with 
instructed GPs, yielding 24% to 45% SpA patients 14, 25-28. However, the limited knowledge of 
referring physicians poses a challenge on successful implementation of referral strategies 
in the common daily primary care setting 24. Hence, it might be useful to consider an easy 
referral structure instead of complex strategies, by just referring patients with back pain 
≥3 months with the onset of symptoms <45 years, like the eligibility criteria of the ASAS 
axSpA criteria. At least in the SPACE-cohort - with the additional restriction of a maximum 
symptom duration of ≤2 years - and in the study by Moltó at al. these criteria yield high 
percentages of SpA (41.4% and 35.1%, respectively) (chapter 2) 9. However, it remains to be 
seen whether this would be successful in other centers or in countries with other healthcare 
systems, and therefore more research is needed. 
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Another important related question is which patients are erroneously not referred to the 
rheumatologist by applying these referral strategies 14,  25-28. We tried to answer this question 
by testing the performance of various referral strategies in the SPACE-cohort, even though 
the SPACE-cohort might not be ideal to sort out this question as patients already had been 
referred 29, 30. Remarkably, almost all non-referred patients that fulfilled the ASAS axSpA 
criteria had (radiographic) sacroiliitis 29, 30. 
Although major improvements have been achieved in classifying and diagnosing patients, 
more research and education is needed, starting with warranted improvements in referring 
the right patients to the rheumatologist. This could be achieved by (further) educating 
referring physicians about SpA-features. Furthermore, both referring physicians and 
rheumatologists could be trained in acknowledging that axSpA should not be ruled out 
if IBP is absent. If performance of the current strategies appears to be insufficient - even 
after educating referring physicians - eventually the development of new referral strategies 
could be considered. These strategies offer the possibility of referring patients with positive 
imaging without the necessity of performing imaging in daily practice (a proxy for positive 
imaging is needed), since with the current strategies precisely imaging positive patients are 
often not referred. 
Moreover, only diagnostic tool for rheumatologists, the ASAS modified Berlin algorithm, 
is not validated in other cohorts than the two validation cohorts yet. In addition to this 
necessary validation, other improvements of the algorithm could be considered. For 
example, it could be investigated whether it is useful to make a distinction in the group of 
HLA-B27 negative patients with 0-1 SpA-features to decide on whether or not performing 
MRI. Patients with 1 feature could fulfill the ASAS axSpA criteria if imaging is positive while 
the patients without any SpA-features will never fulfill the ASAS axSpA criteria. Moreover, 
performing conventional radiographs of the SI-joints after medical history taking and 
physical examination - instead of before - could be considered. 
Moreover, long-term follow-up studies are required in order to study outcomes in patients 
fulfilling the clinical arm and patients fulfilling the imaging arm of the ASAS axSpA criteria, 
and to compare the long-term outcomes of patients in both groups. This will help in 
understanding the disease and in concluding on whether it was the right decision to include 
the clinical arm in the ASAS axSpA criteria. The clinical arm was included as it gave the best 
balanced sensitivity and specificity compared to including the imaging arm only 2. Moreover, 
more knowledge will assist in considering potential adjustments of the ASAS axSpA criteria 
like weighting the various SpA-features (as in the ASAS modified Berlin algorithm) since 
some SpA-features, such as a ‘positive family history for SpA’ and ‘HLA-B27 positivity’ are 
more strongly correlated than others.
Part II: The role of imaging in the early diagnosis of spondyloarthritis
MRI has proven its usefulness in diagnosing and classifying SpA patients over the last years. 
Nevertheless, the newly acquired prominent role of MRI as well as the role of conventional 
radiographs are currently under debate. The discussion regarding the role of radiographic 
sacroiliitis has its origin in the knowledge that it is challenging to recognize radiographic 
sacroiliitis. The undulating articular surface and the complex anatomy of the SI-joints by a 
2-dimensional imaging technique can result in misinterpretations 31, 32.  Recently, the poor 
reliability of evaluating conventional radiographs was emphasized in post-hoc analyses on 
the data of the ABILITY-1 and RAPID-axSpA pivotal clinical trials for the registration of TNF-
blockers in patients with nr-axSpA 12,33-35. The analysis in ABILITY-I pointed out that 37% of 
the patients classified as nr-axSpA by local readers were reclassified as AS by fulfilling the 
mNY criteria according to central readers 12, 34. In the RAPID-axSpA trial a similar analysis 
resulted in reclassification of 36% of the patients; 26% of the nr-axSpA patients according 
to local readers were reclassified as fulfilling the mNY criteria according to central readers, 
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and 10% of the mNY fulfilling patients by local readers were reclassified as nr-axSpA based 
on the central reading 33, 35.
We performed similar analyses in the DESIR-cohort (chapter 5 and chapter 6), in which 
imaging evaluations by both local readers and central readers are available. In daily practice 
the diagnosis of AS is based on the judgment of local radiologists and/or rheumatologists, 
while in cohorts and clinical trials the radiographs are usually judged by one or more 
trained central readers. The comparison described in chapter 5 on the presence/absence of 
radiographic sacroiliitis by local readers versus central readers revealed that the agreement 
was only moderate (κ=0.55). The local readers primarily overrated sacroiliitis in comparison 
with central readers as external standard, resulting in an unacceptably high percentage 
(41.5%) of false-positive diagnoses of AS in daily practice. Only a small minority of patients 
with a classification of AS according to central readers is not recognized in daily clinical 
practice (7.5%). Even in patients with bilateral involvement and patients with at least one 
fused SI-joint major discrepancies are seen between local readers and central readers. 
Moreover, interreader agreement between the two central readers was also only moderate 
(κ=0.54), indicating that evaluating SI-joints on radiographs is very difficult and that training 
does not improve the agreement substantially. But where misclassification by local readers 
almost exclusively consisted of overclassification of positive cases, the disagreement 
between the two central readers was more balanced in two directions. 
Thus far, there is no data on this aspect for sacroiliitis on MRI, except for the data of the 
DESIR-cohort presented in chapter 6. In contrast to the moderate agreement regarding 
radiographic sacroiliitis, agreement regarding sacroiliitis on MRI between the two central 
readers as well as between the local readers and the central readers is substantial (κ=0.73 
and κ=0.70, respectively). Potentially 163/582 patients (28.0%) in whom the MRI and/or 
radiograph reading was different between the local readers and central readers, could have 
been classified differently according to the ASAS axSpA criteria. Yet, only 46/582 patients 
(7.9%) were classified differently. These results point out the robustness of the ASAS axSpA 
classification criteria to differences in reading of the images. This is mainly due to the clinical 
arm; patients fulfilling the clinical arm will always fulfil the clinical arm, regardless of the 
imaging results, as HLA-B27 status will not change. 
Given the only moderate reliability in conventional radiograph reading and the substantial 
reliability in MRI reading, some experts in the field argue that the option of leaving out 
conventional radiographs completely and conducting MRI only should be considered. As the 
current definition of a positive MRI is based on the presence of inflammatory lesions only, 
this discussion is becoming even more interesting if structural lesions (erosions, ankylosis 
and sclerosis) on MRI are taken into account as well. To be able to evaluate the potential 
additive value of adding structural lesions to the definition of a positive MRI, it is first 
important to know whether structural lesions can be detected reliably on MRI. Therefore, the 
performance of MRI in the detection of structural lesions in the SI-joints was tested against 
the conventional radiographs as gold standard. Agreement varied from κ=0.11 to κ=0.15 
for erosions, from κ=0.16 to κ=0.46 for sclerosis, and from κ=0.08 to κ=0.85 for ankylosis 
(partial or total) in the GESPIC-cohort and SPACE-cohort 36, 37. Overall, agreement is poor; 
more erosions and less sclerotic lesions are detected on MRI compared to conventional 
radiographs 36, 37. These comparisons should be extended and repeated with an alternative 
external standard such as CT. 
The incorporation of various combinations of structural lesions and fatty depositions on the 
definition of a positive MRI is presently being investigated in both the SPACE-cohort and the 
DESIR-cohort, but should be investigated and validated in other cohorts as well, especially in 
patients with longer symptom duration. Before we can conclude on the role of conventional 
radiographs and structural lesions on MRI, we will have to wait for the results of these 
studies. In the meantime, we investigated in the DESIR-cohort the possible consequences 
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of this proposal of leaving out conventional radiographs and using the current definition 
of a positive MRI based on inflammatory lesions only (chapter 6). Taking into account 
the complete ASAS axSpA criteria including the clinical arm, this would result in only 11 
to 14 missed patients (1.9-2.4%using either the local reading or the central reading) as 
those patients only fulfill the imaging arm by having radiographic sacroiliitis only (and not 
inflammatory sacroiliitis on MRI). However, it should be stated immediately that this is in an 
early cohort and this may be different in patients with more advanced disease. 
MRI is also used to quantify inflammation in the SI-joints and spine, for example by using 
the SPARCC-score. We tested the metric properties of the SPARCC-score of the sacroiliac 
joints in the SPACE-cohort in chapter 7. We found out that a SPARCC-score of 2 as cut-
off value is the best equivalent of the ASAS definition of a positive MRI. This cut-off value 
can be used (in clinical trials) to create a dichotomous MRI variable of potential prognostic 
interest. Additionally, we calculated smallest detectable changes (SDCs), which in this study 
were close enough to the proposed minimally important change (MIC) of 2.5 SPARCC-units 
to add credibility to a cut-off level of 2.5 units representing a true change rather than only 
measurement error. A large proportion of the SPARCC-score changes seen in the patients 
in the SPACE-cohort could be considered as noise as these changes are smaller than 
the calculated SDCs (62.9% and 45% (3 months, campaign 1 and 2) and 39.1% (1 year in 
campaign 2)). Surprisingly, true (>SDC) changes in SPARCC-score over time (both increases 
and decreases) were frequently observed while patients are on stable treatment. This 
observation strongly suggests that MRI-activity fluctuates over time.
Other intriguing matter is the hypothesis of inflammation being the inciting cause of 
structural lesions including ossification. Prospective long-term follow-up data is necessary 
to study the possible relationship between inflammation and structural lesions in more 
detail 38, 39, in both the SI-joints and spine. To get more insight in why some patients do 
develop spinal lesions and others do not, information is needed on the prevalence of 
spinal lesions (inflammatory and structural), especially in patients without (radiographic) 
sacroiliitis. Several studies already addressed this question, but the results are inconclusive 
as the prevalence of spinal lesions varies with age and disease duration 40-45. In addition, it 
is questioned whether the results of MRI of the spine should be taken into account in the 
diagnostic and/or classification process, which could be of particular interest in patients 
without (radiographic) sacroiliitis. To address these research questions as well as other 
questions, long-term follow-up data is currently being collected in, among others, the 
SPACE-cohort and DESIR-cohort. 
Part III: Treatment of spondyloarthritis and ankylosing spondylitis
ASAS together with EULAR published recommendations for the management of AS in 
2006. As the number of clinical trials and publications on AS therapy is increasing, ASAS 
developed an update of the first recommendations for the management of AS. These 
recommendations are described in chapter 11, based on systematic literature reviews 
(chapter 9 and chapter 10) as recommended by the EULAR standard operating procedures 
for management recommendations 46. In the title, ASAS has restricted the recommendations 
to AS since the evidence from trials in axSpA patients is currently limited and this was 
an update of the previous recommendations on AS (and not axSpA). Nevertheless, the 
project group unanimously agreed that these recommendations could equally be applied 
to patients with axSpA. First because AS is part of the total group of axSpA, and second 
because all available data indicated that efficacy was at least as good in patients with nr-
axSpA as in patients with AS. And indeed, this has been confirmed in all trials that have 
been published since. As described in chapter 11, ASAS recommend tailored treatment, 
taking into account all aspects of the disease including peripheral and extra-articular 
manifestations, level of disease activity, gender, and comorbidities etc. Disease should be 
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monitored regularly, according to the clinical presentation as well as the ASAS core set for 
assessment in clinical practice 47. Treatment should consist of non-pharmacological and 
pharmacological treatment. Non-pharmacological treatment is the cornerstone, comprising 
patient education and regular exercise. The review on non-pharmacological treatment and 
non-biological drugs described in chapter 9 pointed out that home exercises have positive 
effects on physical function (BASFI), patient reported disease activity (BASDAI), pain and 
spinal mobility, but that physical therapy with supervised exercises, either land or water 
based, either individually or in a group, are more effective than home exercises. This is 
adopted in the ASAS recommendations (chapter 11). 
NSAIDs, including coxibs, are recommended as first line drug to relief pain and stiffness 
for both short-term and prolonged periods of treatment (chapter 9 and chapter 11), and 
these should be taken in an anti-inflammatory dose 48. ASAS recommends patients with 
persistently active, symptomatic disease to use NSAIDs continuously (chapter 11) as 
continuous therapy may be superior to on-demand therapy on the prevention of new 
bone formation 49. After the update of the ASAS recommendations was published, a post-
hoc analysis was conducted in this randomized trial comparing continuous to on-demand 
NSAID treatment, revealing that solely patients with elevated acute phase reactants will 
benefit from continuous treatment with NSAIDs 50. Additionally, a study was recently 
performed in the German Spondyloarthritis Inception Cohort (GESPIC), investigating the 
influence of NSAIDs intake on radiographic spinal progression over 2 years in both AS and 
nr-axSpA patients. The results showed that a high NSAIDs intake is associated with retarded 
radiographic spinal progression in AS patients while this effect was less evident in nr-axSpA 
patients, probably due to a low grade of new bone formation in the spine at this stage 51.
Analgesics might be considered for residual pain after previously recommended treatments 
have failed, are contraindicated and/or poorly tolerated. Glucocorticoid injections directed 
to the local site of musculoskeletal inflammation may be considered, but systemic 
glucocorticoid use for axial disease is not supported by evidence. There is no evidence for 
the efficacy of DMARDs, including sulfasalazine and methotrexate, for the treatment of 
axial disease, however, sulfasalazine may be considered in patients with peripheral disease 
(chapter 11). 
The results of the systematic literature review on biologics are described in chapter 10. 
TNF-α inhibitors  should be given to patients with persistently high disease activity despite 
conventional treatments according to the ASAS recommendations 52. Overall, all TNF-α 
inhibitors available for AS have proved to be effective on BASDAI, BASFI and BASMI, both in 
AS patients with established disease as well as in nr-axSpA patients, especially in patients 
with elevated CRP and/or inflammation on MRI. In the presence of IBD, a difference in 
gastrointestinal efficacy needs to be taken into account. There is no evidence to support the 
obligatory use of DMARDs before or concomitant with TNF-α inhibitors in patients with axial 
disease. Switching to a second TNF-α inhibitors might be beneficial, especially in patients 
that lost response (chapter 10 and chapter 11). 
Moreover, ASAS recommend considering total hip arthroplasty in case of refractory pain or 
disability and radiographic evidence of structural damage, independent of age. In case of 
severe disabling deformity, spinal corrective osteotomy may be considered (chapter 9 and 
chapter 11).
Despite the fact that there is conclusive evidence that TNF-α inhibitors can dramatically 
improve disease activity (including inflammation on MRI) and functional capacity, its use is 
associated with high costs and is not suitable for all patients in terms of safety and increased 
risk of infections. Therefore, ASAS developed recommendations for the use of TNF-α inhibitors 
in 2003 53. Those recommendations have been updated twice already 52, 54. Moreover, many 
countries developed national guidelines for the use of TNF-α inhibitors, either or not based on 
the ASAS recommendations. In chapter 8, the national guidelines of 23 countries worldwide 
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were compared, revealing that despite some differences, there is general consensus about 
the use of TNF-α inhibitors in AS. In addition, there is evidence that patients with nr-axSpA 
show good responses to TNF-α inhibitors, although the number of trials is limited and the 
sample sizes in those trials are relatively small 12, 33, 42, 43, 55. Furthermore, only patients with 
high disease activity and/or elevated acute phase reactants and/or a positive MRI were 
included in those trials 11, 31, 40, 41, 51. High disease activity as measured by the ASDAS, elevated 
acute phase reactants and a positive MRI are all identified as predictors for good response 
to treatment with TNF-α inhibitors 56. Recently, adalimumab and certolizumab are approved 
by the European Commission for the treatment of adults with severe nr-axSpA, who have 
had an inadequate response to, or are intolerant to NSAIDs, but only in those nr-axSpA 
patients that show objective signs of inflammation by elevated CRP and/or MRI 57, 58. Still, 
in many countries, patients with active, severe axSpA refractory to NSAIDs are only eligible 
for treatment with TNF-α inhibitors if imaging shows signs of sacroiliitis. However, the only 
difference between nr-axSpA  and axSpA/AS is the presence of (radiographic) sacroilitis, 
which is proven to be challenging to reliably evaluate (chapter 5 and chapter 6) 32. Therefore, 
more research is warranted on the (long-term) effects of TNF-α inhibitors in early nr-axSpA 
patients, including patients without a positive MRI. In addition, long-term outcomes of head-
to-head comparisons of different treatments are needed, focusing on the development of 
structural lesions. For example, head-to-head comparisons of the different available TNF-α 
inhibitors could be studied, with or without concomitant use of, amongst others, NSAIDs. 
In the same manner, TNF-α inhibitors could be compared directly to other types of drugs, 
like NSAIDs and bisphosphonates 59. Moreover, the effect of various treatment strategies, 
like ASDAS-steered treatment, could be investigated. Furthermore, as there is evidence that 
a recent onset of symptoms is associated with higher response rates, and, importantly, a 
greater likelihood of a very good response, the existence of a ‘window of opportunity’ could 
be investigated 56, 60. If a ‘window of opportunity’ exists, it would be favorable in achieving 
clinical and biological benefits as well as preventing structural damage, especially in recent-
onset, active axSpA patients with MRI or laboratory signs of inflammation 60. 
In conclusion, patients with SpA can be recognized earlier with the recent developments, 
thereby offering better treatment options and thus better outcomes. However, in order to 
further improve care of SpA patients, we cannot afford to stand still, but we have to keep 
on moving, just like patients with SpA.
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Ankyloserende spondylitis (AS) of spondylitis ankylopoëtica, ook bekend als de ziekte van 
Bechterew, is een chronische reumatische ziekte, waarbij met name de gewrichten in de 
wervelkolom, en die van het bekken (de sacroiliacale (SI) gewrichten) ontstoken kunnen 
raken. Deze ontstekingen veroorzaken pijn en stijfheid en kunnen leiden tot ernstige 
verbeningen van de wervelkolom wat het dagelijks functioneren steeds meer belemmert. De 
klachten ontstaan meestal tussen het 20e en 40e levensjaar bij zowel mannen als vrouwen 
en rond de 45 jaar is meer dan 95% van de patiënten symptomatisch. Het ontstaan van AS 
wordt door meerdere factoren bepaald, waarbij genetische en omgevingsfactoren een rol 
spelen, maar hoe de ziekte precies ontstaat is nog onduidelijk. Het is in ieder geval bekend 
dat er een sterke associatie met HLA-B27 (een genetische factor) is; in 80-95% van de AS 
patiënten is HLA-B27 in het bloed gevonden. Hoe vaak AS voorkomt in een bevolkingsgroep 
hangt sterk samen met hoeveel mensen HLA-B27 in hun bloed hebben. In centraal Europa 
heeft ongeveer 0.1-0.7% AS (6-9% is positief getest voor HLA-B27 ) en ongeveer 6% van de 
Haida indianen in Noord-Amerika heeft AS (50% is HLA-B27 positief).
Naast klachten in de wervelkolom en het bekken, kunnen er ook klachten optreden in 
de andere gewrichten, zoals knieën, enkels en handen, die veroorzaakt worden door 
ontstekingen (perifere artritis, dactylitis (zogenaamde worstvormige teen of vinger) en 
enthesitis (ontsteking van de peesaanhechting aan het bot)) en er kunnen ook ontstekingen 
ontstaan buiten de gewrichten (extra-articulaire manifestaties), bijvoorbeeld in het oog 
(ontsteking van de voorste oogkamer (uveïtis anterior)), de huid (psoriasis) en de darmen, 
zoals de ziekte van Crohn en colitis ulcerosa (inflammatoire darm ziektes (IBD)). Wanneer 
informatie uit de verschillende onderzoeken bij elkaar wordt genomen, dan blijkt dat 
ongeveer 26% van de AS patiënten tenminste één keer een uveïtis anterior krijgt op enig 
moment tijdens het ziektebeloop. Ongeveer 9% van de patiënten heeft psoriasis en ongeveer 
7% heeft IBD. Het aantal patiënten dat een perifere artritis krijgt tijdens het ziektebeloop 
variëert van 14% tot 47%, voor dactylitis varieert dit van 1.9 tot 3.1%, en voor enthesitis van 
10% tot 49%.
Er bestaan geen geschikte criteria waarmee de diagnose bij een patiënt gesteld kan worden, 
maar er zijn wel classificatiecriteria voor AS die ontwikkeld zijn voor wetenschappelijk 
onderzoek: de gemodificeerde New York (mNY) criteria. Volgens de mNY criteria kan een 
patiënt geclassificeerd worden als AS wanneer de patiënt voldoet aan minstens een van de 
drie klinische criteria: 1) lage rugpijn en stijfheid >3 maanden die verbetert met bewegen 
maar niet met rust, en/of 2) beperkte beweeglijkheid van de onderrug in het sagittale 
en het frontale vlak (respectievelijk zijwaarts buigen en voor- achterwaarts buigen), en/
of 3) beperkte beweeglijkheid van de borstkas in vergelijking met normaalwaarden van 
leeftijdgenoten van hetzelfde geslacht. Daarnaast moeten duidelijke tekenen van ontsteking 
van de SI-gewricht(en) te zien zijn op röntgenfoto’s van het bekken (radiografische sacroiliitis; 
tenminste graad 2 aan beide SI-gewrichten of graad 3-4 aan één SI-gewricht). Helaas 
duurt het vaak 6-8 jaar vanaf het moment van ontstaan van klachten totdat radiografische 
sacroiliitis op röntgenfoto’s zichtbaar is. Op röntgenfoto’s kunnen veranderingen aan 
het bot waargenomen worden, waaronder extra botvorming. Men gaat er vanuit dat de 
veranderingen die te zien zijn op röntgenfoto’s eigenlijk consequenties van de ontsteking 
zijn. Echter, de ontstekingen zelf zijn op een röntgenfoto niet zichtbaar. Een röntgenfoto kan 
dus niet altijd gebruikt worden om een vroege vorm van AS op te sporen. Het onderliggende 
mechanisme, hoe ontsteking exact kan leiden tot excessieve nieuwvorming van bot, is nog 
niet volledig bekend. 
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AS is de meest uitgesproken vorm van spondyloartritis (SpA), een groep gerelateerde 
reumatische aandoeningen met gemeenschappelijke kenmerken, zoals de al eerder 
genoemde ontstekingen in de wervelkolom en het bekken. Maar niet bij elke patiënt met 
SpA staat de rugpijn en/of stijfheid van de rug op de voorgrond. Bij sommige patiënten met 
SpA voeren perifere of extra-articulaire klachten de boventoon. Daarom zijn er in de jaren 
’90 classificatiecriteria ontwikkeld, waarmee naast AS patiënten, ook patiënten met SpA 
geclassificeerd kunnen worden: de Amor en ESSG (European SpondyloArthropathy Study 
Group) criteria. Net als in de mNY criteria, zit in de Amor en ESSG criteria het criterium 
radiografische sacroiliitis. In tegenstelling tot de mNY criteria waar het hebben van 
radiografische sacroiliitis een voorwaarde is om aan de criteria te kunnen voldoen, wordt 
het in de Amor en ESSG criteria meegenomen als één van de SpA-kenmerken die mogelijk 
aanwezig kunnen zijn. Alle tot nu toe genoemde klachten en kenmerken (sacroiliitis, uveïtis 
anterior, IBD, HLA-B27 positiviteit, etc) worden tot de SpA-kenmerken gerekend. Voor het 
voldoen aan de ESSG criteria is de aanwezigheid van perifere artritis en/of inflammatoire 
rugpijn (inflammatory back pain (IBP)) vereist. IBP kenmerkt zich onder andere doordat de 
pijn voornamelijk in rust optreedt en juist afneemt door beweging. Patiënten die naast IBP 
en/of perifere artritis nog één ander SpA-kenmerk hebben kunnen volgens de ESSG criteria 
als SpA geclassificeerd worden. Bij de Amor criteria is er geen sprake van een bepaald vereist 
criterium, maar wordt het aantal aanwezige SpA-kenmerken geteld, welke allemaal één, 
twee of drie punten toegewezen hebben gekregen. Wanneer de patiënt minimaal 6 punten 
heeft, kan de patiënt worden geclassificeerd als SpA. 
Recent heeft de ASAS, een internationale groep van experts op het gebied van SpA, ook twee 
sets classificatiecriteria voor SpA ontwikkeld. Één set kan toegepast worden in patiënten 
met voornamelijk klachten buiten de rug (perifere klachten), de andere set in patiënten 
met voornamelijk klachten in de rug (axiale klachten). In de axiale SpA criteria set speelt 
voor het eerst MRI van de SI-gewrichten een belangrijke rol. Ook ligt er veel nadruk op de 
aanwezigheid van HLA-B27. Dit, omdat gebleken is dat niet elke SpA patiënt radiografische 
sacroiliitis ontwikkelt en het belangrijkste doel bij de ontwikkeling van de ASAS axiale SpA 
criteria dus was om ook niet-radiografische SpA te kunnen identificeren. De axiale SpA 
criteria set is bedoeld voor patiënten met rugpijn die 3 maanden of langer bestaat en die 
ontstaan is vóór het 45e levensjaar. Als bij de patiënt sacroiliitis op röntgenfoto’s of op MRI 
wordt vastgesteld en er nog minstens één ander SpA-kenmerk aanwezig is, of als er naast de 
aanwezigheid van HLA-B27 nog minimaal twee andere SpA-kenmerken aanwezig zijn, kan 
de patiënt worden geclassificeerd als axiale SpA. 
De ASAS perifere criteria set kan worden toegepast in patiënten met perifere artritis, enthesitis 
en/of dactylitis. Als de patiënt daarnaast ook nog psoriasis, IBD, HLA-B27, (radiografische) 
sacroiliitis of een acute uveïtis anterior heeft, of wanneer de patiënt vier weken voorafgaand 
aan de perifere artritis/enthesitis/dactylitis diarree of een infectie van de baarmoederhals 
of van de plasbuis heeft gehad, dan kan de patiënt als perifere SpA worden geclassificeerd. 
Een patiënt met perifere artritis, enthesitis of dactylitis kan ook aan de ASAS perifere criteria 
voldoen als er tenminste nog twee andere van de volgende SpA-kenmerken aanwezig zijn: 
1) perifere artritis (nu of in het verleden), 2) enthesitis (nu of in het verleden), 3) dactylitis 
(nu of in het verleden), 4) IBP of 5) een eerste- of tweedegraads familielid met SpA (AS of 
reactieve artritis) of SpA-kenmerken (psoriasis, acute uveïtis anterior en/of IBD).
Nu sacroiliitis op MRI zo’n prominente rol heeft gekregen in classificatiecriteria heeft de 
ASAS ook aanbevelingen voor het maken en interpreteren van een MRI ontwikkeld. Zonder 
alle technische details te bespreken, komt het er op neer dat ASAS aanbeveelt om altijd 
twee verschillende MRI opnamen te maken; één opname waarop onder andere actieve 
ontstekingen van het beenmerg (bone marrow edema; BME) goed te zien zijn (STIR opname) 
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en één opname waarop schade aan het bot, zoals erosies (gaatjes in gewrichtsoppervlak van 
de botten in de SI-gewrichten) en sclerose (het compacter worden van het bot)  en excessieve 
nieuwvorming van bot goed te zien zijn (T1 TSE fatsat opname). De huidige definitie van een 
positieve MRI  berust alleen op de aanwezigheid van BME laesies zoals te zien op een STIR 
opname en dus wordt de schade aan het bot niet in deze definitie meegenomen.
Het gebrek aan diagnostische criteria in combinatie met vele verschillende klachten 
die SpA kan geven (heterogene klinische presentatie), kan het soms lastig maken voor 
reumatologen om SpA te herkennen, zeker in de afwezigheid van (radiografische) sacroiliitis. 
Vaak wordt de diagnose gesteld op basis van de aanwezigheid van een combinatie van 
kenmerken; de bevindingen van de anamnese, het lichamelijk onderzoek, de beeldvorming 
en de laboratoriumtesten. De reumatoloog kan gebruik maken van een diagnostisch 
instrument, het Berlijn algoritme, waarin alle relevante SpA-kenmerken, zoals de extra-
articulaire manifestaties en sacroiliitis op MRI, in acht worden genomen. Met behulp van 
het Berlijn algoritme kan voor elke individuele patiënt met IBP via verschillende stappen 
de waarschijnlijkheid op het hebben van SpA worden uitgerekend, wat kan helpen bij het 
stellen van de diagnose axiale SpA.
Met behulp van MRI, waarop sacroiliitis dus in een eerder stadium te herkennen is, is het 
nu ook mogelijk om de diagnose SpA eerder te stellen. Het is belangrijk dat de diagnose SpA 
zo vroeg mogelijk wordt gesteld, omdat een vroege diagnose onnodig verder onderzoek 
overbodig maakt en ook voorkomt dat de patiënt ongeschikte behandelingen krijgt. 
Daarnaast kan dan vroeg in de ziekte een geschikte behandeling worden gegeven, wat 
belangrijk is omdat patiënten met een korte ziektegeschiedenis beter lijken te reageren op 
behandeling dan patiënten met een lange(re) ziektegeschiedenis. 
Momenteel rust de behandeling van SpA en AS op een niet-medicamenteuze en een 
medicamenteuze pijler. De niet-medicamenteuze behandeling bestaat uit regelmatig 
bewegen, al dan niet onder begeleiding van een fysiotherapeut, voorlichting en steun van 
patiëntenverenigingen en zelfhulpgroepen. Het is van belang om gedurende het hele leven 
te blijven bewegen - in de vorm van gerichte oefeningen - om de mobiliteit optimaal en de 
conditie op peil te houden. Bovendien kan een sterk spierkorset bijdragen aan het voorkómen 
van houdingsafwijkingen. Daarnaast heeft bewegen een gunstig effect op pijn, lichamelijk 
functioneren en op het ervaren van ziekteactiviteit. De basis van de medicamenteuze 
behandeling bestaat uit ontstekingsremmende pijnstillers, de zogenaamde NSAID’s 
(non-steroidal anti-inflammatory drugs). Deze geven een snelle verlichting van pijn en 
stijfheidsklachten indien ze in de juiste dosering gebruikt worden. Wanneer de behandeling 
met NSAID’s onvoldoende effectief is, bestaat sinds een paar jaar de mogelijkheid om te 
behandelen met TNF-α remmers. Deze TNF-α remmers kunnen een sterk en snel positief 
effect hebben op onder andere rugklachten, algemeen dagelijks functioneren, mobiliteit, 
perifere artritis, enthesitis en op MRI zichtbare ontsteking. Echter, het nadeel van het 
gebruik van TNF-α remmers is dat de behandeling erg duur is en dat een verhoogde kans op 
infecties bestaat.
Dit proefschrift
Ondanks dat er de afgelopen 10-15 jaar grote stappen in de goede richting zijn gezet, zijn 
er nog steeds uitdagingen in het verbeteren van de herkenning en het behandelen van 
(vroege) SpA patiënten. 
De onderzoeken beschreven in de eerste hoofdstukken van dit proefschrift zijn grotendeels 
uitgevoerd in het SPondyloArthritis Caught Early (SPACE)-cohort en het DEvenir des 
Spondylarthropathies Indifférenciées Récentes (DESIR)-cohort. Een cohort is een groep 
personen die gedurende een bepaalde periode een zelfde gebeurtenis heeft meegemaakt 
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en gedurende een bepaalde periode in een onderzoek wordt gevolgd. In dit geval is deze 
gebeurtenis het hebben van rugpijn, en in beide cohorten worden dan ook patiënten 
met rugpijn ingesloten om onder andere te kunnen bestuderen hoe patiënten met axiale 
SpA het beste onderscheiden kunnen worden van patiënten zonder SpA, welke factoren 
voorspellend zijn voor SpA en welke factoren voorspellend zijn voor een progressief beloop 
van de ziekte. Om deze vragen te kunnen beantwoorden wordt informatie verzameld over 
de aan- en afwezigheid van alle SpA-kenmerken. Maar er bestaan ook verschillen tussen 
beide cohorten. Het DESIR-cohort is een puur Frans cohort met 25 participerende centra 
uit heel Frankrijk, terwijl het SPACE-cohort - wat begonnen is als een Nederlands cohort - 
een internationaal cohort is met participerende centra in Nederland, Noorwegen, Italië en 
Zweden. 
De hoofdstukken 2-4 vormen samen deel I van dit proefschrift met de focus op de vroege 
herkenning van (axiale) SpA en classificatiecriteria. In hoofdstuk 2 hebben we in het SPACE-
cohort gekeken welke van de bestaande criteria sets het hoogste aantal patiënten (met en 
zonder SpA) op de juiste manier kan classificeren. Onze speciale interesse ging hierbij uit 
naar de ASAS axiale SpA classificatiecriteria, omdat deze relatief nieuw zijn. Soortgelijke 
vergelijkingen hebben we ook gemaakt in het Leiden Early Arthritis Clinic (EAC)-cohort in 
hoofdstuk 4 om de ASAS perifere SpA classificatiecriteria te testen. Voor het EAC-cohort 
worden sinds 1993 patiënten verwezen naar de polikliniek reumatologie van het LUMC door 
huisartsen uit de omgeving omdat er een verdenking op artritis bestaat. Wanneer bij de 
reumatoloog blijkt dat de patiënt daadwerkelijk een artritis heeft met een symptoomduur 
korter dan 2 jaar, dan wordt de patiënt in het EAC-cohort opgenomen. In hoofdstuk 3 
hebben we gekeken hoeveel juiste diagnoses het originele Berlijn algoritme oplevert in 
onder andere het SPACE-cohort en hebben we ook gekeken of we het Berlijn algoritme nog 
konden verbeteren. 
Deel II van dit proefschrift gaat over de rol van beeldvormende technieken (röntgenfoto’s 
en MRI) in de vroege diagnose van axiale SpA. Omdat uit eerder onderzoek is gebleken 
dat het lastig is om röntgenfoto’s van de SI-gewrichten goed te beoordelen, hebben we in 
hoofdstuk 5 gekeken wat er gebeurt met de classificatie van een patiënt volgens de mNY 
criteria wanneer de röntgenfoto door verschillende beoordelaars geïnterpreteerd wordt. 
In hoofdstuk 6 hebben we een soortgelijk onderzoek uitgevoerd, maar dan hebben we 
gekeken of de classificatie van een patiënt volgens de ASAS axiale SpA criteria veranderde 
wanneer naast de beoordelingen van de röntgenfoto’s ook MRI’s van de SI-gewrichten door 
verschillende beoordelaars geïnterpreteerd worden. 
Tot nu toe is er alleen gesproken over een afwijkende (‘positieve’) en niet-afwijkende 
(‘negatieve’) MRI van de SI-gewrichten, maar het is ook mogelijk om in meer detail naar de 
hoeveelheid ontsteking op een MRI van de SI-gewrichten te kijken, bijvoorbeeld met behulp 
van de SPondyloArthritis Research Consortium of Canada (SPARCC)-methode. Het bereik 
van de SPARCC-score loopt van 0 tot 72 en heeft daarmee een hoge gevoeligheid voor 
veranderingen in ontsteking over de tijd. De SPARCC-methode wordt daarom vaak gebruikt 
om de effecten van behandeling in klinische onderzoeken te beoordelen. De meetkundige 
eigenschappen van de SPARCC-methode zijn echter nog niet uitgebreid onderzocht, en 
daarom hebben wij die geëvalueerd in hoofdstuk 7. 
Deel III van dit proefschrift gaat over het behandelen van axiale SpA en AS. Sinds de 
verschijning van de eerste versie van de ASAS/EULAR aanbevelingen voor behandeling 
van AS in het algemeen en de eerste update van de ASAS/EULAR aanbevelingen voor 
behandeling van AS met TNF-α remmers in 2006 zijn er veel onderzoeken gedaan en 
publicaties verschenen over de effecten van (nieuwe) behandelingen voor AS en SpA, en 
dus waren de ASAS/EULAR aanbevelingen toe aan een update. In hoofdstuk 8 hebben we 
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een overzicht gemaakt van de nationale richtlijnen van 23 landen over de behandeling 
van AS met TNF-α remmers en hebben we gekeken in hoeverre deze nationale richtlijnen 
overeenkomen met en verschillen van de ASAS/EULAR aanbevelingen. Deze informatie is in 
aanmerking genomen bij de update van de ASAS/EULAR aanbevelingen voor behandeling 
van AS met TNF-α remmers. De update van de ASAS/EULAR management aanbevelingen 
staan beschreven in hoofdstuk 11. Twee literatuuroverzichten beschreven in hoofdstuk 9 
en hoofdstuk 10 vormden de basis voor deze update. Een overzicht van de huidige literatuur 
over de niet-medicamenteuze behandeling van AS en de behandeling met medicamenten 
zoals NSAID’s staat beschreven in hoofdstuk 9, gevolgd door een overzicht van de huidige 
literatuur over de behandeling met onder andere TNF-α remmers in hoofdstuk 10. 
De in dit proefschrift uitgevoerde onderzoeken hebben bijgedragen aan het zich continu 
ontwikkelende veld van SpA, en de belangrijkste resultaten en conclusies zijn hieronder per 
deel samengevat en bediscussieerd. 
Deel I: Vroege herkenning van (axiale) SpA en classificatie criteria 
In een groep patiënten met voornamelijk axiale klachten in het SPACE-cohort (hoofdstuk 2) 
en in een  groep patiënten met voornamelijk perifere klachten in het EAC-cohort (hoofdstuk 
4), hebben we getest welke van de bestaande classificatiecriteria (mNY, ESSG, Amor, ASAS 
en CASPAR criteria) het hoogste aantal patiënten op de juiste manier kan classificeren. 
De CASPAR criteria (ClASsification criteria for Psoriatic ARthritis) zijn uitsluitend voor het 
classificeren van artritis geassocieerd met psoriasis (artritis psoriatica). De methodes die 
we in beide hoofdstukken gebruikt hebben om dit te testen zijn zeer vergelijkbaar; in beide 
cohorten gold de diagnose van de reumatoloog als de standaard. Alle patiënten met de 
diagnose artritis psoriatica en de diagnose perifere SpA (ruim 10% van het gehele EAC-
cohort) en een controle-groep met gelijke leeftijd, geslacht en symptoomduur uit het EAC-
cohort zijn bestudeerd in hoofdstuk 4. De ASAS perifere SpA criteria en de CASPAR criteria 
classificeren grotendeels dezelfde artritis psoriatica patiënten, maar de CASPAR criteria 
classificeerden verreweg de meeste patiënten in de artritis psoriatica groep op de juiste 
manier. In de perifere SpA groep classificeerden de ASAS perifere SpA criteria verreweg de 
meeste patiënten op de juiste manier. Aangezien het doel van classificatiecriteria is om een 
homogene groep patiënten aan te kunnen duiden, terwijl de klinische presentatie van SpA 
zo heterogeen is, is het te verwachten dat niet alle patiënten die door de reumatoloog als 
perifere SpA gediagnosticeerd zijn, worden opgepikt door de classificatiecriteria. Van de 
perifere SpA patiënten wordt 48.7% ook als perifere SpA geclassificeerd volgens de ASAS 
perifere SpA criteria (sensitiviteit). Een belangrijke bevinding is dat de ASAS perifere SpA 
en de CASPAR criteriasets de patiënten in de controlegroepen in het overgrote merendeel 
terecht classificeren als niet hebbende de aandoening (89.8% en 95.6% specificiteit voor 
respectievelijk de ASAS perifere SpA en CASPAR criteria). Dit is met name van belang voor de 
ASAS perifere SpA criteria, omdat deze criteria nog vrij nieuw zijn en de angst bestond dat ze 
misschien te veel patiënten ten onrechte classificeerden als perifere SpA. 
De resultaten gevonden en beschreven in hoofdstuk 4 zijn recent ook bevestigd in 
het ESPERANZA-cohort. Dit Spaanse cohort is ontwikkeld om de vroege herkenning 
en  diagnostisering van SpA te faciliteren en om de kennis en praktische vaardigheden 
van huisartsen en specialisten in SpA te verbeteren. Patiënten met klachten (IBP of 
asymmetrische artritis (bij voorkeur van de onderste extremiteiten), of rugpijn/gewrichtspijn 
in combinatie met één ander SpA-kenmerk) kunnen worden geïncludeerd in dit cohort. 
Door deze inclusiecriteria te hanteren, wordt in het ESPERANZA-cohort dus een iets andere 
groep patiënten gevormd dan in het EAC-cohort, maar de gevonden sensitiviteit (56%) en 
specificiteit (85%) van de ASAS perifere SpA criteria zijn zeer vergelijkbaar met de resultaten 
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gevonden in het EAC-cohort. 
We hebben de bestaande classificatiecriteria ook getest in een setting met patiënten met 
voornamelijk axiale klachten, zoals geïncludeerd in het SPACE-cohort (hoofdstuk 2). In 
Nederland heeft ongeveer 20.8% van de bevolking last van rugpijn, waarvan het merendeel 
geduid wordt als aspecifieke rugklachten. Vóór aanvang van het SPACE-cohort was men 
dan ook bang dat de polikliniek reumatologie overladen zou worden met patiënten met 
aspecifieke rugpijn, maar in hoofdstuk 2 hebben we aangetoond dat deze angst ongegrond 
is gebleken. Tijdens de eerste visite wordt bij alle doorverwezen patiënten een anamnese 
afgenomen, lichamelijk onderzoek uitgevoerd, worden laboratoriumtesten uitgevoerd 
(inclusief het testen op de aanwezigheid van HLA-B27) en worden een MRI en röntgenfoto’s 
van de SI-gewrichten en de rug gemaakt. Dit heeft de mogelijkheid geboden om te bepalen 
hoeveel patiënten er ten tijde van de eerste visite aan welke classificatiecriteria voldoen 
(mNY, Amor, ESSG, ASAS axial SpA criteria). Bijna 60% van de patiënten in het SPACE-cohort 
voldoet aan één of meerdere classificatiecriteria; bijna 40% voldoet aan de ASAS axiale 
SpA criteria (hoofdstuk 2). De ASAS axiale SpA criteria presteren in het SPACE-cohort het 
beste van alle classificatiecriteria, doordat de ASAS axiale SpA criteria het hoogste aantal 
patiënten op de juiste manier classificeren. Bijna vijfentachtig procent van de axiale SpA 
patiënten (volgens de reumatoloog) werden ook als axiale SpA geclassificeerd door de ASAS 
criteria en bijna vijfennegentig procent van de patiënten zonder axiale SpA werden ook niet 
geclassificeerd door de ASAS criteria. 
Het percentage patiënten in het SPACE-cohort dat aan de ASAS axiale SpA criteria voldoet 
(38.2%) lijkt op het eerste gezicht misschien wat hoog, wat de indruk kan wekken dat er 
sprake is van toegenomen bewustzijn over het SPACE-cohort onder verwijzende artsen, 
waardoor alleen patiënten met een hoge verdenking op SpA verwezen zouden worden 
(‘referral bias’). Daarom hebben we per jaar dat het SPACE-cohort loopt, gekeken of het 
percentage patiënten dat aan de ASAS criteria voldoet verschilt, maar dit blijkt niet zo te 
zijn. Ook het percentage patiënten verwezen naar het LUMC van buiten de regio Leiden was 
ongeveer gelijk over de jaren. Bovendien zijn er ook 33/157 patiënten (21.0%) verwezen 
zonder SpA-kenmerken of met slechts 1 weinig specifiek SpA-kenmerk. Hoewel nooit uit 
te sluiten, maakt dit ‘referral bias’ minder waarschijnlijk. Bovendien zijn er onlangs zeer 
vergelijkbare resultaten gevonden in een ander onderzoek waarin ook patiënten met rugpijn 
die 3 maanden of langer bestaat en ontstaan is voor het 45e levensjaar zijn geïncludeerd, 
gerekruteerd onder reumatologen in Frankrijk. 
Patiënten kunnen op twee manieren aan de ASAS axSpA criteria voldoen: via de klinische 
arm (aanwezigheid van HLA-B27 plus 2 andere SpA-kenmerken) en via de imaging arm 
(sacroiliitis plus 1 ander SpA-kenmerk). Aangezien er aanwijzingen zijn dat reumatologen en 
registratieautoriteiten (U.S. Food and Drug Administration (FDA)) de klinische arm minder 
accepteren als voldoende specifiek voor classificatie dan de imaging arm, hebben we in 
het SPACE-cohort patiënten in beide armen met elkaar vergeleken (hoofdstuk 2). Patiënten 
in beide armen bleken opvallend gelijkwaardig wat betreft ziekteactiviteit (BASDAI (Bath 
Ankylosing Spondylitis Disease Activity Index) en ASDAS (Ankylosing Spondylitis Disease 
Activity Score)) en de aanwezigheid van SpA-kenmerken. Dergelijke vergelijkingen zijn ook 
gemaakt in het DESIR-cohort en in het ABILITY-1 onderzoek. Het ABILITY-1 onderzoek is 
een gerandomiseerd placebogecontroleerd onderzoek naar de effecten en veiligheid van 
adalimumab - één van de veelgebruikte TNF-α remmers - in patiënten die niet aan de mNY 
criteria, maar wel aan de ASAS axiale SpA criteria voldoen (non-radiografische axiale SpA). 
Ook in deze onderzoeken is gevonden dat patiënten in beide armen van de ASAS axiale 
SpA criteria zeer vergelijkbaar zijn. Wel blijkt het zo te zijn dat reumatologen zekerder zijn 
van hun diagnose zijn als er sacroiliitis op MRI en/of röntgenfoto’s te zien is (hoofdstuk 
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2). Dit lijkt erop te wijzen dat reumatologen hun diagnose zwaar laten afhangen van de 
aan- of afwezigheid van (radiografische) sacroiliitis. Dit is recent ook bevestigd in een 
onderzoek uitgevoerd in Frankrijk (hierboven reeds genoemd) waarbij aangetoond is dat 
(radiografische) sacroiliitis het hoogste voorspellend vermogen heeft voor de diagnose SpA 
volgens de reumatoloog.
Verder hebben we in het SPACE-cohort gevonden dat ongeveer 80% van de patiënten met 
axiale SpA (volgens de ASAS axiale SpA criteria) IBP heeft, en andersom, dat bijna 60% van 
de patiënten zonder SpA IBP heeft (hoofdstuk 2). Deze resultaten tonen aan dat IBP geen 
goed onderscheid kan maken tussen patiënten met en zonder axiale SpA in het SPACE-
cohort en we bevestigen hiermee eerder gevonden resultaten. Maar omdat het uitvragen 
van IBP geen kosten met zich mee brengt, kan IBP toch van nut zijn in het diagnostisch 
proces, zolang het maar in combinatie met andere SpA-kenmerken wordt toegepast (hoe 
meer SpA-kenmerken aanwezig, des te suggestiever voor SpA). Bovendien lijkt er bewijs te 
zijn dat bepaalde items van IBP meer voorspellend voor SpA zijn dan andere items. Maar 
de interpretatie van IBP (items) verschilt van persoon tot persoon, zoals blijkt uit de lage 
overeenstemming tussen huisartsen en reumatologen over de aanwezigheid van IBP. Dit 
alles tezamen maakt de rol van IBP in het diagnostisch proces onduidelijk.
IBP wordt gebruikt als (deel van het) toelatingscriterium in de ESSG criteria en het 
diagnostische Berlijn algoritme. Gezien het feit dat slechts 70-80% van de patiënten met 
axiale SpA typische IBP klachten heeft, betekent dit dat 20-30% van de patiënten met axiale 
SpA niet door het Berlijn algoritme kunnen worden opgepikt. Dit heeft ons gestimuleerd om 
verbeteringen aan het algoritme aan te brengen.
We hebben 2 modificaties van het algoritme voorgesteld in hoofdstuk 3. In de eerste 
modificatie stellen we voor dat patiënten met ≥3 van de 5 (in plaats van ≥4 van de 5) items 
van IBP het algoritme in mogen stromen. In de tweede modificatie verandert de gehele 
structuur van het algoritme daar we voorstellen om IBP als toelatingscriterium te verwijderen 
en toe te voegen aan de lijst van SpA-kenmerken. Bovendien mogen nu alle patiënten met 
rugpijn ≥3 maanden die ontstaan is vóór het 45e levensjaar het algoritme instromen. Dit 
resulteert in drie groepen met respectievelijk ≥4, 2-3 en 0-1 SpA-kenmerken. Alle drie de 
algoritmes hebben we getest in het SPACE-cohort en het ASAS-cohort met de classificatie 
volgens de ASAS axiale SpA criteria, de post-test waarschijnlijkheid op het hebben van SpA 
en de diagnose van de reumatoloog als externe standaards. Net zoals in het SPACE-cohort 
worden in het ASAS-cohort ook patiënten met rugpijn ≥3 maanden ontstaan vóór het 45e 
levensjaar geïncludeerd, maar patiënten moeten daarnaast ook een sterke verdenking 
op SpA hebben (zonder reeds een definitieve diagnose op het moment van verwijzen). In 
beide cohorten pikt modificatie 1 meer juiste SpA patiënten op dan het originele algoritme 
(hogere sensitiviteit), ten koste van slechts een klein beetje verlies aan specificiteit. De 
sensitiviteit van modificatie 2 is nog iets hoger, en ook de specificiteit is iets hoger dan de 
specificiteit van modificatie 1. De resultaten zijn aan de ASAS-leden gepresenteerd tijdens 
een vergadering in januari 2012 in Amsterdam. De leden stemden voor modificatie 2 als het 
nieuwe algoritme.
Maar er valt nog na te denken over verdere verbeteringen. Reumatologen zouden 
bijvoorbeeld kunnen overwegen een MRI te maken in HLA-B27-negatieve (mannelijke) 
patiënten die 2-3 andere SpA-kenmerken hebben. In modificatie 2 verlaten deze patiënten 
het algoritme, maar als de MRI positief zou zijn, dan voldoen deze patiënten aan de ASAS 
axiale SpA criteria. Daarnaast is het waardevol om te onderzoeken of het zinnig is om binnen 
de groep HLA-B27-negatieve patiënten met 0 of 1 SpA-kenmerk onderscheid te maken tussen 
de patiënten zonder SpA-kenmerken en de patiënten met 1 SpA-kenmerk om te beslissen of 
er nog een MRI gemaakt moet worden of niet. In het huidige algoritme wordt geadviseerd 
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om bij al deze patiënten een MRI te maken, maar alleen de patiënten met 1 kenmerk 
zouden aan de ASAS axiale SpA criteria kunnen voldoen als de MRI positief blijkt te zijn, 
terwijl de patiënten zonder kenmerken niet aan de ASAS axiale SpA criteria zullen kunnen 
voldoen. Bovendien valt het nut van het maken van een röntgenfoto van de SI-gewrichten 
als eerste stap te betwijfelen, aangezien dit algoritme vaak toegepast zal worden in nieuw te 
diagnosticeren patiënten met een korte klachtengeschiedenis. Dit wordt gereflecteerd door 
het hoge aantal normale röntgenfoto’s in het SPACE- en het ASAS-cohort. Er zou daarom 
overwogen kunnen worden of het zinniger is om het maken van de röntgenfoto’s van de 
SI-gewrichten één van de vervolgstappen te laten zijn, nadat de informatie uit de anamnese 
en het lichamelijk onderzoek bekend is, zoals ook in de dagelijkse praktijk gebruikelijk is. 
Desalniettemin kan modificatie 2 in de huidige vorm al van nut zijn voor reumatologen in 
de dagelijkste praktijk. De Nederlandse Vereniging voor Reumatologie (NVR) heeft recent 
richtlijnen voor de diagnose en de behandeling van axiale SpA gepubliceerd, waarin dit 
gemodificeerde algoritme is opgenomen. 
Alhoewel er de afgelopen jaren enorme vooruitgang is geboekt in het diagnosticeren 
en classificeren van SpA patiënten, worden nog niet altijd de juiste patiënten naar de 
reumatoloog doorverwezen. Dit komt waarschijnlijk doordat verwijzers slechts geringe 
kennis hebben van de manifestaties die bij SpA horen, zoals geïllustreerd wordt door de 
slechte overeenstemming tussen verwijzers en reumatologen over de aanwezigheid van IBP 
in het onderzoek van een Duitse en een Spaanse onderzoeksgroep. Het blijkt een uitdaging 
voor verwijzers om patiënten met een verdenking op SpA, die naar de reumatoloog verwezen 
zouden moeten worden, te herkennen. Daarom zijn er in de loop van de tijd verscheidene 
(complexe) verwijsstrategieën ontwikkeld met het doel patiënten met een verdenking 
op SpA in een vroeg stadium te identificeren en naar de reumatoloog te verwijzen. Alle 
strategieën doen het goed in een onderzoeksomgeving waarin de verwijzers geïnstrueerd 
zijn (24-45% SpA patiënten onder alle verwezen patiënten), maar de implementatie van 
deze (complexe) verwijsstrategieën in de dagelijkse eerstelijnszorg blijkt lastig. Daarom is het 
wellicht nuttig om een zeer gemakkelijke verwijsstrategie te overwegen, zoals het verwijzen 
van alle patiënten met rugpijn ≥3 maanden die ontstaan is voor het 45e levensjaar - de 
toelatingscriteria van de ASAS axiale SpA criteria. In het SPACE-cohort, waarin de additionele 
restrictie van een maximum van 2 jaar klachten wordt toegepast en in een onderzoek uit 
Frankrijk leveren deze criteria hoge percentages SpA patiënten op (respectievelijk 41.4% 
(hoofdstuk 2) en 35.1%). Maar het moet nog blijken of een dergelijke strategie ook in 
andere centra en in andere landen zal werken omdat de gezondheidszorgsystemen overal 
verschillend zijn. Meer onderzoek hiernaar is dus noodzakelijk. 
Bovendien zijn studies met een lange periode van follow-up nodig om de uitkomsten 
van patiënten in de klinische arm en patiënten in de imaging arm van de ASAS axiale SpA 
criteria te bestuderen en te vergelijken. Dit zal bijdragen aan het begrip van het ziektebeeld. 
Daarnaast zal meer kennis van uitkomsten op lange termijn ook helpen in het overwegen 
van mogelijke aanpassingen aan de ASAS axiale SpA criteria zelf, bijvoorbeeld het wegen 
van de verschillende SpA-kenmerken omdat sommige SpA-kenmerken, zoals een positieve 
familieanamnese voor SpA en HLA-B27 positiviteit, onderling sterker gecorreleerd zijn dan 
andere SpA-kenmerken.
Deel II: De rol van beeldvormende technieken in de vroege diagnose van spondyloartritis
MRI heeft de afgelopen jaren zijn nut bewezen in het diagnosticeren en classificeren van 
patiënten met SpA. Desondanks staat de nieuwverworven prominente rol van MRI, maar 
ook de rol van conventionele röntgenfoto’s, ter discussie. Dit, omdat bekend is dat het 
een uitdaging is om betrouwbaar beelden van de SI-gewrichten te beoordelen, met name 
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röntgenfoto’s. De SI-gewrichten hebben een complexe anatomie, waarbij het golvende 
gewrichtsoppervlak wordt afgebeeld op een 2-dimensionaal beeld en dit kan leiden tot 
verkeerde interpretaties. 
Waar in de dagelijkse praktijk de diagnose AS gebaseerd is op de beoordeling van een 
röntgenfoto door een lokale radioloog en/of reumatoloog, worden beelden in klinische 
onderzoeken en cohorten meestal beoordeeld door één of meer getrainde ‘centrale’ lezers. 
Recent is de variatie in het interpreteren van röntgenfoto’s bevestigd in een post-hoc analyse 
van de data van het ABILITY-1 onderzoek en het RAPID-axSpA onderzoek voor de registratie 
van TNF-α remmers in patiënten met niet-radiografische axiale SpA. De analyses van de 
ABILITY-1 data laten zien dat 37% van de patiënten die door lokale lezers geclassificeerd 
was als niet-radiografische axiale SpA door centrale lezers als AS (mNY criteria positief) 
werd geclassificeerd. In het RAPID-axSpA onderzoek laat een soortgelijke analyse zien 
dat 36% van de patiënten anders geclassificeerd werd; 26% van de door lokale lezers als 
niet-radiografische axiale SpA geclassificeerde patiënten werd door de centrale lezers als 
AS (mNY positief) geclassificeerd, en 10% van de door lokale lezers als AS (mNY positief) 
geclassificeerde patiënten werd als niet-radiografische axiale SpA geclassificeerd door 
centrale lezers. 
Daar in het DESIR-cohort de beoordelingen van MRI en röntgenfoto’s van zowel lokale als 
centrale lezers beschikbaar zijn, bood dit cohort de unieke gelegenheid om soortgelijke 
analyses uit te voeren. De vergelijking van de beoordeling van de aan- of afwezigheid 
van radiografische sacroiliitis staat beschreven in hoofdstuk 5 en laat zien dat de 
overeenstemming tussen lokale lezers en centrale lezers (als externe standaard) slechts 
matig is. Lokale lezers zien veel vaker sacroiliitis dan centrale lezers; 41.5% van de patiënten 
die volgens lokale lezers als AS zijn geclassificeerd, kon niet worden bevestigd door de 
centrale lezers. Zelfs wanneer we een heel strikte definitie van radiografische sacroiliitis 
voor de lokale lezers hanteerden, kon 29.4% van de patiënten, die volgens de lokale lezers 
als AS zijn geclassificeerd, niet worden bevestigd door de centrale lezers. Dit percentage liep 
zelfs op tot 65.1% wanneer we daarnaast ook nog eens een strikte definitie voor de centrale 
lezers hanteerden. Hier moet wel bij gezegd worden dat de lokale lezers op een iets andere 
manier de röntgenfoto’s hebben beoordeeld dan de centrale lezers en dat het werkelijke 
percentage fout-positieve classificaties door lokale lezers dus ergens tussen de 29.4% en 
65.1% ligt. 
Daarnaast werd 7.5% van de patiënten die volgens de centrale lezers als AS zijn geclassificeerd, 
niet herkend door lokale lezers. Dit percentage liep op tot 11.7% met de striktere definitie 
van sacroiliitis voor lokale lezers. Zelfs in patiënten bij wie ankylose (benige brug tussen 
beide gewrichtsvlakken van het SI-gewricht) te zien is of bij wie beide SI-gewrichten zijn 
aangedaan, waren er grote verschillen in de beoordeling tussen lokale en centrale lezers. 
Maar ook de overeenstemming over de aan- of afwezigheid van radiografische sacroiliitis 
tussen de twee centrale lezers onderling is slechts matig. Dit benadrukt nogmaals de 
moeilijkheid van het beoordelen van de SI-gewrichten op röntgenfoto’s en laat tegelijkertijd 
zien dat training de beoordeling niet substantieel lijkt te verbeteren. Maar waar de 
discrepantie tussen de centrale lezers in beide richtingen te zien is, bestaat de misclassificatie 
door lokale lezers bijna volledig uit fout-positieve classificaties, wat resulteert in een 
onacceptabel hoog percentage onterechte diagnoses van AS in de dagelijkse praktijk. Of 
deze patiënten wel non-radiografische axiale SpA hadden, hebben we verder onderzocht in 
hoofdstuk 6. Daar hebben we soortgelijk onderzoek ook voor MRI uitgevoerd  in het DESIR-
cohort. 
In tegenstelling tot de slechts matige overeenstemming over radiografische sacroiliitis, 
bestaat er een aanzienlijke overeenstemming tussen lokale lezers en centrale lezers en 
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ook tussen de twee centrale lezers onderling over sacroiliitis op MRI. Vervolgens hebben 
we gekeken wat er gebeurt met de classificatie van patiënten volgens de ASAS axiale SpA 
criteria wanneer de MRI en/of röntgenfoto mogelijk anders geïnterpreteerd wordt door 
verschillende lezers. 
In 163/582 patiënten (28.0%), bij wie de beoordeling van de MRI en/of röntgenfoto door 
lokale lezers verschilde van de beoordeling door centrale lezers, zou potentieel de classificatie 
volgens de ASAS axiale SpA criteria ook verschillend kunnen zijn. In slechts 46/582 patiënten 
(7.9%) was dit ook daadwerkelijk het geval. Dit toont aan dat de ASAS axiale SpA criteria vrij 
ongevoelig zijn voor verschillen in beoordeling van MRI en/of röntgenfoto. Dit wordt met 
name veroorzaakt door de aanwezigheid van de klinische arm. Patiënten die namelijk aan 
deze klinische arm voldoen, zullen dat altijd blijven doen omdat de HLA-B27-status nooit zal 
veranderen, ongeacht de beoordelingen van de MRI en röntgenfoto en er zijn veel patiënten 
die zowel aan de imaging als aan de klinische arm voldoen.
Gezien de matige betrouwbaarheid van het beoordelen van conventionele röntgenfoto’s en 
de aanzienlijke betrouwbaarheid van het beoordelen van MRI’s, beargumenteren sommige 
experts dat het misschien wel een optie is om helemaal geen röntgenfoto’s meer te maken 
en alleen te volstaan met MRI’s. In het DESIR-cohort hebben we gekeken wat de mogelijke 
consequenties zijn van het compleet weglaten van röntgenfoto’s (hoofdstuk 6). Wanneer 
we kijken naar de volledige ASAS axiale SpA criteria  - inclusief de klinische arm - dan zouden 
11 tot 14 patiënten (1.9-2.4%; gebaseerd op de beoordeling van lokale of centrale lezers) 
gemist worden die op basis van radiografische sacroiliitis (en dus geen sacroiliitis op MRI 
hebben) alleen aan de imaging arm voldoen (en dus niet aan de klinische arm). De resultaten 
zouden er misschien anders uit hebben gezien als een dergelijke analyse niet in een cohort 
als DESIR zou zijn uitgevoerd waar patiënten met kort bestaande klachten zijn geïncludeerd, 
maar in een cohort met patiënten met lange ziektegeschiedenis. 
De huidige definitie van een positieve MRI is momenteel alleen gebaseerd op de aanwezigheid 
van  actieve ontstekingen, die niet te zien zijn op röntgenfoto’s. Op röntgenfoto’s is juist 
alleen schade aan het bot te zien. Dus de discussie over het weglaten van röntgenfoto’s 
wordt pas echt interessant als de aanwezigheid van schade aan het bot (erosies, ankylose en 
sclerose) een rol zou kunnen spelen in de definitie van een positieve MRI. Voordat bepaald 
kan worden of dergelijke structurele afwijkingen ook daadwerkelijk van toegevoegde 
waarde kunnen zijn op de definitie van een positieve MRI, moet er eerst gekeken worden of 
deze afwijkingen betrouwbaar afgebeeld en beoordeeld kunnen worden op MRI. Daarom 
is in het SPACE-cohort en het German Spondyloarthritis Inception Cohort (GESPIC)-cohort 
getest wat het vermogen van MRI is om structurele afwijkingen in de SI-gewrichten te 
detecteren. Het GESPIC-cohort bestaat uit AS patiënten met een klachtengeschiedenis 
≤10 jaar en non-radiografische axiale SpA patiënten met een klachtengeschiedenis ≤5 jaar. 
Om het vermogen te testen van MRI om structurele afwijkingen te detecteren, zijn de 
structurele afwijkingen die te zien zijn op MRI vergeleken met de structurele afwijkingen 
die te zijn op röntgenfoto’s, die tevens als gouden standaard dienden. Over het algemeen 
is de overeenstemming tussen MRI en röntgenfoto’s echter slecht. Om deze resultaten te 
bevestigen of te weerleggen zouden deze vergelijkingen in andere cohorten moeten worden 
herhaald en zouden ze uitgebreid kunnen worden met een alternatieve externe standaard 
zoals CT. 
Momenteel wordt in het DESIR-cohort en het SPACE-cohort onderzocht of en zo ja, in welke 
combinatie(s) structurele afwijkingen aan het bot zouden kunnen worden toegevoegd 
aan de definitie van een positieve MRI. Dergelijke analyses zouden ook kunnen worden 
uitgevoerd in andere cohorten waarin patiënten met een langere klachtengeschiedenis zijn 
geïncludeerd. Totdat de resultaten van deze onderzoeken bekend zijn, kunnen er nog geen 
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definitieve conclusies getrokken worden over de rol die röntgenfoto’s en de mogelijke rol 
die structurele afwijkingen op MRI zouden kunnen gaan spelen. 
MRI wordt ook gebruikt om de hoeveelheid ontsteking in de SI-gewrichten en rug te 
kwantificeren, bijvoorbeeld met behulp van de SPARCC-methode. De SPARCC-methode 
heeft een hoge gevoeligheid voor veranderingen in ontsteking over de tijd, maar het is niet 
bekend of alle veranderingen die gemeten kunnen worden met de SPARCC-methode ook 
daadwerkelijk klinisch relevante veranderingen zijn, of dat het misschien om meetfouten 
gaat. De onderzoeksgroep die de SPARCC-methode ontwikkeld heeft, heeft een voorstel 
gedaan voor een klinisch relevante verandering in de uitkomst (minimally important 
change (MIC)) van 2.5 SPARCC-punten. Maar de kleinst detecteerbare, voor meetfouten 
gecorrigeerde verandering (smallest detectable change (SDC)) is nog nooit berekend en 
daarom is het niet duidelijk of een klinisch relevante verandering te onderscheiden valt van 
een meetfout. Daarom hebben we in hoofdstuk 7 de SDC van de SPARCC-score berekend in 
het SPACE-cohort over periodes van 3 maanden en 1 jaar. De gevonden SDC’s zijn 3.4 en 2.1 
SPARCC-punten over een periode van 3 maanden, en 2.4 SPARCC-punten over een periode 
van 1 jaar en liggen daarmee dus dicht bij de voorgestelde MIC. Een verandering kleiner dan 
de SDC kan beschouwd worden als meetfout of ‘ruis’. Een groot deel van de veranderingen 
in SPARCC-score in de patiënten in het SPACE-cohort over de periodes van 3 maanden en 
1 jaar kan als meetfout beschouwd worden, omdat deze kleiner zijn dan de berekende 
SDC’s (45-62.9% over 3 maanden tijd en 39.1% over 1 jaar tijd). Het is opmerkelijk dat het 
merendeel van de daadwerkelijke veranderingen (de veranderingen die dus groter zijn dan 
de berekende SDC’s), zowel toenames als afnames, worden geobserveerd in patiënten bij 
wie de  behandeling niet veranderd is. Deze observatie suggereert sterk dat ontstekingen op 
MRI spontaan kunnen fluctueren over de tijd. Dit is belangrijke informatie om rekening mee 
te houden bij het bestuderen en interpreteren van de resultaten van klinische onderzoeken 
en bij het verder uitpluizen van de hypothese dat ontsteking zou aanzetten tot het vormen 
van structurele afwijkingen. 
Daarnaast hebben we gekeken welke afkapwaarde van de SPARCC-score het beste 
equivalent van een positieve MRI volgens de ASAS definitie is. Dit blijkt een afkapwaarde 
van ≥2 SPARCC-punten te zijn. Aangezien de SPARCC-methode vaak in klinische onderzoeken 
gebruikt wordt om de effecten van behandeling met geneesmiddelen te meten, kan deze 
afkapwaarde gebruikt worden om patiënten in subgroepen in te delen met en zonder een 
positieve MRI. Dit kan bijvoorbeeld gebruikt worden als een voorspellende factor voor de 
respons op behandeling.
Deel III: Behandeling van axiale SpA en AS
De in 2006 door de ASAS/EULAR gepubliceerde aanbevelingen voor de behandeling van 
AS waren toe aan een update, aangezien sindsdien het aantal klinische onderzoeken 
en publicaties over (nieuwe) behandelingen van AS enorm gegroeid is. De update 
van deze aanbevelingen uit 2010 staat beschreven in hoofdstuk 11. Systematische 
literatuuroverzichten liggen hieraan ten grondslag, zoals geadviseerd wordt door de EULAR. 
Deze literatuuroverzichten staan beschreven in hoofdstuk 9 en hoofdstuk 10. 
In de titel van de update van de aanbevelingen wordt alleen AS genoemd en niet axiale 
SpA omdat het om een update van de bestaande aanbevelingen voor AS ging en omdat het 
bewijs van trials in non-radiografische axiale SpA nog beperkt was ten tijde van de update. 
Desalniettemin was de projectgroep unaniem van mening dat deze aanbevelingen ook in 
axiale SpA kunnen worden toegepast, omdat AS een deel van de totale axiale SpA groep 
is en omdat alle beschikbare data aantonen dat effectiviteit van behandeling minstens zo 
goed is in patiënten met niet-radiografische axiale SpA als in patiënten met AS. Dit laatste is 
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ook bevestigd in alle trials in niet-radiografische axiale SpA die sinds de verschijning van de 
aanbevelingen gepubliceerd zijn. 
ASAS adviseert elke patiënt een behandeling op maat te geven, waarbij rekening 
moet worden gehouden met alle aspecten van de ziekte, inclusief extra-articulaire 
manifestaties, ziekteactiviteit en geslacht etc (hoofdstuk 11). De ziekteactiviteit en klinische 
presentatie van patiënten met AS zou regelmatig gecontroleerd moeten worden volgens 
standaardparameters zoals door ASAS aanbevolen. De behandeling zou moeten bestaan 
uit niet-medicamenteuze en medicamenteuze componenten. Niet-medicamenteuze 
behandeling vormt één van de twee pijlers waarop de behandeling van AS momenteel 
berust en bestaat uit voorlichting en regelmatig bewegen. Het literatuuroverzicht over niet-
medicamenteuze behandeling beschreven in hoofdstuk 9 laat zien dat thuisoefeningen 
een goed effect hebben op fysiek functioneren (Bath Ankylosing Spondylitis Functional 
Index; BASFI), patiënt gerapporteerde ziekteactiviteit (BASDAI), pijn en mobiliteit van de 
rug, maar dat groeps- en individuele fysiotherapie onder toezicht met oefeningen in het 
water of droog, effectiever zijn dan thuisoefeningen. Dit is ook zo opgenomen in de ASAS 
aanbevelingen (hoofdstuk 11).
Ontstekingsremmende pijnstillers (NSAID’s, inclusief coxibs) in een maximale 
(ontstekingsremmende) dosis behoren tot de standaardbehandeling en bestrijden effectief 
pijn en stijfheid op korte en langere termijn (hoofdstuk 9 en hoofdstuk 11). De ASAS adviseert 
dat patiënten met aanhoudend actieve en symptomatische ziekte NSAID’s continu zouden 
moeten gebruiken. Een belangrijk argument daarvoor komt uit één onderzoek waarin is 
aangetoond dat continu gebruik van NSAID’s verbening beter remt dan wanneer NSAID’s 
slechts sporadisch (‘zo nodig’) worden gebruikt. Nadat de update van de aanbevelingen 
was gepubliceerd, is een post-hoc analyse uitgevoerd in dit onderzoek, waaruit is gebleken 
dat het continue gebruik van NSAID’s alleen superieur is aan het sporadisch gebruik van 
NSAID’s in patiënten met verhoogde acute-fase-eiwitten. Daarnaast is recent ook een 
onderzoek uitgevoerd in het GESPIC-cohort waarbij de invloed van NSAID’s op radiografische 
progressie in de rug over een periode van 2 jaar in AS en niet-radiografische SpA patiënten is 
bestudeerd. De resultaten van dit onderzoek tonen aan dat inname van hoge doses NSAID’s 
geassocieerd is met minder radiografische progressie in AS patiënten. 
Er is geen bewijs dat sulfasalazine en methotrexaat effect hebben op klachten in de rug en 
het bekken. Echter, sulfasalazine zou overwogen kunnen worden in patiënten met perifere 
betrokkenheid (hoofdstuk 11). Patiënten met aanhoudend hoge ziekteactiviteit, ondanks 
conventionele behandeling volgens de ASAS aanbevelingen, kunnen in aanmerking komen 
voor behandeling met TNF-α remmers. De resultaten van het literatuuroverzicht over 
behandeling met TNF-α remmers is beschreven in hoofdstuk 10. Alle TNF-α remmers die 
voor AS beschikbaar zijn blijken effectief te zijn in het verbeteren van BASDAI, BASFI, en 
BASMI (Bath Ankylosing Spondylitis Metrology Index) in patiënten met langdurig bestaande 
AS, maar ook in patiënten met niet-radiografische axiale SpA. Niet-radiografische axiale 
SpA patiënten blijken met name goed op behandeling met TNF- α remmers te reageren 
als er sprake is van verhoogde acute-fase-eiwitten in het bloed en/of ontsteking op MRI. 
Als de patiënt ook IBD heeft, zou het verschil in effectiviteit van de verscheidene TNF-α 
remmers op gastro-intestinale klachten meegewogen moeten worden. Verplicht gebruik 
van methotrexaat of sulfasalazine vóór de start van TNF-α remmers of het gelijktijdig gebruik 
van methotrexaat/sulfasalazine en TNF-α remmers in patiënten met axiale SpA wordt niet 
door bewijs ondersteund. Overstappen naar een tweede TNF-α remmer kan een gunstig 
effect hebben, zeker in patiënten die voorheen wel een respons hadden op TNF-α remmers 
maar deze verloren zijn (hoofdstuk 10 en hoofdstuk 11).
Ondanks dat er eenduidig bewijs is dat TNF-α remmers de ziekteactiviteit, inclusief ontsteking 
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op MRI en het dagelijks functioneren in patiënten met AS drastisch kunnen verbeteren, kan 
en hoeft niet elke AS patiënt hiermee behandeld te worden. Daarnaast zijn aan het gebruik 
van TNF-α remmers hoge kosten verbonden. Daarom heeft de ASAS in 2003 aanbevelingen 
voor het gebruik van TNF-α remmers gepubliceerd. Sindsdien zijn deze aanbevelingen al 
twee keer vernieuwd en inmiddels hebben veel landen nationale richtlijnen voor het gebruik 
van TNF-α remmers ontwikkeld, al dan niet op basis van deze ASAS aanbevelingen. 
In hoofdstuk 8 hebben we de nationale richtlijnen van 23 landen met elkaar en met de 
ASAS aanbevelingen uit 2006 vergeleken. Deze vergelijking toont aan dat er, ondanks 
enkele verschillen, over het algemeen consensus bestaat wat betreft het gebruik van TNF-α 
remmers in AS patiënten. Inmiddels zijn er ook voorspellers voor een goede reactie op TNF-α 
remmers geïdentificeerd. Deze voorspellers zijn onder andere een hoge ziekteactiviteit 
gemeten met de ASDAS (Ankylosing Spondylitis Disease activity score), verhoogde acute-
fase-eiwitten en een positieve MRI. Behalve de goedkeuring van verscheidene TNF-α 
remmers voor de behandeling van AS zijn adalimumab en certolizumab ook recent door 
de Europese Commissie goedgekeurd voor de behandeling van volwassenen met ernstige 
niet-radiografische axiale SpA, die inadequaat reageren op NSAID’s of intolerant zijn voor 
NSAID’s. Maar patiënten met niet-radiografische axiale SpA komen alleen in aanmerking voor 
behandeling met TNF-α remmers als er objectieve kenmerken van ontsteking aanwezig zijn 
(verhoogde acute-fase-eiwitten en/of positieve MRI). Toch is het in veel landen nog steeds 
zo dat patiënten met actieve, ernstige axiale SpA, die geen baat hebben bij behandeling met 
NSAID’s, alleen in aanmerking komen voor behandeling met TNF-α remmers als er sacroiliitis 
op de röntgenfoto te zien is. Maar het enige verschil tussen niet-radiografische axiale SpA en 
AS is de aanwezigheid van radiografische sacroiliitis, waarvan nu juist is aangetoond dat het 
lastig is om die betrouwbaar te interpreteren (hoofdstuk 5 en hoofdstuk 6). Er is daarom 
meer onderzoek nodig naar de (langetermijn)effecten van TNF-α remmers in vroege niet-
radiografische axiale SpA, inclusief patiënten zonder ontsteking op MRI. 
Verder zouden de langetermijnuitkomsten van verschillende typen behandelingen (NSAID’s 
versus TNF-α remmers etc) met elkaar vergeleken moeten worden waarbij met name gekeken 
zou moeten worden of er verschillen zijn in het remmen of misschien zelfs tegengaan van 
structurele afwijkingen, wat tot op heden (nog) onvoldoende onderzocht is. Ook zouden de 
effecten van verschillende behandelstrategieën (bijvoorbeeld al dan niet ASDAS-gestuurd 
behandelen) vergeleken kunnen worden. Ook het bestaan van een ‘window of opportunity’ 
zou in detail kunnen worden bestudeerd aangezien er aanwijzingen zijn voor het bestaan 
ervan. Een ‘window of opportunity’ wordt gezien als een korte periode waarin het starten 
van een behandeling een beter effect heeft op zowel korte als lange termijn. Gedacht wordt 
dat dit ‘window of opportunity’ zich vroeg in het ziektebeloop opent (en sluit) aangezien 
er is gebleken dat recent ontstane klachten namelijk geassocieerd zijn met betere reacties 
en, belangrijker nog, een grotere kans op een goede respons. Dus als er daadwerkelijk een 
‘window of opportunity’ bestaat dan zou dit klinische en biologische voordelen hebben, en 
zou structurele schade voorkomen kunnen worden, vooral in de actieve axiale SpA patiënten 
bij wie de ziekte recent is ontstaan en die tekenen van ontsteking op MRI of in lab waarden 
laten zien.
Al met al kunnen we stellen dat we door de recente ontwikkelingen beter in staat zijn 
patiënten met SpA tijdig te herkennen, de behandelmogelijkheden verbeterd zijn en er ook 
een gunstiger beloop van de ziekte met minder schade en beter functioneren mogelijk is. 
Maar om de zorg voor patiënten met SpA nog verder te optimaliseren, kunnen we het ons 




ACR  American College of Rheumatology
AS  Ankylosing spondylitis
ASAS  Assessment of SpondyloArthritis international Society
ASDAS  Ankylosing Spondylitis Disease Activity Score
ASQoL  Ankylosing Spondylitis Quality of Life
axSpA  axial SpondyloArthritis
BASDAI  Bath Ankylosing Spondylitis Disease Activity Index
BASFI  Bath Ankylosing Spondylitis Functional Index
BASMI  Bath Ankylosing Spondylitis Metrology Index
BME  Bone Marrow Edema
CASPAR  ClASsification criteria for Psoriatic ARthritis
Cox2  Cyclo-oxygenase-2
CRF  Case Record Form
CRP  C-reactive Protein
CT  Computed Tomography
DESIR  DEvenir des Spondylarthropathies Indifférenciées Récentes
DMARD  Disease Modifying Anti-Rheumatic Drug
EAC  Early Arthritis Clinic
ESPAC  Early SPondyloArthritis Clinic
ESR  Erythrocyte Sedimentation Rate
ESSG  European SpondyloArthropathy Study Group
EULAR  European League Against Rheumatism
Gd  Gadolinium
GESPIC  German Spondyloarthritis Inception Cohort
GP  General practitioner
HLA-B27  Human Leucocyte Antigen B27
IBD  Inflammatory Bowel Disease 
IBP  Inflammatory Back Pain
LR-  negative Likelihood Ratio
LR+  positive Likelihood Ratio
LUMC  Leiden University Medical Center
MIC  Minimally Important Change
mNY  modified New York
MRI  Magnetic Resonance Imaging
mSASSS  modified Stoke Ankylosing Spondylitis Spinal Score
nr-axSpA non-radiographic axial SpondyloArthritis
NSAID  Non-Steroidal Anti-Inflammatory Drug
NVR  Nederlandse vereniging voor Reumatologie
OA  OsteoArthritis
PsA  Psoriatic Arthritis
pSpA  peripheral SpondyloArthritis
RA  Rheumatoid Arthritis
SDC  Smallest Detectable Change
SI  sacroiliac
SLR  Systematic Literature Review
SPACE  SPondyloArthritis Caught Early
SPARCC  SPondyloArthritis Research Consortium of Canada
TNF  Tumor Necrosis Factor
UA  Undifferentiated Arthritis
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